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Abstract 
Uveal melanoma (UM), the most common cancer of the adult eye, is known to have poor 
prognosis. Over 50% of patients are likely to develop metastasis. In more than 80% of the 
cases UM is driven by an activating mutation in the Gq/11 protein. Thus, many attempts 
have been made to target downstream signaling of this oncogene. Unfortunately, none of 
these approaches have succeeded so far in clinical trials. Targeting only one or even two 
downstream effectors in combination, may not be sufficient to blunt the oncogenic 
dynamics of the Gq/11 protein. Direct inhibition of the oncogene itself was believed to be 
ineffective, since the mode of action of the only known inhibitors for Gq/11 proteins, 
FR900359 (FR) and YM-254890 (YM) respectively, was considered unsuitable for 
targeting the constitutively active oncogenes.  
FR is a macrocyclic depsipeptide, produced by symbiotic bacteria. Recent studies have 
shown that by binding to Gα-subunits of Gq/11 proteins FR inhibits the nucleotide 
exchange that is crucial for their activation. Because FR interferes with the rate-limiting 
step of Gα activation, it was reasoned that this approach might be unsuitable to target a 
protein, which is already trapped in the active state. 
Accidentally, however, Evelyn Gaffal, Thomas Tüting and coworkers found that FR 
inhibited diverse cancer hall marks in melanoma cells, harboring an activating mutation in 
the G11 protein. These surprising results prompted us to further investigate the inhibition 
properties of FR on the oncogenic Gq/11 protein. In the frame of this work, we 
demonstrate FRs’ ability to suppress mitogenic pro-survival pathways over the canonical 
phospholipase C (PLC) effector cascade. Taking advantage of genome edited HEK293 
cells lacking Gαq and Gα11 proteins, we were furthermore able to show direct interaction 
of the molecule with its target protein. Results of FRET experiments together with 
molecular modeling gave first hints regarding the mechanism underlying the inability to 
target PLC-Gqmut interaction. Whole cell label-free technology unveiled a possible mode 
of action of FR on the mutated protein. Most importantly, we were able to proof inhibition 
of the oncogene in a therapeutically relevant system. By using different uveal melanoma 
cell lines, we demonstrated in vitro and in vivo the inhibition of tumor progression by FR 
treatment. Further, direct comparison of FR with the other well described Gq-inhibitor YM, 
revealed the long-term superiority of FR, as we observed different drug vulnerability 
between the two molecules. 
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Kurzfassung 
Krebs ist eine der häufigsten Todesursachen weltweit. Der Krebsentstehung liegt die 
ungebremste Zellteilung von Zellen mit abnormalem Wachstumsverhalten zugrunde. Das 
asoziale Verhalten bestimmter Zellen, sich unabhängig von den vorherrschenden 
Umgebungsbedingungen zu teilen, hängt mit der genetischen Veränderung des Erbgutes 
dieser Zellen zusammen. Aufgrund zahlreicher Kontrollmechanismen, die unkontrolliertes 
Wachstum und Replikation von defekter DNA in der Zelle verhindern, reicht oft eine 
Mutation im Genom nicht für die pathogenetische Transformation aus. Die Tumorgenese 
setzt ein Zusammenspiel von Mutationen, die zu Überaktivität wachstumsfördernder 
Onkogene, und Mutationen, die zu Aktivitätsverlust von Tumorsuppressoren führen, 
voraus. Doch hat sich die gezielte pharmakologische Suppression bestimmter Onkogene 
in klinischen Studien als effektive Strategie zur Bekämpfung der Tumorprogression 
bewiesen.  
Aderhautmelanome gehören zu den häufigsten aber auch aggressivsten Melanomarten 
im adulten Auge. Über 50% der Patienten mit Primärtumoren entwickeln in den 
Folgejahren der Erstdiagnose Metastasen. Verglichen mit anderen Krebsarten ist die 
genetische Alteration relativ gering. Eines der bekanntesten Onkogene in diesem 
Zusammenhang ist das Gq/G11 Protein. Über 80% der Patienten, die an 
Aderhautmelanom erkrankt sind, tragen eine somatische Mutation in einer funktionellen 
Domäne des Proteins. Der Austausch einer einzigen Aminosäure an der betreffenden 
Domäne, führt zum Verlust der autokatalytischen Ausschaltregulation. Dies hat eine 
konstitutive Überaktivität des wachstumsfördernden Proteins zur Folge. 
Im Rahmen dieser Arbeit befassten wir uns mit einem makrozyklischen Naturstoff, der 
kürzlich als selektiver Gq/11 Hemmstoff charakterisiert wurde. FR900359 ist ein 
Depsipeptid, das durch nicht ribosomale Synthese einer in Symbiose mit dem 
Immergrün-Gewächs Ardisia Crenata lebenden Bakterienart produziert wird. Das 
Depsipeptid verankert sich zwischen die Hauptdomänen des Gq/11-Proteins und 
verhindert dessen sterische Flexibilität. Durch die Einschränkung der Beweglichkeit 
innerhalb des Proteins kann der normale, rezeptorvermittelte Aktivierungsmechanismus 
nicht mehr stattfinden. Da aber das onkogene Gq/11 Protein durch die Mutation bereits 
im Grundzustand aktiviert vorliegt, hatte man dem Molekül zunächst die Fähigkeit 
abgesprochen, auch das onkogen mutierte Analogon des Proteins zu hemmen.  
Durch einen Zufallsbefund an einer Melanom-Zelllinie mit mutierten G11 Protein wurde 
bewiesen, dass FR in der Lage war verschiedene krebstypische Merkmale zu 
unterbinden. Zellen, die mit FR behandelt wurden, zeigten vermindertes Wachstums- und 
Migrationsverhalten. Dafür schienen die Zellen in einen differenzierten Zustand 
überzugehen. Auf Grund dieser Beobachtungen entschieden wir uns das Phänomen der 
Hemmung des aktiven Gq/11-Onkogens durch FR näher untersuchen.  
Anhand verschiedener Melanom Zellen sowie genomisch veränderter artifizieller HEK293 
Zellen konnten wir zeigen, dass FR präferiert wichtige Gq/11 initiierte 
Überlebenssignalwege der Zelle gegenüber dem herkömmlichen Gq-Effektorprotein 
Phospholipase C-β (PLCβ) hemmt. In diesem Zusammenhang gelang es uns darüber 
hinaus mit Hilfe von FRET-Experimenten, die Protein-Protein-Interaktionen 
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veranschaulichen, sowie mit molekularer Modellierung erste Hinweise für diese selektive 
nicht-Hemmung der PLCβ zu sammeln.  
Liganden-induzierte, dynamische Massenumverteilung in HEK Zellen mit onkogenem Gq, 
enthüllte eine Rezeptor-aktivierbare Fraktion des Gαq Proteins und gab somit erste 
Aufschlüsse über die mechanistische Funktion des Hemmstoffs am aktiven Analogon. 
Die Existenz dieser Fraktion konnte dann mittels His-Pull-Down Assays sowie 
Dünnschichtchromatographie verifiziert werden. Die direkte Interaktion des Hemmstoffes 
am Protein belegten wir mit einer Mutagenese-loss-of-function-Studie.  
Im Anschluss konnten wir die imposante Wirkung des Inhibitors in vitro aber auch in vivo 
im therapeutisch hoch relevanten Aderhautmelanom Kontext zeigen. Dabei führte die FR-
Behandlung kultivierter Aderhautmelanomzellen mit Mutation am Gq/G11 Protein zu 
einer Hemmung diverser wachstumsfördernder Signalwege, dem Zellwachstum und auch 
der Tumorentstehung in einem xenographischen Mausmodell. Die Antwort der Zellen auf 
die Behandlung konnte auf die spezifische Hemmung des Gq/11-Onkogens 
zurückgeführt werden, da das Zellwachstum in den Kontrolllinien mit anderen onkogenen 
Treibermutationen unbeeinflusst blieb. Darüber hinaus zeigten wir die Überlegenheit von 
FR gegenüber einem strukturell verwandten und kommerziell erhältlichen Molekül YM 
hinsichtlich des Langzeitinhibitionspotentials.   
Somit diente diese Studie dem Nachweis, dass die direkte Adressierung des konstitutiv 
aktiven Gq/G11 Proteins in der Aderhautmelanom-Therapie durchaus ein attraktives 
Konzept darstellt. Die Moleküle FR und YM konnten dabei als erste strukturelle Basis für 
die Entwicklung therapeutisch relevanter Inhibitoren identifiziert werden. Zukünftig 
könnten diese Inhibitoren durch Modifikationen oder auch durch die Verbindung mit 
Transportmolekülen, die das mutierte Protein oder spezifisch das Gewebe mit der 
Mutation adressieren, realisierbare therapeutische Optionen darstellen.  
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Introduction 
Cancer is one of the major antecedents for death nowadays. It can be caused by external 
factors like tobacco, alcohol or chemicals leading to somatic mutations and gene fusions. 
However, internal factors like germline mutations, or immune conditions can also cause 
cancer (American Cancer Society). For cancer development it is more likely that multiple 
genes are altered than only one. In fact, often abnormal growth is initiated by a 
cooperative network of gain-of-function oncogenes and loss-of-function tumor-
suppressors (Croce 2008). These oncogenic hits transform a normal cell into a tumor cell 
with stem cell properties supported by proto-oncogogenes (Vicente-Dueñas et al. 2013).  
Proto-oncogenes are proteins that are involved in cell growth, proliferation, differentiation 
and regulation of apoptosis. Due to mutational changes or chromosomal rearrangement 
these proteins lose their regulatory mechanisms and become overactive (Croce 2008). At 
that point in time the proto-oncogene transforms into a proper oncogene. Thereby, 
oncogenes do not only function as initiator for tumorigenesis but also play a role 
throughout cancer progression (Vicente-Dueñas et al. 2013). The cancer cell becomes 
dependent on its oncogenic drivers. In xenograft mouse models overexpression of certain 
proto-oncogenes have been reported to lead to tumorigenesis. But even though more 
than one gene alteration is believed to be needed for tumor development, this was not a 
one-way observation. Knockdown of a single cancer initiating gene was shown to arrest 
the cell’s cell cycle, force the cells into differentiation or even induced programmed cell 
death (Weinstein 2002; Dancey 2006). Therefore, one therapeutic approach is to target 
one certain oncogene directly or indirectly by inhibiting downstream proteins that are 
activated by this oncogene (Dancey 2006). 
Targeted therapy has become quite common in the treatment of cutaneous melanoma 
(CM). Activating mutations in certain genes responsible for expressing C-Kit, N-Ras or B-
Raf are frequently found in this cancer type (Gray-Schopfer et al. 2005; Platz et al. 2008; 
The Cancer Genome Atlas Network 2015). They all belong to a group of proteins that 
promote the pro-proliferative mitogen activated protein kinase (MAPK) pathway (McArthur 
and Ribas 2013). Vemurafenib, which specifically targets the mutated version of B-Raf, 
has been shown to be more effective than dacarbazine, a chemotherapeutic agent that 
unselectively targets all rapidly dividing cells (McArthur and Ribas 2013; Knapen et al. 
2018). Uveal melanoma (UM) is a subtype of ocular melanoma (Eagle 2013). On one 
hand these melanoma cells often show a lack of mutations in the MAPK pathway, but on 
the other hand they were detected with elevated tonus of this pathway. Instead another 
oncogene, the Gq/G11 protein has been found to be somatically activated in over 80% of 
the UM patients (van Raamsdonk et al. 2009). This work will focus on the GNAQ/GNA11 
oncogene and its specific inhibition with a recently characterized molecule FR900359 
(Schrage et al. 2015).   
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1.1. Uveal melanoma 
Uveal melanoma is the most common 
cancer type in the adult eye with a high 
risk to form metastasis. Malignancy arises 
from melanocytes located anywhere in the 
uveal contact including the ciliary body, 
the iris and, most commonly, the choroid 
as shown in figure 1 (Krantz et al. 2017; 
Carvajal et al. 2016; Eagle 2013).  There 
are several risk factors counting into uveal 
melanoma incidence such as age, sex 
and race. Most cases of uveal melanoma 
are diagnosed between the age of 70 and 
79 with a prevalence for light toned skin, 
blue eyes and male sex (Harbour 2012). 
Typical symptoms include the eyesight as 
diseased patients often suffer from visual 
field loss or blurry vision. However, around 
30% of patients are without symptoms at 
the time of diagnosis. Early diagnosis is 
important as primary tumor size correlates 
with survival rates. Around 50% of the patients with primary tumors are likely to develop 
metastases that are disseminated by the blood stream and are prevalently found in the 
liver but also in lung or bone (Krantz et al. 2017). 
1.1.1 Chromosomal alterations and frequent mutations 
Chromosomal alterations are relatively rare in uveal melanoma compared to other cancer 
types, but certain abnormalities were found to correlate with prognosis of the disease. 
Most common alterations occur in chromosomes 1, 3, 6, 8 and 9. Thereby, the loss of 
one copy of chromosome 3 is one of the most prominent markers. Monosomy 3 is 
detected in almost 50% of all UM samples and has been used to predict metastatic 
behavior. This chromosome 3 encodes a tumor-suppressor gene that is frequently 
mutated in UM. Higher risk to generate metastasis of these cells is suggested to be 
caused by downregulation of this suppressor, the BRCA1-associated protein 1 (BAP1) 
(Krantz et al. 2017; Harbour 2012). BAP1 is a deubiquitinating enzyme, which regulates 
important steps of the cell cycle like DNA repair or even differentiation (Masoomian et al. 
2018).  
In 2004 Onken et al. established a gene expression profile (GEP) system to categorize 
primary uveal melanomas into two classes based on their gene expression (Onken et al. 
2004). The categorization correlated perfectly with metastasis behavior. In a later study 
by Monzon and co-workers the GEP-method could be evaluated as a reliable tool for 
prognostic use and is even recommended by the American Joint Committee on Cancer 
(AJCC) since 2017 (Plasseraud et al. 2017). Tumors of class 1 with a low risk to develop 
metastasis were detected with enhanced DNA copy numbers of genes on chromosome 
6p and 8q and downregulated copy number on 6q. Significant alterations were not 
observed for this class on chromosome 3. In class 2 tumors, more likely to develop 
metastasis, upregulation of genes on 8q and downregulation of genes on 6q was 
Figure 1: Uveal melanoma arising from 
the choroid; Borrowed from RC Eagle Jr 
Eye 2013 
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frequently detected. Thereby, no alterations were found in 6p. Additionally, gene clusters 
on chromosome 3 were affected. This observation was correlating with monosomy 3 as a 
risk factor for invasive behavior (Onken et al. 2004).  
Another retrospective study with 81 patients revealed 5 genes that were mutated in the 
patients with high frequency: BAP1, SF3B1, EIF1AX and GNAQ/GNA11. Here mutations 
in BAP1, SF3B1 and EIF1AX were almost mutually exclusive. Same was observed for 
mutation of GNAQ and GNA11. BAP1 mutation was strongly correlated with class 2 GEP, 
whereas mutation in EIF1AX was associated with class 1 GEP. Mutation in SF3B1, 
GNAQ nor GNAQ11 did not show any significant higher occurrence in one of the classes 
compared to the other (Decatur et al. 2016). As mutations in GNAQ and GNA11 are 
commonly found in UM samples independent of the progression state of the tumor, it was 
suggested that this mutation occurs in early stage of tumor development and therefore 
does not correlate with prognosis of the disease. Furthermore, this led to speculation if 
mutation in GNAQ/GNA11 might be an initiator of oncogenic conduction (Onken et al. 
2008).  
1.1.2. Gq-signaling as oncogenic driver 
The role of Gq signaling in uveal melanoma was further emphasized when two other 
mutations were discovered that affected proteins of the Gq-signaling-pathway (Moore et 
al. 2016; Johansson et al. 2015).  Deep sequencing of UM samples identified a mutation 
in PLCB4 that was suggested to be of activating nature (Johansson et al. 2015). PLCβ is 
the best known direct downstream effector of the Gq-family proteins (Harden et al. 2011). 
Occurrence of PLCB4 mutations was conformed in a later study by Yu Chen and co-
workers. In this study another additional activating mutation was found on the Gq-coupled 
cysteinyl leukotriene receptor 2 (CysLTR2). Substitution of leucine with glutamine on 
position 129, a residue that normally stabilizes inactive G protein-coupled receptor 
(GPCR) conformation, was present in 4 of 9 UM samples, that did not carry mutations in 
either GNAQ/GNA11 or PLCB4. According to their prediction, these mutations were 
mutually exclusive (Moore et al. 2016). This observation is quite common for driver 
mutations affecting the same pathway (Cisowski and Bergo 2017). Transfection of the 
mutated receptor-induced cell growth in human melanocytes, demonstrating its 
proliferation driving function (Oldham and Hamm 2008).   
1.2. Gq and G11 belong to the family of G proteins:  
GNAQ/11 genes encode for proteins that belong to the family of guanine nucleotide-
binding proteins (G proteins). These are heterotrimeric proteins consisting of a 
monomeric α-subunit encoded by 16 different genes and a βγ-heterodimer, encoded by 5 
and 14 genes for β and γ respectively, in mammals. Based on the homology of the α-
subunit amino acid primary sequence, these proteins are categorized into 4 main classes: 
αs, αi/o, α12/13 and the αq family (Milligan and Kostenis 2006; Oldham and Hamm 2008).  
The αq family is divided into 4 subclasses Gαq, Gα11, Gα14 and Gα15/16 (mouse and human 
orthologs) based on their amino acid sequence and their common feature to activate 
phospholipase C dependent calcium and diacyl glycerin production (Hubbard and Hepler 
2006). Whereas Gq and G11, which share 88 % sequence homology, can be found 
ubiquitously, G14 is primarily expressed in lung, liver, spleen and testis. G14 has less 
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similarity with Gq, as they share 81 % identical sequence. At least homology with Gq 
shows G16 with only 57 % match in protein sequence (figure 2).  
G16 and its ortholog G15 are also rarely expressed, as they are exclusively found in 
hematopoietic cells (Wilkie et al. 1991; Offermanns and Simon 1995; Strathmann and 
Simon 1990).   
 
Most structural diversity is found in the N terminus, where lipid modifications are attached 
post translationally (Sánchez-Fernández et al. 2014). These modifications affect the 
membrane localization of the protein as well as the effector and receptor interaction 
(Oldham and Hamm 2008). Whereas effector interaction among the family is considered 
to be the same, the range of receptor coupling differs a lot. G14, G15 and G16 have been 
found to couple to wide range of receptors in as much as G15 and G16 are even 
approached for agonist screening methods as universal adaptor G proteins (Milligan et al. 
1996; Ho et al. 2001; Hubbard and Hepler 2006). 
These proteins perform important tasks, as they transduce signaling initiated by 
extracellular ligands due to GPCR activation into the cell. In a sedentary state the 
heterotrimeric protein, is bound to guanine diphosphate (GDP) that is exchanged to 
guanine triphosphate (GTP) as a reaction on receptor coupling (Milligan and Kostenis 
2006; Oldham and Hamm 2008). Activation causes dissociation of the βγ-heterodimer 
from α, and both divisions can then interact with different effector proteins as illustrated in 
figure 3. 
The alpha subunit has two domains, a Ras-like domain and a helical domain connected 
by two interdomain linkers. The helical domain is unique for each different alpha subunit, 
whereas the Ras-like domain is conserved throughout all families. This Ras-like domain 
provides the GTPase function and therefore operates as an autoregulated switch-off. 
Three flexible switches within this domain allow conformational rearrangements within the 
Figure 2: Homology between the Gq-family members. Shown are the sequence 
similarities between the proteins within the Gq family. Borrowed from Strathmann et al. 
Science 1991 
Amino acid identity (%)  
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α-subunit. The guanine nucleotide TCAT binding motive is located at the loop between 
the 6β-sheet and the 5α-helix at the end of the GTPase domain. Adapted to the TCAT 
sequence site GDP is trapped between the GTPase and helical domain in the inactive 
heterodimeric state of the protein (Oldham and Hamm 2008; van Eps et al. 2011; 
Wettschureck and Offermanns 2005). 
 
 
 
 
 
 
 
                       
 
 
 
 
 
 
1.2.1. Mechanism of GDP release and GTP entry upon receptor activation 
Upon ligand binding to the GPCR a conformational change occurs within its cytoplasmic 
domains, revealing a binding pocket for the C-tail of the α-subunit (Oldham et al. 2006; 
Mahoney and Sunahara 2016). Additional binding of βγ-heterodimer is required to 
stabilize these contact points (Taylor et al. 1996; Kisselev et al. 1994). Paramagnetic 
resonance spectrometry revealed that receptor attachment to the C-tail of the alpha 
causes a shift within the subunit of its 5 α-helix to the 6 β-sheet (Oldham et al. 2006). 
Another consequence of receptor interaction is a rotating movement of βγ-inter-subunit 
towards alpha that forces rearrangement of switch 1 and 2 within alpha. Both events 
together are suggested to initiate an outward directed movement of the two domains and 
Figure 3: Receptor-mediated G protein activation. Schematic representation of the G 
protein-activation-cycle: The inactive GDP-carrying heterotrimer (I) can be activated by a ligand-
bound receptor, that causes nucleotide exchange (II). The GTP-bound α-subunit loses affinity 
towards the βγ-heterodimer. Consequently, both divisions separate from each other and can 
interact with different effectors (III). Using its intrinsic GTPase activity the α-subunit is able to 
transform the GTP to GDP (IV) and therefore regains its affinity towards the βγ-heterodimer and 
they form a sedentary heterotrimer (I). Scheme adapted by Oldham & Hamm Molecular Cell 
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thereby simultaneously to increase the size of the interdomain space allowing GDP to be 
released from its binding site. The empty state of the G protein is a short transient one as 
the empty pocket is quickly occupied by the activating GTP (Oldham and Hamm 2008; 
van Eps et al. 2011).  
1.2.2. GTPase function as a switch off 
Gα-proteins, as mentioned, exist in three different states: inactive binding GDP, transient 
no-G-binding and active binding GTP. To determinate the active state the G protein uses 
its GTPase function to autocatalyze γ-P-hydrolysis and thereby converting GTP to GDP 
(figure 4). As a consequence the effector interaction is disrupted and the GDP-bound α-
subunit can be re-associated with 
the βγ-subunit to reset the 
inactive heterotrimer (Bourne et 
al. 1990).  
In 1993 and 1994 two crystal 
structures of transducin, a light-
responding receptor-coupled G 
protein, with GTPγS and GDP-
[AlF4]- were published. These 
publications gave important 
insights into the geometrical 
configuration of the α-protein 
during the process of GTP-γ-
phosphate hydrolysis. A H20 
molecule performs a nucleophilic 
attack towards the γ-P of GTP. 
Noel et al. proposed arginine 174 
and glutamic acid on position 203 
to promote the γ-phosphate 
release by stabilizing the 
negatively charged transition state 
(Noel et al. 1993). Shortly thereafter, the transducin-GDP-[AlF4]- structure by Sondek et 
al. revealed Glutamine 200 as one major player in this process. As a requirement for the 
nucleophilic attack, the water molecule must be deprotonated. They suggest Q200 to be 
involved in the proton donation to the water molecule as well as in stabilization of the 
intermediate complex (Sondek et al. 1994). R174 and E203 are only present in the Gα-
family and are not found in the small G proteins (Noel et al. 1993). Therefore, it was 
suggested that these amino acids are responsible for more than 100-fold faster GTPase 
function compared to the small p21RAS homologs (Mixon et al. 1995). 
1.3. GTPase-deficient mutants and cancer 
Before GTPase-deficient mutants were found in G proteins, they were reported in Ras 
genes. These Ras proteins belong to the class of small G proteins only consisting of the 
Ras-like domain. These mutations affected the GTPase activity and bestowed the protein 
with malignant transformation properties in NIH3T3 cells. Single point mutations on codon 
12, 13, 61 and 63 in Ras were suggested to transform the protein into an oncogene 
(Barbacid 1987).  Indeed, residue Q61 in Ras that corresponds to the Q200 in transducin 
Figure 4: GTPase function as autocatalytic 
switch off. Upon receptor activation GDP can dissociate 
from the α-subunit. In this empty sate the binding pocket 
can be re-occupied by GTP. The α-subunit uses its 
autocatalytic GTPase domain to enhance hydrolysis from 
the γ-phosphate of the GTP and thereby returns the 
protein to the inactive state. Scheme adapted and 
modified from Bourne et al. Nature 1990 
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(Mixon et al. 1995), has been found mutated in cancer from a wide spectrum of tissue 
e.g. skin, eye, pancreas, lung and many more. Activated Ras promotes pro-survival and 
inhibits anti-survival signaling regulated by an enzyme called mitogen-activated protein 
kinase (MAPK) (Pylayeva-Gupta et al. 2011).  
Later, mutations of Gs proteins affecting the GTPase domain were first described in 
human pituitary tumors. These mutations affected Q277L (Ras corresponding Q61) and 
R201C/H of the GTPase domain of the Gαs protein, impairing its proper function. To 
determine GTPase activity the mutated constructs were transfected in αs-deficient S49 
cyc- cells and the GTPase rate was measured in GTPase turn-off reaction (kcat-GTP) on 
membranes. Both mutations reduced kcat-GTP approximately 30-fold compared to wild type. 
Elevated cAMP levels could be measured caused by the elongated active state of the Gs 
protein in those cells. These mutations led to overactivity of growth stimulating pathways, 
which is why they were also considered as  oncogenes (Landis et al. 1989). Not much 
later, analogous activating mutations were also found in Gαi2 (Lyons et al. 1990) and Gαq 
(Kalinec et al. 1992). Like the GTPase impaired p21Ras gene also the GαqQ209L was able 
to transform NIH3T3 cells and induce proliferation. Furthermore, in the same study 
Kalinec et al. showed enhanced tumor formation in nude mice injected with GαqQ209L 
expressing cells (Kalinec et al. 1992). 
1.3.1. GTPase-deficient GNAQ/GNA11 is often found in uveal melanoma 
In 2004 Van Raamsdonk and colleagues brought overactive Gq signaling and hyper-
pigmentation into context for the very first time. A screening of over 30.000 mice revealed 
a dominant dark skin phenotypic sub-class (Dsk). Dsk1, Dsk7 and Dsk10 mice showed 
high pigmentation in the hair-bearing skin and some specific pigmentation patterns in 
non-hairy skin that delineated these mice from other Dsk with accumulating melanin in 
the epidermal skin layer. Hints as how hyper-pigmentation might occur was exposed as 
Dsk1, Dsk7 and Dsk10 were found to harbor activating mutations in either GNAQ or 
GNA11 (van Raamsdonk et al. 2004). Sensitized for GNAQ mutations in correlation with 
pigmentation Raamsdonk and colleagues performed sequencing for mutations in the 
GNAQ and GNA11 genes for a wide range of melanocytic neoplasms in a follow-up 
project. A total number of 236 samples was tested. The samples were categorized into 
naevi with 84, cutaneous and mucosal melanoma with 78 and uveal melanoma with 74 
samples. Thereby, GNAQ mutations were detected in the highest frequency in blue naevi 
(83%) and uveal melanoma (46%) (van Raamsdonk et al. 2009).  Similar results were 
obtained by Onken et al. in the same year. In this study he tested 49% of 67 primary and 
54% of 58 posterior uveal melanoma samples to be positive for GNAQ mutation (Onken 
et al. 2004). The most extensive study followed in 2011. Van Raamsdonk et al. verified 
713 melanocytic neoplasms of different types for mutations on position Q209 and 453 for 
mutations on position R183 of GNAQ and GNA11. Results were quite convincing as 
mutation in either of these genes was found in 83% of the uveal melanoma samples. By 
this means, codon Q209 was affected with higher frequency as only 6% of the samples 
had an amino acid replacement on position R183 (van Raamsdonk et al. 2010).  
1.4. Diversity of Gq-signaling  
For a better understanding of the complexity and diversity of Gq signaling, the most 
prominent effector proteins that are activated by Gq will be introduced first, before the 
description will move on to Gq signaling specifically in context of uveal melanoma.   
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1.4.1. Important effector proteins of the Gq-family 
1.4.1.1. Phospholipase C  
The best studied Gq-effector protein by far is the phospholipase C beta (PLCβ). The 
mammalian phospholipase C is a membrane anchored enzyme that catalyzes the 
hydrolysis of phosphatidylinositol-4,5-phosphate (PIP2), a membrane-bound phospholipid, 
into the second messengers diacyl-glycerin (DAG) and phosphor-inositol-triphosphate 
(IP3) as indicated in figure 5 (Kadamur and Ross 2013; Thore et al. 2005). These second 
messengers regulate a broad range of cellular processes.  
 
Figure 5: Gq activates PLC catalytic activity to hydrolyze PIP2 into DAG and IP3 
Scheme adapted by Thore et al. Journal of Cell Science 2005 
1.4.1.1.1. DAG-regulated effects 
By binding to a conserved lipid binding cysteine rich domain (C1) that is found within a 
variety of kinases, DAG controls their activity. The most prominent kinase carrying the C1 
domain is the protein kinase C (PKC). Two classes of PKCs are sensitive to DAG 
activation, the conventional PKCs (α, β, γ) and the novel class of PKCs (δ, ε, η, θ). They 
are distinguished by an additional C2 domain only found in the class of conventional 
PKCs. This additional domain is speculated to be involved in Ca2+-dependent membrane 
binding. PKC activation leads to a variety of physiological processes like constriction in 
smooth muscle cells, proliferation and even apoptosis (Harden et al. 2011; Webb et al. 
2000).  
1.4.1.1.2. IP3-regulated effects 
IP3, the other second messenger generated by PLCβ-induced hydrolysis process of PIP2, 
binds to Ca2+ channels that are distributed on intracellular calcium stores. Binding of IP3 
on the tetrameric channel causes a conformational change within the protein and 
promotes the opening of the channel for calcium release. Additionally, autoregulation of 
these receptors prevents too high intracellular calcium levels, as elevated cytosolic levels 
spontaneously inhibit receptor function (Hanson et al. 2004). Receptor-regulated calcium 
release shows distinct temporal patterns on oscillating ion waves that affect different 
processes within the cell like proliferation, transformation, constriction and again even 
apoptosis, as it was shown that reduction of IP3 receptors can inhibit apoptosis (Hanson 
et al. 2004; Berridge 2009).  
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1.4.1.1.3 Mechanistic insight into PLCβ activation by Gq protein 
Thirteen different isoforms of the mammalian PLC are known so far. They are divided by 
their properties into 6 different subclasses. Large structural patterns within the protein 
family are conserved as the catalytic X and Y domain, the triose phosphate isomerase 
(TIM), a C-terminal (CT) cysteine-rich C2 and a N-terminal pleckstrin homology (PH) 
region as well as the array with 4EF-hands (Harden et al. 2011; Yin and Janmey 2003). 
EF-hands are a specific helix-loop-helix motif within the protein that are discussed to bind 
calcium (Lewit-Bentley and Réty 2000). But only PLCβ subclass has been shown to 
couple to Gq, as purified protein GPA-42, declared as Gq family member, was not able to 
activate isoforms γ and δ. Solely interaction with the beta class of PLC led to hydrolysis of 
phosphatidyl inositol 4,5-bisphosphate (Taylor et al. 1991). Some structural features are 
exclusive for this subclass, such as the long α-helix with 450 amino acids at the CT 
domain (Adjobo-Hermans et al. 2013). 
The PLCβ family includes 4 isoforms: β1, β2, β3 and β4. The expression pattern between 
the subfamily is quite diverse. PLCβ1 is mostly found in the brain, PLCβ2 is expressed in 
cells of the hematopoietic system, PLCβ3 is found ubiquitously and interestingly PLCβ4 is 
exclusively expressed in brain and eye. It is noteworthy to mention, that this isoform was 
found to be mutated in several UM patients (Johansson et al. 2015). Even though all of 
the PLCβ isoforms possess a long helical C-terminus, the sequence identity between 
those are quite low (Webb et al. 2000). These proteins are soluble and can be found in 
the cytosol, but a large fraction is also bound to the membrane under intrinsic conditions 
(Lee et al. 1987). Fluorescent-microscopy imaging of fluorescents-protein tagged PLC 
isoforms revealed cytoplasmic enrichment of isoforms 1 and 4 whereas 2 and 3 were 
constitutively bound to the membrane. By fractioning the protein and tagging the different 
sections the membrane binding effect could be associated to the C-terminus (Adjobo-
Hermans et al. 2013).  
The basal orientation of the protein at the plasma membrane is suboptimal for its catalytic 
activity as the active site is not facing its membrane-bound substrate phosphatidylinositol-
4,5,-bisphophate. Disorientation of the active site could be associated to certain residues 
of the X/Y-linker. This linker is isolating the two catalytic TIM barrels and was found to be 
directed differently in active vs non-active protein. Activation of PLCβ therefore requires a 
reorientation of the active site (Harden et al. 2011; Waldo et al. 2010).  
Before Waldo et al. published the crystal structure of PLCβ3 together with the ALF4- 
activated Gαq, other groups have already shown the C-terminus of PLC to be one of the 
most important residues for protein-protein interaction. In this study it was shown that by 
truncation of the C-terminus from Gly934 or Ala867 activation by Gαq was severely 
impaired (Lee et al. 1993). Later the crystal structure of the active complex of PLCβ3 with 
Gαq did not only give insights to the binding sites but also promoted a special dynamic 
behavior of these two proteins described as a catch-and-release mechanism (Harden et 
al. 2011). 
 1.4.1.1.3.1. Catch and activation: 
Three regions in Gαq are important for the interaction with this effector: a binding surface 
between switch 1 and 2 interacts with the connecting residue of the TIM barrel of PLC, 
secondly the canonical effector-binding surface formed by switch 2 and the α3-helix of the 
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GTPase domain interact with a helix-turn-helix segment of PLCβ3. And a third connecting 
point is the GTP-binding residue that directly interacts with a short amino acid sequence 
between EF3 and EF4 of the PLCβ3. Upon Gq binding the orientation of the autoinhibiting 
X/Y-linker of PLCβ3 is sterically altered to unplug the catalytic site and therefore releasing 
intrinsic activity of the protein to hydrolyze phosphatidylinositol-4,5-phosphate and 
generate the second messengers IP3 and DAG (Waldo et al. 2010).  
1.4.1.1.3.2. Release: 
PLC does not only serve as a Gq 
effector but also acts as an 
GTPase-accelerating protein (GAP) 
as shown in figure 6. By using 
quench-flow kinetic methods Ross 
and coworkers have observed a 
1000 fold increased GTPase activity 
in the presence of PLCβ1 
(Mukhopadhyay and Ross 1999; 
Berstein et al. 1992). GTPase activity 
of PLCβ is related to the loop 
between EF3 and EF4. Here the 
crystal structure showed asparagine 
on position 260 to interact with Q209 
and E212 of the GTPase domain of 
Gq, thereby stabilizing a transition 
state important for the water molecule 
to perform hydrolysis of the γ-
phosphate of GTP. GTP hydrolysis is 
proposed changing the conformation 
within Gq in a way that separates the 
binding sites and releases the 
effector. The functional asparagine is also found in other GAP proteins like RGS9 
(Berstein et al. 1992) and RGS2 (Nance et al. 2013).  
1.4.1.2. Trio and other RhoGEFs: 
The Rho-guanine nucleotide exchange factors regulate the activation of small GTPases 
of the Rho family. These proteins promote different cellular processes as dynamic 
changes of the cytoskeleton by inducing actin polymerization or expression of genes 
encoding proteins that are important for the cytoskeletal building e.g. actin (Jaffe and Hall 
2005).  In addition Rho activation has been recently connected to enhanced levels of 
Yes-associated protein (YAP) that upregulated the expression of pro-cell-growth genes 
as connective tissue growth factor (CTGF) and cysteine-rich angiogenic inducer 61 
(CYR61) (Yu et al. 2012; Feng et al. 2014; Vaqué et al. 2012). RhoGEFs enhance the 
GDP release and thereby promote GTP entry to the guanine-nucleotide binding pocket of 
the small G proteins. Direct interaction of Gαq and the Trio family of RhoGEFs including 
Trio, Duet and RhoGEF61, has been reported multiple times (Vaqué et al. 2012; Feng et 
al. 2014; Rojas et al. 2007). These Dbl-RhoGEFs possess a conserved structural feature 
of a catalytic Dbl-domain altering with a PH domain. In the resting state, the PH domain 
Figure 6: PLC acts as a GAP for Gq proteins.  In 
the presence of a ligand the inactive G protein (I) can be 
activated by the receptor. Activation leads to interaction 
of the α-subunit with PLC (II). This interaction has fast 
dynamics as PLC enhances the GTPase activity of α-
subunit and therefore promotes the transformation of 
GTP to GDP.  
Introduction 
11 
 
acts as a plug for the catalytic Dbl-domain and serves the protein as an autoinhibiting 
module (Lutz et al. 2007). By interacting with the C-terminal PH domain Gαq revokes the 
autoinhibiting function and restores the protein’s guanine nucleotide exchanging activity 
(Rojas et al. 2007). 
1.4.1.3. PKCζ 
PKCζ belongs to the family of the atypical PKC isoforms that are insensitive towards DAG 
activation (Colón-González and Kazanietz 2006; Ananthanarayanan et al. 2003). 
Activation of PKCζ by Gq is reported to induce phosphorylation of ERK5 involving direct 
interaction of MEK5, PKCζ and Gq. Ribas and coworkers demonstrated ERK5 
phosphorylation upon either ligand or mutational initiated Gq activation. ERK5 stimulation 
was independent of PLCβ activation as same results were observed by using a 
constitutively active Gq construct lacking important sites for PLCβ binding. Furthermore, 
they could demonstrate direct interaction in an immunoprecipitation assay as HA-tagged 
PKCζ and Gq were found together while PKCζ did not associate with Gs, Gi nor G12-
isoforms (García-Hoz et al. 2010). In the follow-up study Ribas and co-workers exposed a 
new binding site for this effector in the Gq protein β4-α3 loop in Gαq, as mutated Gαq 
lacking residues critical for PLCβ and RhoGEF61 binding did not lower the amount of co-
immunoprecipitated complex of Gq-PKCζ (Sánchez-Fernández et al. 2016). 
1.4.2. Gq signaling in uveal melanoma 
Gq signaling is quite complex as it has regulating 
function in many crucial cellular processes like 
apoptosis, autophagy, cell differentiation, 
migration, cytoskeletal dynamics and much more.  
Furthermore signaling is dependent on the cellular 
background38. Multiple reports were published in 
the last decades elucidating Gq as the perpetrator 
for the onset of different pro-survival pathways in 
uveal melanoma. In these reports Gq was shown 
to activate MEK, PI3K, or YAP dependent on its 
mutational status (van Raamsdonk et al. 2009; 
Zuidervaart et al. 2005; Chen et al. 2014; 
Ambrosini et al. 2013; Feng et al. 2014; Vaqué et 
al. 2012) (figure 7). These events will be 
introduced here in detail:  
1.4.2.1. Activation of the MAPK-pathway: 
MAPK is a serine-threonine kinase cascade typically known to be activated by growth 
factor binding to tyrosine kinase receptors (TKR). Onset of this kinase cascade leads to 
enhanced cell proliferation. This pro-proliferative pathway is found to be over-active in 
many malignant epithelial melanocytes. Over-activity is mostly associated with gain-of-
function mutation in MAPK-upstream proteins as B-Raf or N-Ras (Dong et al. 2003) that 
are often detected in CM. UM cells lack mutations in these genes but also show high 
basal ERK activity (van Raamsdonk et al. 2009; Zuidervaart et al. 2005). Despite the 
absence of mutations in the classical ERK driver proteins, Zuidervaart et al. reported 
elevated ERK activity in 10 out of 19 established UM cell lines (Zuidervaart et al. 2005).  
Figure 7: Overview of GNAQ/11 
driven pro-survival pathways. 
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Beside of the TKRs also GPCRs have been found to activate this pathway (Gutkind 
2000). Additionally it has been shown that in absence of the G proteins in the state of 
zero-G, GPCRs fail to signal to ERK (Grundmann et al. 2018). Whereas it is long known 
that mutated GNAQ is able to transform NIH3T3 cells since the early 90s (Kalinec et al. 
1992) more in-depth investigations on GNAQ signaling in human melanocytes has been 
assessed only for the last 10 years.  
2009 Bastian and coworkers could show for the very first time that transfection of 
GNAQQ209L into transformed primary melanocytes empowered the cells to grow 
unattached to substrate, which is a common nature of transformed cells. Furthermore, 
injection of melanocytes transfected with mutant GNAQ but not wildtype GNAQ initiated 
tumor growth in nude mice. To evaluate whether activation of the MAPK pathway by 
GNAQ contributes to the malignant behavior, they looked for ERK phosphorylation in 
these transfected melanocytes. GNAQQ209L transfected cells clearly showed elevated 
pERK levels. Further proof for the GTPase-deficient mutant to signal via ERK activation 
was done by using short interfering RNA to knockdown GNAQ in UM cells carrying this 
activating mutation (OMM1.3 and Mel202).  ERK levels were significantly decreased in 
these cells compared to empty vector treatment (van Raamsdonk et al. 2009).  Similar 
results were obtained in a later study where additional GNAQ involvement in PKC 
signaling was proven as knockdown of GNAQ not only depressed pERK but also PKC 
activity. Thus, they suggest PKC to be the missing link between GNAQ and ERK on-set, 
as PKCi could also depress pERK levels. But surprisingly they found synergistic effects 
on cell growth deceleration when combining PKC and MEK inhibitors (Chen et al. 2014). 
1.4.2.2. Protein-kinase B (AKT) activation  
The AKT/PI3K pathway is predominantly activated by growth factors and highly 
associated with cell cycle progression. Upregulation of this pathway has been observed 
in many cancer types. Cell cycle promotion by AKT activation occurs due to Cyclin D1 
induction (Chang et al. 2003). Cyclin D1 binds to cyclin-dependent kinases (Cdk), which 
serve as cell cycle check-point regulators. The Cyclin D1-Cdk complex supports cell cycle 
steps and increases the expression of proliferation promoting genes such as E2F. 
Moreover, substantial evidence indicates Cyclin D1 upregulation to be a major 
requirement for metastasis (Casimiro et al. 2012).  
Uveal melanoma cell line treatment with the PI3K inhibitor (PI3K-i) LY294002 (LY) 
inhibited cell proliferation and induced apoptosis. LY also blunted AKT phosphorylation of 
the cell samples demonstrated in western blot. An additional effect of the PI3K-i was the 
decreased expression of cyclin D1 (Babchia et al. 2010). The tested cell lines 92.1 and 
Mel270 both harbored a mutation in GNAQ (Griewank et al. 2012). By combining LY with 
the MEK inhibitor (MEK-i) UO126 synergistic effects were observed on cell proliferation 
and cyclin D1 expression (Babchia et al. 2010). Similar synergistic effects were observed 
by Woodman and co-workers. They could show that combination of the MEK-i and AKT-i 
was superior to single agent-treatment in cell proliferation as well as in apoptosis. The 
results were similar regardless of the mutational GNAQ/GNA11 state. But in cells with 
activating mutation in this gene basal levels of MAPK activation could be associated with 
GNAQ-signaling as GNAQ-siRNA inhibited MAPK phosphorylation. This correlation was 
not observed in GNAQ wildtype cells. GNAQ signaling in this study was only associated 
with ERK activation as GNAQ siRNA did not influence pAKT levels in any cell line. 
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Interestingly, Ambrosini et al. obtained different results by using the same cells. In this 
study, which was published only one year later, GNAQ siRNA inhibited both pERK and 
pAKT in GNAQ mutated cells (Ambrosini et al. 2012). But both studies indicate another 
driver for ERK and AKT in UM cells lacking mutation in GNAQ, as these cells had also 
high basal pERK and pAKT but were not sensitive to GNAQ knockdown. In all tested cell 
lines again, best results in depressing cell viability were achieved by the combination of 
MEKi and AKTi. In a xenograft experiment with injected 92.1 cells tumor growth was 
smallest in the cohort of mice, which were fed with both compounds (Ambrosini et al. 
2012). 
1.4.2.3. YAP 
Most recently another pro-survival pathway has been demonstrated to be regulated by 
Gq signaling (Yu et al. 2014; Feng et al. 2014; Vaqué et al. 2012). YAP a transcriptional 
co-activator initiates the expression of proliferation activating proteins. Classically, YAP 
has been known to be a downstream target of the hippo-pathway. In this hippo pathway 
two major kinases MST1/2 and LATS1/2 function as core components that suppress YAP 
activation and therefore inhibit tissue growth and limit organ size (Zhao et al. 2011b). The 
hippo-pathway is activated under apoptotic stress e.g. high cell density in mammalian 
NIH-3T3 cells. Cell-cell contact in these cells decreased YAP activity, as YAP was 
excluded from the nucleus (Zhao et al. 2007).  MST1/2 can be activated by caspase 
cleavage and in turn activate LATS1/2 that then will phosphorylate YAP. Phospho-tag at 
Ser127 is required for binding of a protein called 14-3-3. Adaptor protein 14-3-3 regulates 
the activity and localization of many proteins in numerous tissues (Schumacher et al. 
2010). 14-3-3-YAP complex is unable to enter the nucleus and thereby, it is enriched in 
the cytoplasm. Further phosphorylation of the protein at Ser381 can lead to its 
ubiquitination. The recruitment of ubiquitin ligases to the phosphorylated YAP initiates the 
ubiquitination-dependent degradation (Zhao et al. 2010). Non-phosphorylated YAP is 
predominantly found in the nucleus and can bind to the transcription factor TEAD, a 
protein with TEA domain for DNA binding (Zhao et al. 2011b). Vassilev et al. could show 
that TEAD is mostly associated with YAP by using different mouse linages. Furthermore, 
they could demonstrate that co-expressing YAP increased TEAD activity by 300x fold 
(Vassilev et al. 2001). TEAD-promoted activation of different genes e.g. Cyr61 and CTGF 
that are important for tissue development but that also has been linked to tumorigenesis 
in different cancer types (Zhou et al. 2016). Furthermore, elevated expression of Cyr61 in 
uveal melanoma compared to normal melanocytes was associated with the angiogenetic 
character of the tumor (Walker et al. 2002).  
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In 2012 two independent groups 
published for the first time that 
serum initiated hippo-pathway 
deactivation could be contributed 
to an GPCR activation (Miller et al. 
2012; Yu et al. 2012). Serum 
influence on YAP activity is well 
established in the field (Meng et al. 
2015; Yu et al. 2014) but the 
knowledge about the mechanism 
was new when Yu et al. 
discovered that nuclear localization 
initiated by serum addition could 
not be mimicked by the addition of 
different growth factors. Instead 
they could identify phosphatidic 
acids as the activating compound. 
Further investigation revealed that 
activation of GPCRs by the 
lysophospholipids sphingosine 
1-phosphate (S1P) or 
lysophosphatidic acid (LPA) 
causes deactivation of the LATS 
enzyme and thereby increases 
YAP activity. Knockdown of 
G12/13 abolished LPA effect on HEK cells as well as the Rho inhibitor C3. Further tests 
to clarify the role of other G proteins on YAP activity indicated a YAP promoting role for 
G12/13 and Gq/11-coupled GPCRs whereas Gs signaling seemed to antagonize the 
effects on YAP (Yu et al. 2012). Similar results were obtained by Miller et al. who also 
showed that activation of YAP can be induced by S1P. S1P effect was mediated by the 
S1P2 receptor as the effect could be prevented by using a specific antagonist of this 
receptor. They could also show that ligand-mediated activation via this GPCR was also 
Rho-dependent, as the results were converted by using the ROCK inhibitor Y-227632 
(Miller et al. 2012). 
Two years later in 2014 cell press released two articles back-to-back in Cancer Cell, that 
demonstrated YAP activity in uveal melanoma to be promoted by oncogenic 
GNAQ/GNA11 signaling. Both articles reported that increased fraction of nuclear YAP 
correlates with the mutational status of the Gq protein. Additionally, transfection of 
QNAQQ209L but not wild type GNAQ into HEK293 cells led to increased nuclear 
localization of YAP (Feng et al. 2014) or decreased fraction of phosphorylated protein107. 
GNAQ signaling could be identified as perpetrator for YAP activation as knockdown of 
GNAQ by shRNA/siRNA in 92.1 (Yu et al. 2014)  and in the metastasic-prone UM cell 
lines OMM1.3 (Feng et al. 2014)  inverted YAP localization or phosphorylation state. 
Further knockdown approaches to elucidate GNAQ signaling pathway to YAP activation 
revealed a new pathway involving TRIO, Rho and Rac (figure 8). Thereby, it is 
suggested that RhoA and ROCK inhibit LATS activity and in addition the activation of 
RhoA decreases the fraction of angiomotin (AMOT) associated YAP in favor for active 
YAP by inducing actin polymerization, as shown in figure 8. F-actin and YAP both then 
Figure 8: GNAQ signaling to induce YAP 
activity. Borrowed from Feng et al. Cancer Cell 
2014. 
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compete for AMOT binding (Feng et al. 2014; Vaqué et al. 2012). Guan and coworkers 
have described YAP-AMOT interaction as a mechanism that regulates YAP localization 
and phosphorylation (Zhao et al. 2011a). TRIO is a RhoGEF that enhances the exchange 
of GDP to GTP in Rho proteins and therefore promotes it’s signaling. Trio is closely 
related to the p63-RhoGEF that has been co-crystalized with a Gαi/q chimera. In the same 
study, Lutz et.al. could show that Gq was able to bind and activate Trio (Lutz et al. 2007). 
1.5. Therapeutic options in uveal melanoma 
Primary uveal melanoma is treated with either radiotherapy or surgery. Newer 
approaches e.g. with the ICON 1, a immunoconjugate of the tissue factor 7, is currently 
under clinical phase 1 study for primary UM (Yang et al. 2018). These are good options, 
but the problem is, that 50% of the UM develop metastasis. Once metastasis is detected 
survival rates drop. The median survival then decreases to less than 14 months as 
median (Krantz et al. 2017).  Unfortunately, there is no successful standard therapy 
developed by now. Classic chemotherapeutics as Dacarbazine or Cisplatin were quite 
disappointing in their effects towards metastasizing UM (Carvajal et al. 2016). Checkpoint 
inhibitors as immunotherapy that have shown good results in the treatment of cutaneous 
melanoma did not show the desired effect in UM. Targeted therapy has become 
interesting since mutation in GNAQ/GNA11 have been revealed to be oncogenic driver 
for approximately 80% of all UM. Different approaches to target the downstream effectors 
as MAPK, PI3K, PKC or these in different combinations did not show great efficacy in 
clinical studies (Yang et al. 2018). At the beginning of our study direct targeting of the 
oncogene itself was not approached, very likely due to the lack of a chemical inhibitor to 
aim the oncogenic GNAQ. In the course of this project two other studies came out that 
considered this tactic to inhibit cell growth of uveal melanoma cells in vitro(Onken et al. 
2018; Lapadula et al. 2018) . These emerging studies together with our study underline 
the value and the essential need to investigate this field. 
1.6. GNAQ inhibitors 
Whereas modulation of G protein signaling on the receptor level with agonist or 
antagonist is widely in use, the direct inhibition of G proteins remains quite a challenge. 
Not many tools are available so far to modify the activity of this protein family. Pertussis 
toxin (PTX) is a well-established inhibitor of the Gi subfamily, but no inhibitors are known 
to reliably abolish Gs or G12/13 signaling directly (Schrage et al. 2015).   
In the past 10 years multiple reports about the two depsipeptides YM-254890 (YM) and 
FR900359 (FR) have progressively emerged in the GPCR community (figure 9).  
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Figure 9: Comparison of YM-254890 and FR900359 structures. Borrowed from 
Schrage et al. nature communication 2015. 
These two analogs have been validated regarding their biological behavior and 
mechanism of action and could be described as Gq/11 inhibitors (Schrage et al. 2015; 
Nishimura et al. 2010) (figure 10).    
1.6.1. YM 
YM, a depsipeptide isolated from the chromobacteria strain QS3666, was first described 
to inhibit ADP-induced platelet aggregation in human plasma (Taniguchi et al. 2004). 
Later on, Takasaki et al. could link the anti-thrombotic effects of YM to its ability to block 
Gq signaling. Inhibition of Gq was not receptor-dependent as signaling was abolished 
after activation of multiple Gq-coupled GPCRs. Additionally, activity of non-receptor 
dependent analog GqR183C could be blunted with the inhibitor. The mutation on R183C 
leads to elevated intrinsic activity without receptor involvement. But effects of YM were 
only observed for Gq/11/14 mediated signaling as it did not show any effect on the 
production of the second messenger cAMP upon Gi or Gs protein activation. Moreover, 
the mechanism of inhibition-activity could be accounted for the GTP-GDP exchange, as a 
mutation that completely lacks GTPase activity could not be addressed by YM 
application. This hypothesis was supported by a crystal-structure that showed the binding 
site of the depsipeptide in the inactive GDP-bound Gαi/q-chimera-Gβ1-Gγ2 heterotrimer. YM 
was shown to occupy two distinct regions that link the GTPase and helical domain on the 
alpha-subunit. Flexibility in these interdomain-linkers is important for the dissociation of 
the guanine-nucleotide and therefore for its activation (Nishimura et al. 2010). According 
to its function as a guanine-dissociation inhibitor (GDI) and in line with published data it is 
unable to inhibit the oncogenic GNAQ/11 protein (Takasaki et al. 2004; Kimple et al. 
2011; Xiong et al. 2016).  
1.6.2. FR 
FR is a depsipeptide that is closely related to YM. Only 3 methyl-groups distinguish the 
two molecules structurally (Xiong et al. 2016). Originally FR is extracted from an 
evergreen plant called Ardisa crenata that is found in far eastern countries as Japan or 
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Korea. Its structure was first obtained by a Japanese working group in 1988 that also 
reported about the compounds ability to depress blood pressure and inhibit platelet 
aggregation (Miyamae et al. 1989).  
It took more than a quarter of a century after structural clarification until the true nature of 
the FR compound was fully characterized in the course of a former study by our working 
group (Schrage et al. 2015). Here we identified FR as a specific inhibitor of Gq/11 and 14 
proteins over all other Gα isoforms. FR significantly reduced high affinity ligand binding, 
which occurs under guanine nucleotide-free ternary complex formation of ligand, receptor 
and G protein. Its mechanism of action was therefore identified as a guanine nucleotide 
dissociation inhibitor (GDI).  
Shortly afterwards Kukkonen presented similar results on FR specificity in a relatively 
small study (Kukkonen 2016). In addition to the selectivity of FR we could demonstrate 
the lack of effects on cells in the absence of Gαq proteins, and therefore could proofed the 
pharmacological value of this depsipeptide (Schrage et al. 2015). As expected from its 
mechanism of action HEK293 cells transfected with the oncogenic GqQ209L protein 
could only be partly inhibited in IP1 accumulation assay. Here we will further investigate 
FR’s capability to target the oncogenic GNAQ/GNA11 protein. 
 
Figure 10 Scheme of FR function as a GDI. FR binds between the helical and the GTPase 
domain of the Gα-subunit and prevents receptor-mediated interdomain rearrangement that 
normally allows the GDP to dissociate from its binding pocket.  
.  
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Goal of this study 
Activating mutations, disrupting GTPase function of Gq are present in 5.6% of human 
cancer (O’Hayre et al. 2013). Inhibition of this activated protein would therefore be highly 
desirable. FR900359 was recently described as selective inhibitor of the Gq/11/14 protein 
heterotrimer. Thereby FR significantly reduced high affinity ligand binding, which occurs 
under guanine nucleotide-free ternary complex formation of ligand, receptor and G 
protein. Thus, its mechanism of action could be identified as a guanine nucleotide 
dissociation inhibitor (GDI) (Schrage et al. 2015). One would assume that inhibition of 
GDP dissociation would not be the right strategic approach and therefore FR the wrong 
tool to silence signaling of those GTPase-deficient proteins. Here in this study we want to 
evaluate FR’s capability to diminish mitogenic signaling in melanoma cell lines with high 
Gq tonus derived from either overactive wt or GTPase impaired Gq.  
To verify the primary observation and to proof FR interaction with the GTPase-deficient 
mutant we further investigated FR’s mechanism of action and want to unravel the 
reasons for selective pathway inhibition. HEK cells lacking Gq/G11 proteins offer an ideal 
genetic background for this endeavor because we can reintroduce the modified targets by 
transfection without confounding expression of endogenously expressed Gq/11 proteins 
with label-free dynamic mass redistribution technology, we were furthermore investigating 
the whole cell response upon the inhibition of a constitutively active protein. By examining 
the fractions of GTP-bound monomeric and receptor-activatable GDP-bound 
heterotrimeric state of the GTPase-malfunctioning Gq protein we want to rationalize our 
approach to target the oncogenic Gq with an inhibitor described as GDI.  
Mutations on one of the hot spot residues Q209 or R183 are detected in over 80% of 
uveal melanoma samples from patients and are considered as oncogenic drivers. Many 
studies have focused on targeting Gq downstream effectors as therapeutically attempt 
towards uveal melanoma progression. So far, no effective therapy has been developed. 
In the course of this study we want to certify the direct inhibition of the oncoprotein itself 
as a feasible and effective strategy for UM tumor treatment.  
YM another macrocycle, structurally close related to FR, has been described to have 
similar inhibition properties. In a head-to-head comparison we compared the drug 
vulnerability as well as the long-term inhibition capacity of these molecules regarding 
inhibition of proliferative behavior in a uveal melanoma cell system with mutated Gq. This 
comparison ideally helps to validate the best candidate for future translational medicine 
efforts and to develop a targeted therapy for stratified forms of uveal melanoma. 
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Materials 
2.1. Cell lines  
2.1.1. Melanoma Cells 
Name Biological source GNAQ/GNA11  Producer 
HCmel12  mouse GNA11Q209L Professor Thomas Tüting 
University of Magdeburg 
B16 mouse wild type from the American Type Culture 
Collection 
BRIM4 human GNAQQ209P Professor Richard Marais 
University of Manchester 
Skmel28 human wild type Professor Dirk Schadendorf, 
University of Essen 
MaMel119 human wild type Professor Dirk Schadendorf, 
University of Essen 
2.1.2. Uveal Melanoma Cells 
Name Biological source GNAQ/GNA11  Producer 
Mel290 human wild type Professor Martine Jaeger 
University of Leiden 
Mel285 human wild type Professor Martine Jaeger 
University of Leiden 
Mel270 human GNAQQ209P Professor Martine Jaeger 
University of Leiden 
Mel202 human GNAQQ209L Professor Martine Jaeger 
University of Leiden 
92.1 human GNAQQ209L Professor Martine Jaeger 
University of Leiden 
OMM1.3 human GNAQQ209P Professor Bruce R. Ksander 
Harvard Medical School 
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2.1.3. Human Embryonal Kidney 293 cells (HEK293) 
Name Genome edited Producer 
HEK293 non-edited Professor Evi Kostenis       
University of Bonn 
HEK293Gαq/11-null ΔGαq/11 by CRISPR Cas9 Professor Asuka Inoue          
Tohoku University 
HEK293 FFA2 Stably expressing FFA2 Flp-in Professor Evi Kostenis      
University of Bonn 
 
2.2. Cell culture media and supplements 
2.2.1. media 
Name Manufacturer Reference Number 
RPMI 1640 Thermo Fischer Scientific 21875-034 
DEMEM Thermo Fischer Scientific  41965-039 
MCDB 153 Sigma-Aldrich now MERCK M7403-10X1L 
 
2.2.2. Supplements and solutions for cell culture treatment 
Name Manufacturer Reference Number 
Penicillin/Streptomycin Thermo Fischer Scientific 15140 
Blasticidin Thermo Fischer Scientific  A1113902 
Hygromycin B Sigma-Aldrich H3274-50MG 
Fetal calf serum PANTM Biotech GmbH P30-3702 
Non-Essiencial Amino  Thermo Fischer Scientific  11140068 
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Acids (NEAA 100X) 
HEPES Thermo Fischer Scientific  14025050 
2-mercaptoethanol Sigma-Aldrich M6250-10ML 
Trypsin-EDTA 0.05% Thermo Fischer Scientific  25300054 
   
2.2.3. Cell culture media and buffer 
2.2.3.1. Washing buffer 
Phospho-buffered saline solution (PBS) 
Ingredients Volume (ml) Weight (g) Final concentration 
PBS tablets - - 10 mM 
dH2O 500   
KCL - 0.1 2.68 mM 
NaCl - 4.0 140 mM 
pH was adjusted to 7.45 with HCL 
 
2.2.3.2. Cell culture media 
2.2.3.2.1. media for HEK293 and HEK293Gαq/11-null 
Ingredients Volume (ml) Final concentration 
DEMEM 500 10 mM 
Penicillin/Streptomycin 5 1% 
Fetal calf serum 50 10% 
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2.2.3.2.2. media for HEK293 FFA2 
Ingredients Volume (ml) Final concentration 
DEMEM 500 10 mM 
Penicillin/Streptomycin 5 1% 
Fetal calf serum 50 10% 
Blasticidin 0.75 (of 10 mg/ml) 15 µg/ml 
Hygromycin B 0.5 (of 10 mg/ml) 100 µg/ml 
 
2.2.3.2.3. media for CM cells B16, HCmel12, Skmel28, MaMel119 
Ingredients Volume (ml) Final concentration 
RPMI 1640 500 10 mM 
Penicillin/Streptomycin 5 1% 
Fetal calf serum 50 10% 
NEAA (100X) 5 1x 
HEPES 0.5 1 mM 
2-mercaptoethanol 0.18 20 µM 
 
 
 
 
2.2.3.2.4. BRIM4  
Ingredients Volume (ml) Final concentration 
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MCDB 153 500 10 mM 
Penicillin/Streptomycin 5 1% 
Fetal calf serum 50 5% 
 
2.2.3.2.5. media for UM cells Mel290, Mel285, Mel270, Mel202, 92.1, OMM1.3 
Ingredients Volume (ml) Final concentration 
RPMI 1640 500 10 mM 
Penicillin/Streptomycin 5 1% 
Fetal calf serum 50 10% 
 
2.3. Plasmids, Bacteria, Primers  
2.3.1. generated pcDNA3.1+ plasmids with ampicillin resistance;  
Insert gene template Primer forward Primer reverse 
GNAQ-HA Was obtained by internal source form Professor Evi Kostenis; 
Served as template to generate all following constructs: 
GNAQQ209L-HA GNAQ-HA 5′-GAT GTA GGG 
GGC CTA AGG TCA 
GAG AG-3′ 
5′-CTC TCT GAC CTT 
AGG CCC CCT ACA 
TC-3′ 
GNAQR183C-HA GNAQ-HA 5′-CAA CAA GAT GTG 
CTT AGA GTT TGT 
GTC CCC ACC ACA 
GGG ATC ATC-3′ 
5′-GAT GAT CCC TGT 
GGT GGG GAC ACA 
AAC TCT AAG CAC 
ATC TTG TTG-3′ 
GNAQF75K-HA GNAQ-HA 5’-GCG CGG CAA AAC 
CAA GCT GGT GTA 
TCAG-3’ 
5’-CTG ATA CAC CAG 
CTT GGT TTT GCC 
GCG C-3’ 
GNAQF75KQ209L-HA GNAQQ209L-HA 5’-GCG CGG CAA AAC 
CAA GCT GGT GTA 
TCAG-3’ 
5’-CTG ATA CAC CAG 
CTT GGT TTT GCC 
GCG C-3’ 
GNAQI190W-HA GNAQ-HA 5’-CAG GGA TCT GGG 
AAT ACC 
5’-GTA AGT CAA AGG 
GGT ATT CCC AGA 
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CCT TTG ACT TAC-3’ TCC CTG-3’ 
GNAQI190WQ209L-HA GNAQQ209L-HA 5’-CAG GGA TCT GGG 
AAT ACC 
CCT TTG ACT TAC-3’,  
5’-GTA AGT CAA AGG 
GGT ATT CCC AGA 
TCC CTG-3’ 
GNAQI190N-HA GNAQ-HA 5’-CAG GAT CAA CGA 
ATA CCC CTT TGA 
CTT ACA AAG-3’ 
5’-CAA AGG GGT ATT 
CGT TGA TCC CTG 
TAG TGG G-3’ 
GNAQI190F-HA GNAQ-HA 5’-CAG GGA TCT TCG 
AAT ACC CCT TTG 
ACT TAC-3’ 
5’-GTA AGT CAA AGG 
GGT ATT CGA AGAT 
CCC TG-3’ 
GNAQF75A-HA GNAQ-HA 5’-GCG CGG CGC 
CAC CAA GCT GGT 
GTA TCA G-3’ 
5’-CTG ATA CAC CAG 
CTT GGT GGC GCC 
GCG C-3’ 
GNAQR60K-HA GNAQ-HA 5’-CAA GCA GAT GAA 
GAT CAT CCA CGG 
GTC GGG-3‘ 
5’-GTG GAT GAT CTT 
CAT CTG CTT GAT 
GAA GGT GCT C-3‘ 
GNAQV184M-HA GNAQ-HA 5’-GCT TAG AGT TCG 
AAT GCC CAC 
TAC AGG GAT C-3’  
5’-GTA GTG GGC ATT 
CGA ACT CTA AGC 
ACG TCT TGT TG-3’ 
 
2.3.2. Bacterial strain 
DH5αTM competent cells purchased from Invitrogen (ref. number: 18265017) were used 
for amplification of recombinant plasmids.  
 
 
2.4. Mouse strains 
NOD scid gamma is an immune deficient laboratory mouse line lacking NK-cells and 
lymphocytes.  
Athymic Nude Mouse NU(NCr)-Foxn1nu mice is another immune deficient nude 
laboratory mouse line. These mice have a deletion in the FOXN1 gene and are athymic. 
Therefore, they are unable to produce T-cells.  
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Lack of immunity enables the mice to host a wide range of human cells and is therefore 
suitable for xenograft experiments. Here we used mice at the age of 7 to 8 weeks with 
female sex. 
 
2.5. Buffer and Solutions for Assays 
2.5.1. Aluminum fluoride for G protein activation used in IP1 assay 
AlCl3 and NaF were dissolved in IP1 assay buffer to the concentration of 2.4 AlCl3 and 80 
mM NaCl. Due to poor stability of [AlF4]-, AlCl3 2.4 mM and NaF 80 mM were freshly 
combined directly before use in a ratio of 1:1:2 (AlCl3: NaF: IP1-buffer) to a final 
concentration of 300 µM.  
 
2.5.2 HBSS Buffer for DMR assay 
HBSS buffer from Invitrogen (ref. number: 14025-050) was supplemented with HEPES to 
a final concentration of 20 mM. 
 
2.5.2. Poly-D-Lysin (PDL) plate-coating solution 
Aliquots of 50 ml 1x solutions were prepared by dissolving 5 mg of PDL in 50 ml dH2O. 
Afterwards solution was sterile filtered.  
 
2.5.3. Polyethyleneimine transfection solutions 
Polyethylenemine from PolyScience (ref. number: 23966) was dissolved in PBS 1x to a 
final concentration of 1mg/ml. 
 
2.5.4. LB (Luria Bertani) Medium for bacterial growth 
In 1000 ml distilled water 10g Tryptone, 5 g yeast extract and 5 g sodium chloride are 
dissolved. Medium was autoclaved before use. 
2.5.5. Agar plate coating for bacterial colony growth 
1.2 g of agar was dissolved in 80 mL of warm LB medium to a final concentration of 
approximately 1.5%. Ampicillin was added for colony selection. Medium was 8 mL of 
dissolved agar solution, which was poured on 56 cm² bacterial culture plates. 
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2.5.5. EtOH 70% for DNA extraction 
730 mL of absolute EtOH were mixed together with 270 mL of distilled water. 
 
2.5.6. Tris 1 M buffer  
129.1 g of Tris was dissolved in 1000 mL distilled water. Afterwards HCL was used to 
adjust the pH to 6.8. 
 
2.5.7. Lysis buffer for western Blot  
56640 µl distilled water was mixed together with 1500 µl 1 M Tris buffer and 1800 µl of 5 
M NaCl. Triton and IGEPAL were both added to a final concentration of 1%.  
 
2.5.8. Washing buffer for western Blot  
1 mL Tween was added to 999 mL of PBS solution. 
 
2.6. Reagents 
2.6.1. Compounds and Assay Reagents 
Name Manufacturer Reference Number 
Agarose Invitrogen 05040 
Aluminium Fluoride ZVE Bonn 125098 
Antioxidant NuPage  Life Technology NP0005 
Ampicillin Roth K.029.1 
Atropin Sigma-Aldrich A0132 
Bis-Tris 10% Life Technology NP0315Box 
BSA Bovine serum albumin Sigma-Aldrich A6003 
C3 Sigma-Aldrich 402907 
Carbachol Sigma-Aldrich C4382 
DNA 1kb ladder New England Biolabs N3272 
DMSO Roth A994.2 
EDTA   
EGF Sigma-Aldrich E 9644 
Ethidiumbromide Roth 2218.1 
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Fasudil Tocris 541 
FR900359 University of Bonn in house production (AG König) 
Fsk Tocris 1099 
Glycerin 99% Grüssim 11052 
Gö 6976  Calbiochem 365250 
Gö 6983 Tocris 2285 
IGEPAL   
Kaleidoscope standard Bio-Rad 161-0324 
LDS SB Life Technology NP0007 
LY294002  Sigma-Aldrich L9908 
Methanol Sigma-Aldrich 125678 
MOPS SDS RB Life Technology NP0001 
Natrium Chloride Fischer Bioreagenz BP358-212 
Pfu-DNA-Polymerase Promega M774A 
Poly-D-lysine hydrobromide 
(PDL) Sigma-Aldrich P6407 
Protease Inhibitor Cocktail Sigma-Aldrich P8340 
Roti-Block Roth A151.2 
Sample Reduction Agent Life Technology NP0009 
Temed Roth 2367.3 
Trametinib selleckchem S2673 
Transfer Buffer Life Technology NP000P-6 
Tris AppliChem A2264 
Triton X Fluka 93420 
Tryptone Roth 8952.1 
Tween Sigma-Aldrich P1379 
U73122 Tocris 1268 
U73343 Tocris 4133 
vemurafinib selleckchem S1267 
Yeast extract Merck 1.03753.0500 
YM254890 wako 253-00633 
 
2.6.1. Antibodies for Western blot 
Name AB classification Manufacturer Reference Number 
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actin AB primary  Santa Cruz sc-47778 
gp100AB primary abcam ab137078 
anti-rabbit secondary antibodies-online ABIN102010 
 
2.7. Assay and Microbiological Kits 
Name Manufacturer Reference Number 
Pierce™ BCA Protein 
Assay Kit 
Thermo Scientific 23225 
Amersham ECL prime 
Western Blotting 
GE Healthcare RPN2236 
innuPREP DNA Mini Kit  Analytik jena 845-KS-1040250 
innuPREP Gel Extraction 
Kit  
Analytik jena 845-KS-5030050 
IP -One HTRF® assay kit Cisbio bioassays 62IPAPEJ 
NucleoBond Xtra Midi Macherey-Nagel 740414.10 
Phospho-AKT -Ser473 
HTRF® assay kit 
Cisbio bioassays 64NKPPEG 
Phospho-ERK -
Thr202/Tyr204 HTRF® 
assay kit 
Cisbio bioassays 64ERKPEI 
Phospho-YAP-Ser127 
HTRF® assay kit 
Cisbio bioassays 64YAPPEG 
total-AKT HTRF® assay kit Cisbio bioassays 64NKTPEG 
total-ERK HTRF® assay kit Cisbio bioassays 64NRKPEH 
total-YAP HTRF® assay kit Cisbio bioassays 64YATPEG 
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2.8. Consumables 
Consumables Company Model 
12-well plate Costar Corning 3512 
6-well plate Costar Corning 3506 
96-well plate Costar Corning 9017 
Blotting sponge Thermo Fischer Scientific EI9052 
cell culture dish 21 cm² Corning 430161 
cell culture dish 55 cm² Corning 430167 
cell culture flask 175 cm² Corning 431079 
cell culture flask 25 cm² Corning 430168 
cell culture flask 75 cm² Corning 430729 
cyrogenic vials 1.5 ml Thermo Fischer Scientific 5012 
Falcon 15 ml Corning 430791 
Falcon 50 ml Corning 430829 
Gel cassette Thermo Fischer Scientific NC20.15 
Gel loading tips Bioplastics B71932 
Hydrobond TM-C membreanes GE Healthcare  RPN203E 
ibidi microscopy plates ibidi 89626 
micro tubes 1.5 ml labomedic 115105 
micro tubes 2 ml Eppendorf 30119401 
micro tubes 5 ml labomedic 115106 
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microplate 384-well Epic plate Corning 5042 
microplate 384-well Greiner plate Greiner 784080 
Parafilm labomedic 1447011 
Pipette tips 10 µl labomedic 110.727 
Pipette tips 1000 µl Greiner 686290 
Pipette tips 200 µl labomedic 70.760.002 
Pipetting tip 10 ml Eppendorf 0030069463 
Pipetting tip 2.5 ml Eppendorf 0030069447 
Pipetting tip 25 ml Eppendorf 0030069390 
 
2.9. Labor Equipment  
Apparates Company Model 
Autoclave Systec Brunswick Scientific 3850 ELV 
Bacterial Incubator Buch+Holm HT-INFORS 
Cell Culture Bench Thermo Fischer Scientific Herasafe 
Cell Incubator CO2 Thermo Fischer Scientific HERAcell 240 
Centrifuge adjustable temperature Sigma-Aldrich 6K10 
Centrifuges for Eppis Eppendorf Mini spin 
Centrifuges for Falcons Eppendorf 5810 
Chamber for Cell counting  Brand Neubauer 
Fluorescence microscope (FM) Leica DM IL LED Fluo 
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FM Camera  Leica DFC 360 FX 
Freezer max. -20°C Liebherr comfort Liebherr 
Freezer max. -80°C Heraeus Herafreeze 
Heater for Eppis Grant Instruments QBT2 
Liquid nitrogen cell tank GermanCryo MVE-Tec 3000 
Microplate Reader for Bredford Tecan Sunrise-Basic 
Microplate Reader for HTRF®  Berthold Technologies Mithras LB940 
Microwave LG Intello Wave 
pH meter Mettler Toledo Seven Easy 
Pipette Assistent Accu-jet pro Brand 
Pipette automatic medium Rainin E4 XLS 20-200 μL 
Pipette automatic small Rainin E4 XLS 2-20 μL 
Pipette large Eppendorf 100 - 1000 µl 
Pipette medium Eppendorf 0.5 - 10 µl 
Pipette multi-channel Brand Transferpette-12 
Pipette small Eppendorf 10 - 100 µl 
Pipette stepper Eppendorf Multipette plus 
Precision Scale Sartorius TE6101 
Refrigerator 4-8°C Thermo Fischer Scientific 
Laboratory 
refrigerator 
Scale Sartorius TE64 
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Vacuum pump system HLC BioTech 
AP 15 Membrane 
Pump 
Vortexer Heidolph Reax Top 
Water purifier Millipore 
Milli Q Water 
system 
XCell II Blot Module Thermo Fischer Scientific EI0002 
XCell SureLock Thermo Fischer Scientific EI0002 
 
2.10. Software for Data Analysis 
Name Company Usage 
Adobe Acrobat Reader  DC Adobe Systems Inc. Data Research 
Epic Transform table to 
column macro Corning® Inc. data Configuration 
Citavi Swiss academic software Citation 
DeVision® G v1.0 Decon Science Tec GmbH Imaging 
Epic Autoalign Corning® Inc. Plate Alignment 
Epic Imager Corning® Inc. Trace Visualization 
GATC Viewer 1.0 GATC Biotech AG Sequencing 
Gel-Pro Analyzer Media Cybernetics, L.P. Blot Quantification 
Gelscan software V6.0 Bioscitech Gel Analysis 
GraphPad Prism6&7 GraphPad Software Inc Data Analysis 
Leica Application Suite 
3.3.1 Leica Microsystems Imaging 
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Mendeley Mendeley Ltd. Literature 
MikroWin® 2000 AdvII 
v4.41 Mikrotek Laborsysteme GmbH  Plate Reading 
Office Excel® 2010 Microsoft Corporation Data Analysis 
Office PowerPoint® 2010 Microsoft Corporation Scheme Configuration 
Office Word® 2010 Microsoft Corporation Text Configuration 
X-Flour4 Microsoft Tecan sunrise Plate Reading 
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Methods 
3.1 Cell culture protocols 
For all cell culture procedures whereupon the cells were kept in culture or were meant to 
be stored, working steps were performed under aseptic conditions using a sterile bench 
with integrated laminar air flow system. Benches were cleaned with 70% EtOH before 
use and additionally, the benches were irradiated with UV-light for 30 minutes on every 
working day. 
3.1.1. Freezing and Unfreezing Cells for Culturing or Storage 
Not all cell lines were used at the same time. To assure the durability of cells, the storage 
took place in liquid nitrogen tanks with -196°C. To revitalize frozen cell lines in purpose to 
in-cooperate them to the culturing procedure, medium was preheated in the water bath to 
37°C. Cryogenic vials containing cells from the nitrogen tank were quickly thawn and 
resuspended in warm medium. Cell suspension was centrifuged for 3 min Afterwards, 
medium was resorbed carefully, and cells were provided with new medium. Medium 
exchange after thawing is important, as the medium for freezing contains 10% DMSO. 
DMSO addition serves to prevent the formation of larger crystals in the medium, that 
would harm the intact cells. For cells under culture conditions DMSO in high 
concentrations is toxic and must be removed quickly. Thereafter cells were seeded into 
cell culture flasks.   
To utilize cells later, they were frozen in cryo-medium consisting of pure FCS 
supplemented, as already stated, with 10% DMSO. Therefore, cells were detached with 
trypsin and resuspended in growth medium. A centrifuging step followed for 3 minutes 
with 800 g. Afterwards the medium was removed, and the pellet was dissolved in 
approximately 3 ml cryo-medium for a 75 cm² culture flask with a confluency of 
approximately 80% to 90%. Next, 1 ml of the cell suspension was respectively transferred 
into 3 cryogenic vials, and immediately transferred in styrofoam boxes in the -80 freezer 
for 24 hrs before placing them into the liquid nitrogen tank. Direct freezing in the nitrogen 
tank would harm the cells, as the freezing rate is an important factor for crystal growth. 
Large crystals possibly could punctuate the cell membrane and destroy the cells. 
3.1.2. Cell Culture Conditions 
Cell lines were cultivated at 37°C in a moisture atmosphere with 5% CO2. All media were 
supplemented with penicillin (100Uml/1) and streptomycin (100 mg/ml). 5% FCS was 
added to MCDB 153 medium designed for low-serum growth while all other media were 
enriched with 10% FCS.  
 
3.1.3. Passaging and Harvesting Cells 
To prevent over-growth and to ensure a good cell viability cells were splitted one to two 
times a week depending on cell proliferation activity. And a new cell flask was used after 
at least 10 passages. 
First, old medium was aspirated, and cell ground was washed with 5 ml 1x PBS for 75 
cm² cell culture flasks. Then 2-3 ml trypsin-EDTA (0,05%) was added to detach the cells. 
Depending on the cell’s adhesion to the surface, the cells were incubated with trypsin for 
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2 min at room temperature or for stickier cells 2 min at 37°C. To stop trypsin reaction 8 ml 
of FCS supplemented medium were added to the detached cells. Cells then where either 
used for cell counting and were prepared for assays or simply passaged. For passaging 
cells were divided in a ratio of 1:2 up to 1:10 for fast dividing cells. After passage-
procedure was repeated over 80 times, new cells were thawn to ensure reproducible 
results.   
3.1.4. Cell counting 
The hemocytometer (Neubauer) was used for cell counting purpose. This hemocytometer 
possesses two counting chambers with a grid of 9 subdivisions. A glass cover was placed 
over the grid area. The distance between glass cover and chamber is 0.1 mm and 
created a defined volume space for 10 µl cell suspension. For the cell counting procedure 
cells were first detached and afterwards the suspension was diluted to a concentration 
between 250.000 and 2.500.000 cells/ml. Finally, 10 µl of the cell suspension was loaded 
with a micro-pipette to the chamber and at least tree squares were counted. The number 
of cells were averaged. To calculate the amount for 1 ml cell suspension, the cell number 
was multiplied by 104 and corrected by the dilution factor.  
 
3.1.5. Transfection of HEK293 cells with PEI  
All DNA-constructs used in the study were transfected transiently with plasmids into the 
host cells. All assays with these cells were performed 48 hrs post transfection. 
In a 6-well plate with a growing area of 9 cm² the following procedure was used: 
Cells were seeded 24 hrs before transfection to grow adherent. 
Preparation of 2 tubes:  
Tube 1: 1 µg DNA was added to 100µl PBS 
Tube 2: 3 µl PEI solution was added to 100µl PBS 
Both tubes were vortexed and tube 2 was added slowly to tube 1. Afterwards the tube-
mix was again vortexed and incubated at room temperature for 15 minutes. Transfection 
solution was dropwise added to the adherent growing cells at a density of approximately 
80%. 
In case, larger number of transfected cells were needed for the assays, cell were seeded 
either in 21 cm² or 55 cm² cell culture plates. The amount of ingredients then was 
extrapolated proportionally to the increased growing area.   
3.1.6. Poly-D-lysine coating 
For assays that require performance under adherent conditions, and that were carried out 
in a 96-well plate format, the plate was coated with PDL to enhance cell adhesion on the 
ground. Each well was coated with at least 50 µl of PDL solution under the sterile bench. 
Next, the plates were incubated for 1 hr at 37°C in the cell culture incubator. Afterwards, 
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the plates were washed with 1x PBS for two times and the liquid was removed by 
centrifuging the plates upside down. Before use, the plates were sterilized under UV light 
for 1 hr or stored at 4°C for a maximum of two weeks. 
 
3.2. Cell-based assays 
3.2.1 Homogenous time resolved fluorescence (HTRF®) cell-based assays 
HTRF®-technology is based on fluorescence resonance energy transfer technology 
(FRET). A FRET signal is generated when an energy donor is activated by excitation light 
and is in close proximity to its acceptor molecule. The special feature for this technique 
lies in the combination of FRET with a time resolved measurement. Therefore, 
lanthanides with a long half live emission are used as FRET donors. This method 
provides much higher sensitivity of the assay, as short life background noise of scattered 
excitation light or other disturbing fluorescent material in the sample, can be ignored. The 
FRET measurement is performed with a delay of 50 to 150 micro-seconds after excitation 
at two wave lengths, 620 nm (donor) and 665 nm (acceptor). A ratio between both 
measurements helps to correct well-to-well variability, as quenching trough disturbing 
compounds would occur at both weave lengths, and therefore should not affect the ratio. 
Thereby the donor emission serves as an internal reference signal and the acceptor 
signal provides information about the proximity of both molecules (Degorce et al. 2009). 
3.2.1.1. IP1 accumulation assay 
The HTRF®  IP1 assay takes advantage of LiCl addition, that prevents the last step in 
IP3 degradation, as it blocks dephosphorylation of IP1 and therefore leads to an 
accumulation of this second messenger (Zhang and Xie 2012). In this Cisbio designed 
competitive immuno assay, endogenously expressed IP1 and artificial D2-labeled IP1 
compete for the Tb3+-cryptate labeled IP1-antibody. The more IP1 is produced by the cell, 
the lower are the detectable FRET signals.  
IP1 accumulation was measured by using the above described HTRF® technology by 
Cisbio® by following the suspension cell-based assay protocol in 384-well greiner plates. 
First, cells were harvested and washed in 1x PBS. Then cells were centrifuged for 3 
minutes with 800 g and PBS was removed.  Afterwards, cells were resuspended in IP1 
stimulation assay buffer containing the LiCl. Next, 7 µl of the cell suspension was pipetted 
in each well followed by compound addition to a total volume of 14 µl. For basal IP1 
detection cells were incubated with 7µl FR 2x concentrated for 1 hr at 37°C. To expose 
inhibition of ligand-induced IP1 accumulation, FR was added in a 3.5 µl volume 3x and 
incubated for 1 hr, followed by an additional 30 minutes incubation step with desired 
ligand in 3.5 µl in a 4x concentration. Afterwards, 3 µl of IP1 d2 conjugate and 3 µl of anti-
IP1 Eu cryptate, dissolved in lysis buffer, were added. The plate was measured after 1 hr 
at room temperature with Mithras LB 940 Multimode Microplate Reader (BERTHOLD 
TECHNOLOGIES). The ratios were either normalized to an internal control or converted 
to IP1 in nM by using the kit’s standard curve and non-linear regression. Cell numbers 
were adjusted to the linear range of the assay kit as follows: Hcmel12 10kc/w; B16 
50kc/w; BRIM4 25kc/w; HEK293: 60kc/w; all UM cell lines: 10kc/w. In cases when assays 
were performed with multiple cell numbers, these are indicated in the respective figures. 
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3.2.1.1.2. IP1 accumulation assay wash-out experiment: 
To analyses drug vulnerability of the Gq-i FR and YM cells were incubated with 1 µM of 
the inhibitors for 1 hr in PBS solution. Afterwards cells were spun down for 3 min at 8,000 
g and the buffer was separated from the cell pellet. Next, the cell pellet was resuspended 
in fresh buffer and incubated for 5 min at room temperature. The procedure was repeated 
for 6 times. In the last step, cells were resuspended in IP1 stimulation buffer and 7 µl of 
the cell suspension was transferred into 384-well greiner plates. Subsequently the cells 
were treated with carbachol for 30 min before they were lysed and treated with antibodies 
as described in 3.2.1.1. 
 
3.2.1.2. HTRF®-based phospho-kinase ERK, YAP and AKT assays 
Compound-induced changes in phosphorylated fractions of proliferation activating 
proteins were quantified by using HTRF® technology (Cisbio) following the two-plate 
assay protocol for adherent cells in PDL-coated 96-well plates. This assay utilizes two 
antibody-binding sites on the protein surface at a short distance. These anti-bodies are 
labeled with d2 or Eu3+ cryptate to create FRET signaling.  
 
Total and phosphorylated protein amounts were measured from the same lysates.  
 
For optimizing the assay window cell density and starvation conditions were modified as 
follows:   
Total/pERK: HEK 40,000 cells/well, HCmel12 25,000 cells per well, B16 50,000 cells/well; 
Uveal melanoma cells 25,000 cells/well. Inhibition of basal ERK phosphorylation was 
detected without prior starving while cells were starved at least 4 hrs before stimulation 
with a receptor agonist.  
Total/pYAP: To ensure activation of the Hippo-pathway cells were starved over-night and 
were seeded in a high cell density (100,000 cells/well of HEK and 75,000 cells/well of UM 
cells) 
Total/pAKT: All cell lines were seeded to a density of 75,000 cells per well. Cells were not 
starved, and medium was changed 1 hr before compound addition to promote basal 
proliferation and cell survival pathway. 
Procedure for ERK and AKT assay: 
Cells were harvested and counted, and cell suspension was adjusted to the final 
concentration of required cells per 100 µl growth medium. Next 100 µl were seeded into 
96-well PDL coated assay plates 18 hrs before the assays were performed. On the next 
day the medium was exchanged for 40 µl of fresh medium, to create a growth friendly 
atmosphere. FR was added in 20 µl (3x) medium and incubated for 1 hr or in case of 
kinetic measurement for 15 min, 30 min, 1 hr and 2 hrs Afterwards, cells were either 
directly lysed or, for ligand-induced ERK or AKT phosphorylation, stimulated for another 3 
minutes with 20 µl of carbachol or with propionic acid dilution (4x). All incubation steps 
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were performed under cell culture conditions at 37°C. Thereafter, the adherent cells were 
lysed with 50 µl lysis buffer per well and the plate was incubated at room temperature 
while shaking for at least 1 hr. Next, 16 µl of the lysates were transferred for detection of 
phosphorylated and another 16 µl for total protein amounts into 384-greiner plates. To 
avoid an overflow of the anti-bodies in the following step, the plate was centrifuged 
shortly before 4 µl freshly mixed D2 and Cryptate anti-body-mix was added to the wells. 
To protect the probes from light exposure, the plates were covered in aluminum folio over 
night before the homogenous time resolved FRET signal was detected by using Mithras 
LB 940 multiplate reader according to manufacturer’s instruction. HTRF® ratios were 
either normalized to internal assay control or shown as raw data. 
Procedure for YAP assay: 
Four hours after cells were seeded in 50 µl into the 96-well plates and the cells were 
attached to the PDL-coated ground the growth medium was exchanged for 50 µl medium 
lacking FCS. The cells were starved over-night and on the next day compounds were 
added in 25 µl (3x) and FR and forskolin were incubated for 1 hr, or in case of kinetic 
measurement for 15 min, 30 min, 1 hr and 2 hrs Next cells were lysed, and lysates were 
handled analog to the ERK and AKT assay. 
3.2.2. Cell Imaging 
A portray of cell morphological changes or cell density under different treatment 
conditions on adherent cells were taken by Leica DFC 360FX microscopy. 
3.2.2.1. Imaging of HCmel12 cells after 72 hrs of FR treatment 
HCmel12 cells were seeded in a density of 30,000 cells per well in a PDL-coated 6-well 
cell culture plate in 2 ml growth medium. FR and vehicle control were added three hours 
later in 1 ml medium solution (3x), and cells were incubated for three days under cell 
culture conditions.  
3.2.2.2. Imaging of UM cell density after 72 hrs of FR, LY or trametinib treatment 
To capture antiproliferative effects of vehicle control, FR, PI3K-i LY and trametinib on 
uveal melanoma cells, the cells were seeded at the density of 15,000 cells per well for 
92.1 and Mel285 and at the density of 30,000 cells per well for Mel270, Mel290, Mel202 
and OMM1.3, in 100 µl RPMI medium on 96-well ibidi® plates for high resolution 
microscopy coated with PDL. Three hrs after seeding the cells the compounds were 
added in 100 µl medium and the plates were placed for another 72 hrs into the incubator 
under cell culture conditions. Afterwards, cells were fixed with 4% PFA for 20 min at room 
temperature and washed twice with PBS. Images were taken by Leica DFC 360FX 
microscopy.  
3.2.2.3. Imaging of anti-proliferative effects of the Gq-i FR and YM in a head-to-head 
experiment 
Mel270 UM cells were seeded in 2 ml growth medium at a density of 200,000 cells per 
well in a PDL-coated 6-well plate. 500 µl FR, YM or vehicle, in a final concentration of 10 
µM, were added and incubated for 1 hr. Afterwards the medium was removed, and the 
Methods 
42 
 
cell ground was washed with 1x PBS. Next, new medium was applied to the cells and 
microscopic pictures were taken after 4 and 6 days.  
3.2.3. gp100 protein detection via western blot  
3.2.3.1. Cell treatment: 
HCmel12 cells were seeded in 6 cm petri dishes to reach 80% confluence on day 3. Five 
hours after seeding, cells were treated with FR in 10 nM, trametinib in 1 µM or vehicle 
control (DMSO). Cells were then lysed to perform Western Blot analysis for gp100 
expression.  
3.2.3.2. Cell lysates: 
To analyze gp100 protein expression in HCmel12 cells, the medium was aspirated, and 
the cell layer was washed with cold 1x PBS. Ice cold lysis buffer supplemented with 
protease cocktail inhibitor was added in the following step. Thereafter, the cell 
suspension in lysis buffer was transferred into 1.5 ml tubes that were directly placed on a 
shaker at 4°C. Finally, the tubes were centrifuged at 15,000 g at 4 °C for 10 min and the 
supernatant was used to determine the protein concentration. 
 
3.2.3.3. Determination of the protein content of lysates 
To ensure that equal amounts of protein lysates were used for each sample in the 
western blot analysis the concentration of the protein lysates was determined with the 
Pierce BCA Assays Kit using a BSA standard curve from 0 µg/µl to 10 µg/µl. Thereby, 
200 µl of protein detection reagent was added to each sample and incubated for at least 
30 min at 37°C. Afterwards, the absorbance was measured at 560 nm and the 
concentration was determined by using the standard curve. 
 
3.2.3.4. SDS-Gel electrophoresis and blotting 
The protein amount of the samples was detected by 10% SDS gel electrophoresis. 10 µg 
total protein was mixed together with NuPage reducing agent and sample buffer to a 1-
fold end concentration. Next, 500 µl of NuPage antioxidant was added to the chamber 
filled with running buffer. The samples were pipetted to the gel wells. To define protein 
size 2.5 µl Magic Marker and 5 µl Kaleidoscope Standard were used. The probes were 
separated over 3 hrs at 60 V. Thereafter, the gel was blotted on a nitrocellulose 
membrane for 2 hrs at 25 V in NuPage transfer buffer. Blotted membranes then were 
rinsed in PBS supplemented with 0.1% Tween-20. To minimize unspecific binding of the 
antibodies, membranes were treated with Roti-Block for 1 hr at room temperature before 
primary antibodies were incubated overnight in Roti-Block. Thereby gp100 was diluted in 
a ratio of 1:5,000 and actin was diluted in a ratio of 1:2,500. On the next day the 
membranes were washed and incubated for 1 hr with anti-mouse secondary antibody 
diluted 1:10,000 in Roti-Block. Finally, the separated protein fractions were visualized by 
using the chemiluminescence-based blotting detection reagent Amersham ECL Prime 
Western. Pictures of the blots were used to quantify the amounts using the Gelscan 
software. Actin served as the internal standard to normalize the amount of gp100 in the 
different treated samples. 
Methods 
43 
 
 
3.2.4. Dynamic mass redistribution 
Whole cell response upon Gq-inhibition was monitored by using the label-free 
measurement of real time mass redistribution taking advance of the Epic® System 
developed by Corning®. This highly sensitive method allows visualizing a whole cell 
response upon ligand stimulation of certain proteins in or on the cells. Thereby, the 
activation or inhibition of proteins cause changes in the cellular signaling that triggers re-
localization of cellular compartments  (Schröder et al. 2010). To detect these dynamic 
redistribution processes within the cell, the cells are grown in an mono-layer on a 
transparent cell culture plate with integrated biosensor at the bottom (Lee et al. 2008). 
Here the bottom is exposed to polarized brightfield light. The reflection of these light rays 
is dependent on the optical density of the cells within the first 150 nm from the biosensor. 
Compounds that causes rearrangement of mass in the cell, affect the density. Thereby 
shifts of the reflecting light in pm are translated into optical traces (Schröder et al. 2010). 
 
3.2.4.1. DMR procedure 
Transfected CRISPR-Cas9 Gαq/11 ko cells and non-transfected UM cell lines were 
harvested and seeded in 30 µl growth medium at in the density of 15,000 cells per well 24 
hrs before detection into fibronectin coated 384-well sensor microplates. The cell 
suspension was spun down shortly, and the plate was placed over night in the cell culture 
incubator. On the next day the medium was removed, and the cells were washed with 
HBSS buffer supplemented with 20 mM HEPES and adjusted with the respective DMSO 
concentration that is used at the application-step during the assay. This DMSO-
adjustment is important as many compounds are dissolved in DMSO, but DMSO itself 
can cause huge traces. In the final washing-step 30 µl were left in the wells and the plate 
was positioned on the reader for 1 hr This resting time is implemented before starting the 
experiment to let the cells equilibrate as mechanical stress during washing can negatively 
impact the results. All steps, expect washing, were performed under 37°C, as the reader 
itself is also placed in an incubator.  
During the resting time compounds are prepared and 25 µl were transferred into 
compound plates. Then the liquids were spun down. As DMR is very sensitive to 
temperature the compound plate with a lid was placed in the incubator for at least 15 
minutes before 10 µl were mechanically added to the plate by using the automatic 
pipetting system Selma (CyBi). 
Before the measurement was started, the cell layer within the plates was aligned with the 
Epic aligner tool. Then the optical traces were recorded with the Epic Imager tool. Shifts 
of the reflected light upon compound addition were measured over 3600 sec, thereby 
every 30 sec new data were collected. After the measurement the data were transformed 
into Excel sheets by using the option ‘Transform table to column’ of the software. 
To subtract the mechanical impact on cells due to compound addition, all traces were 
baseline-corrected by the traces caused by buffer addition. 
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To quantify basal FR effects the AUC of negative DMR traces were calculated for 1 hr 
and normalized on the maximal response. For FR effects on ligand-induced traces the 
AUC was evaluated for positive DMR for the same time frame. 
 
3.4. Microbiological protocols 
 
3.4.1. LB plates for bacterial growth 
To prepare plates for bacterial growth, Luria Bertani agar was heathen in the microwave 
till it was completely liquified. Ampicillin was added in 100 µg/ml for colony selection. To 
avoid degradation of the antibiotics the LB Medium was prior cooled down to 60°C. 
Afterwards, approximately 8 ml were added in 55 cm² plates and stored upside down at 
4°C until used. 
 
3.4.2. Transformation of plasmid DNA 
DH5-α E. coli cells were used for plasmid amplification. Therefore, tubes containing 100 
µl of competent cells were taken from the -80°C freezer and were thawn on ice before 
approximately 20 to 50 ng plasmid DNA was added to the tubes. To ensure that the 
bacterial cells were permeable for transformation, the cells were heat shocked. After 30 
min of incubation on ice with the DNA the tubes were placed on a heat block, that was set 
to 42°C, for 90 seconds and placed immediately afterwards back on ice. Subsequently 
500 µl of LB medium were applied to the bacterial cell solution and incubated while 
shaking at 37°C for 1 hr 100µl of bacterial suspension was plated on the LB covered 
dishes with selective antibiotic. The plates were placed up-side down into the incubator 
overnight and on the next day a colony was picked. 
 
3.4.2. Plasmid DNA extraction 
After transformation a colony was picked and grown in 5 mL LB medium overnight on a 
shaker at 37°C. On the next day the LB medium was removed by using a centrifuge and 
the amplified plasmid DNA from competent cells was isolated with the innuPREP Plasmid 
DNA Midi kit following the protocol for high copy plasmids. Thereby, the cells were lysed, 
and the plasmid were isolated by column chromatography. The column was washed to 
purify the DNA with washing buffer and finally the DNA was eluted by using elution buffer. 
The DNA was precipitated with pure isopropanol and the pellet was spun down. Next the 
DNA was washed with small amount of 70% EtOH and afterwards air dried under the 
bacterial bench. When the DNA was completely dried, the pellet was resuspended in 
DNAse-free pure water and stored at -20°C. 
 
3.4.3. Determination of DNA concentration 
DNA concentration and purity were detected by using a UV-spectrometer. The 
concentration of the DNA sample diluted in water was determined at 260 nm by using the 
following formula: 
C [µg/ml]: OD260nm x D x 50 
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OD: optical density; D: dilution factor 
Additionally, the purity was determined by measuring the absorbance at 280 nm. The 
ratio of the optical density at 280 nm to 260 nm should be between 1.6 and 2 for good 
quality. 
 
 
3.4.4. Site directed mutagenesis 
Amino acid substitutions to create GTPase-deficient Gαq versions GαqQ209L and  GαqR183C 
(Kalinec et al. 1992) or loss of Gαq inhibitor-function (Nishimura et al. 2010) were 
introduced by site-directed mutagenesis (Zheng et al. 2004). This method requires single 
stranded DNA as template. Optimally, the plasmid DNA was obtained from an E.coli 
source, that produce Dam-methylated DNA, that can be used to digest the template after 
the product is produced by PCR (Mierzejewska et al. 2014). We used pcDNA3.1+ that 
was amplified in E. coli strain DH5α. The target mutation was introduced by the primers 
that include the desired modification in the nucleotide sequence. Primers where either 
designed using the bioinformatic primer design tool PrimerX or manually by following a 
non-overlapping primer design protocol (Zheng et al. 2004). The polymerase chain 
reaction was performed using the Pfu-polymerase for higher precision in a thermo-cycler. 
Proof-reading ability of Pfu allowed very small amounts of starting DNA, due to high 
efficiency and low incidences of random mutations. 
Used primer sequences can be found in the material section 
 
 
3.4.4.1. Mutagenesis PCR 
A master mixed was prepared on ice and a negative no-template (nT) control was 
implemented to each reaction performance as follows: 
 
 
Components Volume (µl) 
Template (water for nT control) 1  
Primer mix 2  
DMSO 2.5  
dNTP 1 of 10 mM 
DNase free-water 37.5  
Methods 
46 
 
Reaction buffer 5  
Pfu-polymerase 1 
 
The Pfu-polymerase was added directly before placing the samples in the thermo-cycler. 
The thermo-cycler was programmed as follows: 
Steps Temperature (°C) Time (s) 
Initial denaturation 95 120 
Denaturation 95 50 
Annealing 60 50                       17 x cycles 
Elongation 72 480 
Storage 4 Until use 
 
3.4.4.2. Digestion of template DNA 
To digest the template 1 µl of digestion enzyme DpnI was added to each reaction tube. 
The mixture was vortexed shortly and centrifuged afterwards. Subsequently, the tubes 
were incubated for at least 1 hr at 37°C. Finally, the DNA was either stored at -20°C or 
amplified by transformation. 
 
3.4.5. Sequencing for mutation c. G1888T (p. D630Y) in PLCß4 in Mel290 
cells 
To verify the presence or absence of the hot-spot activation mutation G→T in PLCB4 
gene at G1888 in the uveal melanoma cell line 290 we amplified a 240 bp long segment 
of the DNA including the region. Therefore, we extracted the DNA and amplifies the 
region of interest by PCR. Afterwards, we send the extracted DNA for sequencing. 
3.4.5.1. DNA extraction 
The DNA was extracted using innuPREP DNA Mini Kit (Analytik Jena) following protocol 
#4 for DNA extraction form cell culture. Therefore, we harvested 3x106 cells of Mel290. 
The cells were spun down, and the cell pellet was washed with PBS. Then, the cells were 
centrifuged at 5,000 g for 10 min and the supernatant was discharged. Next, the cells 
were lysed, and the DNA was separated chromatographically. To purify the DNA the 
column was washed and finally the DNA was.  
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3.4.5.2. Amplification of DNA fragment 
Forward and reverse primers were designed to frame the region of interest. Shown is the 
exon that encodes pD630. The exon is marked in red embedded in non-marked intron 
sequence (figure M1).  Region in Sequence with Introns (Exons red) source Ensembl!.  
CCATGGCAGCTGTGACAATCTGCCCAAATGAAAATTGTTTTTATAATCCACACAGTGAAC 
TGTGATCTTAAGCATCATTTGTAAATGTGAAATCTGCTCTGTGCTGTCTACTTGTTTGTC 
ATTGTTGGCCTAGACCTTTGTTGTTTTAGCTCTTTGTTGTTTATTTTTCTCTGCTGTAGG 
ACTCTTTTTTTCTGTTTTCCTTAATAAGTTACAGTTATAACAAACGGCAAATGAGTCGCA 
TTTACCCCAAGGGAGGCCGAGTCGATTCCAGTAATTACATGCCTCAGATTTTCTGGAACG 
CTGGCTGCCAGATGGTTTCACTGAACTATCAAACCCCAGGTAGGAGCTGATGTCCAGTGA 
CCCCAAATTCCATGAGAACACTTTGACAGGATGGTGCCAGCACTTCCCATCAGTTGGCTG 
TGGGCATTTTTTAAAGGAAGCAGACATATGGCAAAGCAATGTGTTATTGGATTTATATAA 
TGGTGAGAAATAAAAAAAAAAAAACCAAAATAGAGCAAACAATGGTAGAAGATAATGTGT 
TGTGATTGGAATTTAATTCCTTTCATAAATGCCATGACTATTCCTGCTAACCATTATCCC 
ATATTCCAAAATATTTCTCATTTTTCTTCCTTTTGGATCAAAGTTGTTATCTTTGTTTCC 
Primers are marked in grey, marked thereby reverse primer was reversed and 
complemented to perform PCR; amino acid of interest is marked in blue G1888.  
The polymerase reaction was performed by using GoTaq polymerase enzyme and 
reaction buffer. 
 
Components Amounts 
Template 0.5 µg 
primer sense 0.5 µM  
primer antisense 0.5 µM  
dNTP 1 µl of 10 mM 
GoTaq G2 Polymerase  0.25 µl  
Reaction buffer 10 µl 
DNase free-water Ad 50 µl 
 
The thermo-cycler was programmed as follows: 
Figure M1: Sequence of PLB4 
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Steps Temperature (°C) Time (s) 
Initial denaturation 95 120 
Denaturation 95 30 
Annealing 52 30                  40 x cycles 
Elongation 68 15 
Final extension 68 300 
 
3.4.5.3. DNA separation by agarose gel-electrophoresis 
To separate the PCR product the from the genomic DNA, the sample was separated by 
agarose gel electrophorese. Here the negatively charged backbone moves towards a 
positive charged anode in an electric field. Thereby the size of the DNA fragments is 
crucial for the velocity.  
To prepare the gel agarose was dissolved under heat exposure in 1x TAE buffer to a final 
concentration of 5 %. Next, 2.5 mg/ml ethidium bromide to visualize the DNA fragments 
under UV light were added. The solution was poured into the chamber form and a comb 
to form wells was inserted. After the gel stiffened it was placed into an electrophoresis 
chamber and the wells were loaded with the sample a no-template control and a 100 bp 
ladder to determine the band sizes. Finally, the gel was run for 20 minutes at 100 V.  
 
3.4.5.4. DNA Gelextraction 
The expected DNA length was 264 bp and could be detected under UV light.  
 
 
 
Figure M2: PLCB4 PCR product. 
Band size 264bp  
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The innuPREP Gel Extraction Kit was used to extract the DNA product from the gel for 
sequencing purpose. Therefore, the band was cut out of the gel under UV light and 300 
mg of the gel was solubilized with the kit’s lysis buffer. The DNA was extracted from the 
solution by a chromatographic column and after separation, the prob was send to GATC-
sequencing. 
3.5. Data analysis 
To analyze the obtained data we made use of the Prism 7 and Excel software. Dots and 
bars, if not states otherwise, represent the mean of n indicated experiments with s.e.m. 
Concentration-response or -inhibition curves were obtained by non-linear regression with 
4 parameters. Quantification of DMR traces was succeeded by calculating the area under 
the curve for restricted areas and defined duration. For statistical analysis unpaired t-test 
or, in case that the values were compared to a 100 % reference, a one-sample t-test was 
used. IC50 values were attained by non-linear regression. Significance levels were set as 
follows: *P<0.05 was considered significant, **P<0.01 very significant, and ***P<0.001 
extremely significant.  
  
Methods 
50 
 
  
Results 
51 
 
Results 
4.1. FR inhibits canonical wild type Gαq but not GTPase-deficient 
GαqQ209L signaling in HEK cells  
FR has been characterized as a specific Gq/11/14 inhibitor with high potency. The 
molecule binds to the alpha subunit of the heterotrimer to prevent receptor initiated 
interdomain movement (Schrage et al. 2015). If this movement is impaired, GDP release 
and, as a consequence, GTP entry cannot take place (Nishimura et al. 2010). Activation 
of further signaling cascades is inhibited as GTP is unable to cause structural 
rearrangements within the G alpha subunit to cause dissociation of the βγ-heterodimer 
from the α-subunit (Oldham and Hamm 2008). Ostensibly clear, targeting a GTPase-
deficient Gα subunit with an inhibitor that prevents GDP dissociation was thought to be 
ineffective (Nishimura et al. 2010; Takasaki et al. 2004; Kimple et al. 2011). This 
assumption was made, as the GTPase-deficiency within the Gα-subunit has been 
reported to trap the protein in the activated GTP-bound state (Kleuss et al. 1994) and 
therefore, inhibition of GDP dissociation consequently would be pointless. In line with this 
hypothesis, FR did not blunt basal IP1 accumulation in immortalized HEK293 cells 
transfected with GαqQ209L fully, while inhibition was easily achieved in cells transfected 
with even higher amounts of the Gαqwt (figure 11). As a caveat, inhibitor effects are 
potentially confounded in the HEK cell system by the activity levels of Gq and G11 
proteins which are endogenously expressed in the cells.  
 
Figure 11: Gq inhibitor FR lacks capability for complete inhibition of GαqQ209L-
induced IP1 accumulation.  
HEK293 cells transiently transfected with 1.5 µg/21 cm² wild type or 0.2 µg/21cm² GαqQ209L or 
vector. 30 kc/w were incubated with stated concentration of FR for 2 hrs. Bars represent the 
means with error bars indicating s.e.m. of 3 independent experiments. 
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4.2. FR blunts mitogenic signaling in cutaneous melanoma cells 
with activated Gq/11 
Astonishing results were reported by Tanja Slodczyk in her doctoral thesis. She found 
that FR was able to blunt typical oncogenic markers in HCmel12 mouse melanoma cells 
harboring the Gα11 protein with a point mutation on this activating hot spot residue Q209. 
In her thesis she could show that cell growth as well as metabolic activity was highly 
reduced when the cells were treated with the Gq inhibitor FR. While most other 
antitumoral agents reduce cell growth in a cytotoxic manner, FR did not trigger the 
number of apoptotic cells compared to control. Instead, inhibition of cell growth was 
linked to enhanced cell number in the G1 phase of the cell cycle and therefore, reduced 
number in the other cell cycle phases. Higher fractions of the cells in the G1 phase, 
indicates differentiation (Tanja Alten 2017). 
4.2.1. FR forces HCmel12 cells into differentiation and blunts pERK over 
PLC signaling 
Differentiation in cutaneous melanoma cells is associated with higher pigmentation and 
enlarged cell shape. Thus, we could confirm these phenotypic changes using light 
microscopy images (figure 12A). The cells seemed flatter and darker in the FR treated 
group versus cells treated with vehicle control only. 
Gp100 belongs to the group of melanocyte differentiation antigens (MDA) that are 
upregulated at the stage of differentiation. This MDA plays an important role in the 
polymerization of melanin and the genesis of melanocytes (Pitcovski et al. 2017). 
Treatment of the HCmel12 cells with FR or the MEK inhibitor trametinib resulted in a 
significant increase of gp100 expression (figure 12Bi, Bii). Subsequent to these findings, 
we took a closer look into Gq related signaling cascades in these cells. Initially, we 
verified activated Gα11 tonus by measuring IP1 accumulation. Gα11 was found to be 
intrinsically active, as we detected approximately proportionally increased IP1 production 
by elevating cell numbers without any agonist stimulation (figure 12C). 
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Figure 12: FR suppresses downstream pro-survival but not canonical PLC 
signaling pathway of oncogenic Gα11Q209L in the mouse melanoma cell line 
HCmel12. 
Cell morphological changes captured by brightfield microscopy imaging after 72 hrs incubation 
with either FR 10 nM or vehicle control. Scale bar represents the length of 5 µm (A). Images were 
kindly provided by Julian Patt (AG Kostenis, University of Bonn). (B) Representative western blot 
detection (Bi) and quantification (n=4) using β-actin as standard (Bii) of cells preincubated with FR 
10 nM, MEK-i trametinib 1 µM or vehicle control for 72 hrs before lysis. Western blots were done 
by Eva Pfeil University of Bonn (lab of Evi Kostenis). Basal IP1 tonus measured after 1 hr 
incubation in buffer containing LiCl to prevent degradation and to initiate accumulation for 
increasing cell numbers as stated (5 kc/w n=4; 10 & 20 kc/w n=6; 50 kc/w n=2) (C). Inhibition 
potency of FR measured after 1 hr incubation for adherent cells in medium (ERK) or for cells in 
LiCl assay-buffer suspension (IP1). Protein levels were detected with HTRF anti-bodies for either 
phospho-ERK (n=7), total-ERK (n=3) or IP1 (n=7) (D). (Bii-D) bars or dots represent the means 
with s.e.m. of n independent experiments. Bii) Significant effect to buffer was calculated by one-
sample t-test. 
 
In accordance to so far published data (Xiong et al. 2016) and our own data (figure 11) in 
HEK293 cells, IP1 accumulation triggered by the oncogenic G11 protein was affected 
only at very high FR concentrations. In contrast, inhibition of phosphorylation of the 
proliferation promoting protein ERK was completely blunted by FR at low nanomolar 
concentrations. Simultaneously, FR did not affect the amount of total ERK proteins 
(figure 12D). 
4.2.2. Mitogenic signaling and IP1 accumulation may not share the same 
upstream regulator 
Both, pERK and IP1 production are reported to share the same Gq-dependent upstream 
signaling regulator PLCβ (Gutkind 2000). Interestingly, only ERK signaling was FR 
sensitive. Whereas, IP1 accumulation was only inhibited to a very small degree in 
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HCmel12 cells with even much higher inhibitor concentrations. Provided that ERK 
phosphorylation occurs as downstream event of PLCβ activation in this cell line, 
theoretically, IP1 accumulation should be blunted in a similar concentration range as ERK 
phosphorylation. To further investigate this discrepancy, we tried to prevent ERK 
signaling by blocking PLC signaling. For this purpose, we used the widely known PLC 
inhibitor U73122 (Bleasdale et al. 1990). Specificity of U73122 has been questioned, as 
the molecule was additionally shown to inhibit calcium channels (Macmillan and 
McCarron 2010) and was even reported to function as an activator on purified PLCs 
(Klein et al. 2011). Hence, we included the non-functional but structurally very closely 
related molecule U73343 (Bleasdale et al. 1990) to distinguish between specific and 
unspecific effects.  
As predicted by literature (Vaqué et al. 2012), U73122 inhibited ERK phosphorylation in a 
concentration-dependent manner. But, biological relevance of these results remained 
uncertain, as the non-active analog also depressed activation of the protein (figure 13A). 
Thus, we chose to focus on PKC as a chain link between PLCβ and ERK activation 
(Gutkind 2000). Pan PKC inhibitor Gö 6983 (Gschwendt et al. 1998) was able to abolish 
ERK phosphorylation completely. Interestingly, the same effect was not observed with the 
selective PKC inhibitor Gö 6976, which targets the Ca2+-dependent PKC isoforms α and 
β, that are often related as downstream effectors of PLC (Martiny-Baron et al. 1993), 
retaining the possibility of PLC-independent PKCs to be additionally involved in the Gq/11 
mediated ERK1/2 phosphorylation in HCmel12 cells (figure 13B).  
 
 
Figure 13: Inhibition of basal ERK phosphorylation in HCmel12 cells by targeting 
various Gq-downstream effectors. 
Intrinsic HCmel12 pERK levels after 2 hrs incubation with U73122 or U73122 (n=4-6) in the 
indicated concentrations (A) or with selective α/βPKC-i Gö 6976 1 µM (n=6) and pan-PKC-i10 µM 
(n=3) (B) or fasudil in the indicated concentrations (n=3-5) (C). MEK-i trametinib was used as 
control in 1 µM (A-C). Dots and bars represent mean with s.e.m. of n independent experiment 
days. All experiments were performed with adherent cells using a density of 25 kc/w in PDL-
coated 96-well plates. 
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Another hint for the involvement of multiple Gq/11 effectors in ERK phosphorylation was 
achieved with the Rho-kinase inhibitor fasudil (Ying et al. 2006). RhoA was reported to be 
activated by the direct Gq effector family of the RhoGEFs (Rojas et al. 2007; Vaqué et al. 
2012). Fasudil reduced the fraction of phosphorylated ERK protein by approx. 60-70% 
(figure 13C). This is not a surprise, as RhoA was demonstrated to enhance cell cycle 
progression and increasing cyclin D1 expression by constant activation of ERK (Etienne-
Manneville and Hall 2002). However, high concentrations were needed for detectable 
effects and therefore specificity of these effects can be questioned.  
These findings further underline the hypothesis that mechanism of Gq-regulated 
MAPK-signaling activation is quite complex and may not be as straight forward like the 
often described Gq-PLC-PKC-RAF-MEK-ERK (Gutkind 2000) pathway. 
 
4.2.3. ERK phosphorylation is insensitive to FR in cutaneous melanoma 
cells with mutated B-Raf 
Next, we looked for another cutaneous melanoma cell line, the BRIM4 with a mutated 
GαqQ209P protein. In addition to the mutation on this hot spot residue of the Gq protein, 
these cells harbor a mutation in B-RafV600E. B-Raf is a common proto-oncogene known to 
drive proliferation by permanent ERK activation. Mutations in B-Raf or N-Ras are typically 
found in this type of cancer (Gray-Schopfer et al. 2005). Substitution of valine on position 
600 in the amino acid sequence to glutamic acid is the most common mutation in the B-
Raf protein. This amino acid substitution enhances the enzyme’s catalytic properties and 
thereby increases mitogenic signaling by MEK-ERK activation (Rubinstein et al. 2010). 
This cell line was very interesting to investigate FR’s potential to diminish mitogenic ERK 
signaling in a system, where ERK phosphorylation is not exclusively driven by the 
constitutive activity of the Gq protein. 
Again, we first confirmed constitutive activity of the Gq protein by measuring PLC activity 
by IP1 accumulation assays, as the canonical effector protein of Gq. Massive IP1 
accumulation was observed even by low cell numbers. Furthermore, IP1 production 
correlated with increased cell numbers (figure 14A). Consistent with the results obtained 
by the HCmel12 cells, treatment of BRIM4 cells with FR led only to moderate inhibition of 
IP1 accumulation, as 1 µM FR could only depress 50% of the elevated basal IP1 
production. But in these cells ERK phosphorylation was only impaired to a small degree 
(figure 14B) suggesting that Gq/11 is unlikely to be the main ERK driver in these cells. 
Rather the mutated B-Raf protein is suspected for MAPK-pathway initiation. This 
hypothesis is supported by the fact that ERK signaling was highly sensitive to the 
selective mutant B-RafV600E inhibitor vemurafenib (Kim and Cohen 2016) (figure 14C).  
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4.2.4. Preferential inhibition of pERK over PLC by FR is a characteristic 
feature for cells harboring a GTPase-deficient mutant 
To test, whether preferential inhibition of the ERK signaling cascade over canonical PLC 
is a general occurrence, or if it is strictly related to GTPase-deficient mutants, we 
examined these pathways in the mouse cutaneous melanoma cell line B16 that is wild 
type for Gq-family proteins (Schrage et al. 2015).  
B16 cells showed high basal IP1 levels compared to other cutaneous melanoma cell lines 
such as Skmel28 and Mamel19 with wild type Gq/11 proteins, indicating intrinsic Gq 
activity (figure 15A). Elevated Gq activity can arise for many more reasons than 
malfunction of the GTPase domain. High Gq tonus might be explained e.g. by 
constitutively active receptors (Moore et al. 2016) or a receptor cross talk of autocrine-
activatable tyrosine receptor kinases that transactivate GPCRs (Garcia-Recio et al. 
2013).  
In accordance to FR’s mode of action as a GDI that prevents the initial activation of the 
protein and therefore should preclude signaling of all downstream cascades, FR inhibited 
pERK as well as IP1 accumulation in a very sensitive manner. Direct comparison 
between the inhibition of these pathways exposed ERK phosphorylation to be slightly 
more sensitive (figure 15B). Additionally, we confirmed that FR did not impact total 
amount of ERK proteins (figure 15C). However, the difference between pathway 
sensitivity was by far less pronounced as compared with the HCmel12 cell line.  
These results only reflected the inhibition behavior of permanent intrinsic Gq activity. To 
further confirm, whether ligand-induced signaling could be blocked in the same manner, 
we stimulated either HEK293 cells, which endogenously express the muscarinic receptor 
Figure 14: FR partly attenuates pERK in melanoma cells with additional B-Raf 
mutation. 
Basal IP1 tonus measured after 1 hr incubation in stimulation buffer containing LiCl using 10 and 
25 kc/w (n=3) (A). 10 & 20 kc/w n=6; 50 kc/w n=2). FR inhibition curve measured after 1 hr 
incubation for adherent cells in medium (ERK) or for cells in LiCl assay-buffer suspension (IP1). 
pERK or IP1 levels were detected with HTRF anti-bodies for either phospho-ERK (n=3) or IP1 
(n=4) (B). ERK phosphorylation after pretreatment with FR in 100 nM, or vemurafenib in 1 µM or 
the combination of both, or trametinib 1 µM (n=3) (C). Dots and bars represent mean with s.e.m. of 
n independent biological replicates. All experiments were performed using 25 kc/w in PDL-coated 
96-well plates for ERK and 384-well format for IP1. 
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M3 with carbachol (figure 15D) or HEK293 cells stably expressing the FFA2 receptor 
with the receptor ligand propionic acid (figure 15E). As expected, in both cases Gq-PCR 
stimulated IP1 and ERK phosphorylation were perfectly inhibited. Again, FR did neither 
enhance nor degrade the total amount of ERK proteins (figure 15F). The huge 
discrepancy between PLCβ and ERK inhibition potency of FR seemed to be an exclusive 
hallmark for the GTPase-deficient mutant. 
 
 
 
 
 
 
 
 
4.3. FR directly interacts with mutated GαqQ209L 
To further proof FR interaction with the GTPase-deficient analog of the Gαq protein we 
took advantage of HEK cells lacking Gαq and Gα11 proteins engineered by CRISPR Cas9 
technologies. These cells offer the possibility to truly discriminate between the different 
constructs in a perfectly clean background, whereas in the melanoma cell-background 
one of these proteins would always be un-mutated as GNAQ/GNA11 are mutually 
exclusive (van Raamsdonk et al. 2009). Transfection to non-genome edited HEK293 cells 
Figure 15: FR inhibits canonical and mutagenic signaling driven by wild type Gq/11. 
Basal IP1 tonus of different cutaneous melanoma cell lines measured after 1 hr incubation in 
stimulation buffer containing LiCl using 10 and 50 kc/w (n=3) (A). Inhibition potency of FR on B16 
mouse melanoma cells measured after 1 hr incubation for adherent cells in medium (ERK; n=4) or 
for cells suspended in LiCl assay-buffer (IP1; n=3) (B). Total ERK levels of B16 cells after 1 hr FR 
incubation in concentration as indicated and trametinib 1 µM (n=3) (C). Ligand-induced inhibition of 
pERK (n=6) and IP1 (n=4) accumulation in HEK cells endogenously expressing M3-muscarinic 
receptor (D) or stably transfected with FFA2 receptor (E). Cells were preincubated for 1 hr with FR. 
Receptor agonists were incubated for 3 min for pERK and 30 min for IP1 in following 
concentrations: 30 µM CCh (D) or 1 mM C3 (E). FR effect on total ERK protein in HEK293 cells 
after 1 hr incubation of FR as indicated in the figure and trametinib 1 µM (F). Dots and bars 
represent mean with s.e.m. of n independent experiments (A-F). 
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would as well not be the perfect option, as HEK293 cells endogenously express Gαq and 
Gα11 proteins (Atwood et al. 2011).  
4.3.1. FR blunts wild type but not GTPase-deficient activation of canonical 
PLC signaling 
Upon transfection of the plasmids into the HEK293Gαq/11-null cell system, the expression of 
both constructs was verified by measuring IP1 generation as readout of the canonical 
Gq-effector PLCβ. Cells expressing either wild type or QL-mutant variation of the Gαq 
showed elevated basal IP1 levels compared to cells treated with vector control (figure 
16A). While non-genome edited HEK293 cells showed much higher IP1 levels with the 
GTPase-deficient mutant (figure 16B), the difference between wild type and QL was not 
significant in the HEK293Gαq/11-null cells (figure 16A). 
 
 
Figure 16: Transiently expressed Gαq wt and mutated GαqQ209L increase PLC activity 
in HEK293 cells. 
Basal IP1 tonus of HEK293 lacking Gq/11 (A) proteins or non-genome edited HEK293 cells (B) 
after 1 hr incubation in IP1 stimulation buffer. Cells were tested 48 hrs post transfection with equal 
amounts of plasmid DNA without or with inserted sequence for either wild type Gq or GqQ209L 
(1,2 µg/21 cm²). Significance was calculated by using the unpaired t-test. 
 
Yet again, in the Gq/11 null background PLCβ-GαqQ209L-interaction could not be blunted 
by FR up to very high concentrations, indicating the impossibility to target the GTPase-
deficient protein with an inhibitor that acts as GDI. Consistent with the data obtained in 
B16 Gq/11 wild type cells and the data generated in ligand-induced IP1 accumulation in 
non-Gq-transfected HEK293 cells (figure 15B,D,E), FR perfectly counteracted the 
activation of PLC by the transfected wild type Gαq construct fully (figure 17A).  
Subsequently, we wanted to re-evaluate inhibition of mitogenic ERK signaling driven by 
the GTPase-deficient mutant, as seen in HCmel12 cells. By measuring total ERK, we 
could show that expression of the Gq proteins itself depressed the total amount of ERK 
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proteins (figure 17B). Thus, we calculated the attained phosphorylated protein levels by 
accounting the phosphorylated fraction in relation to the total protein amount (figure 
17C).  
Tendency in inhibition could be observed for the Q209L construct and could be confirmed 
for wild type Gq but diverging amounts of the phosphorylated fraction and a relatively 
small assay window for the oncogenic protein forced us to look for other pro-survival 
pathways to really quantify effects. The results were not completely surprising as reports 
about elevated ERK levels upon Q209L transfection are quite diverse (Gutkind 2000; 
Thomas et al. 2016). Thus, we concluded that HEK cells might not be the right system to 
investigate basal ERK activity driven by oncogenic G proteins.  
   
 
 
 
 
 
 
 
 
 
4.3.2. FR effects on Gq downstream signaling effectors AKT and YAP in 
endogenous Gq/11-clean background 
As ERK signaling in HEK cells was not found to be suitable to appraise FR effects on the 
GTPase-deficient mutant, we looked for other Gq downstream effectors with similar 
function in proliferation. Like ERK, AKT is a critical factor for tumorigenesis in cutaneous 
melanoma or uveal melanoma. The activation PI3K-AKT/Protein-kinase B pathway leads 
to cyclin D1 overexpression and appropriately enhances cell cycle progression (Porta et 
al. 2014; Kanzler and Swetter 2003). Therefore, we wanted to test, whether we could use 
AKT phosphorylation as an appropriate tool to evaluate FR effects on more pro-survival 
pathways by using the Gq/11 null background.  
In uveal melanoma with Gq-mutations, AKT phosphorylation has been associated with 
constitutive Gq-signaling, as silencing of the protein by siRNA reduced the 
phosphorylated fraction of AKT (Ambrosini et al. 2013). In contrast Gq has been reported 
to play an opposite role in AKT activation in HEK-cell context. Wong and his co-workers 
could show inhibition of the AKT signaling pathway that was initiated by the transfection 
of the oncogenic GαqQ209L protein into the HEK293 cell system (Chen et al. 2014).  
Figure 17: FR effect on canonical PLC activation versus mitogenic ERK 
phosphorylation in HEK cells expressing wild type and Q209L construct. 
Inhibition of intrinsic IP1 tonus after 1 hr incubation with FR in stated concentrations n=3 (A). Total 
ERK protein n=4 (B) or pERK to totalERK in n=4 (C) after 1 hr incubation of vehicle, FR in 10 µM 
or trametinib in 1 µM in HEK293Gαq/11-null cells 48 hrs post transfection with the indicated 
constructs. Dots and bars represent means of n independent experiments. Significance was 
calculated by using the unpaired t-test. 
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For these reasons we expected to see enhancement of AKT phosphorylation by FR 
application to HEK cells transiently expressing Gαq proteins. However, in contrast to the 
published data, we were not able to sense any phosphorylation-stimulus of Gαq signaling 
by transfection of these constructs into our HEK cells lacking endogenous Gαq-family 
proteins. These observations accounted for both proteins, wild type and the Q209L-
mutant. AKT phosphorylation at basal level was comparable to vector transfected cells 
and FR did neither significantly enhance nor reduce these fractions (figure 18A). 
Apparently, the transient expression of these constructs does not account in AKT 
signaling. 
To verify the accuracy of our assay, we tried to reconstruct published data and detect Gq-
receptor ligand carbachol-induced depression of phosphorylated AKT (Bommakanti et al. 
2000). Therefore, we tested HEK293 cells with endogenous Gq/11 expression-levels. We 
found Gq involvement in AKT signaling in these non-genome edited HEK cells. Activation 
of the muscarinic M3 Gq-coupled receptor by carbachol decreased basal AKT 
phosphorylation as published. Additionally, we were able to regain basal level by using 
the Gq inhibitor FR (figure 18B). The FR effect on carbachol signaling was 
concentration-dependent and was maximal at 10 µM (figure 18C).  
This might hint that signaling modulation of AKT through Gq can differ between 
permanent and acute activation of Gq proteins. High basal Gq tonus that is also observed 
for Gq wt transfected HEK293Gαq/11-null cells might initiate a compensation mechanism. 
However, as results were not inherently conclusive, we moved on to test FR-Gqmut 
interaction on other Gq-cancer related pathways.  
 
 
 
 
 
 
 
 
 
 
Yes-associated-protein (YAP), a transcriptional coactivator regulated by the hippo 
pathway, was recently linked to oncogenic Gαq signaling. This signaling is reported to be 
mediated by a complex machinery involving Trio-Rho/Rac-promoted LATS inhibition and 
actin polymerization (Feng et al. 2014; Vaqué et al. 2012; Yu et al. 2014). In the presence 
Figure 18: AKT phosphorylation regulated by Gq signaling in HEK293 cells. 
Phosphorylation of AKT proteins after 1 hr incubation with either FR in 10 µM or PI3Ki LY294002 in 
30 µM in either wild type or GTPase-deficient Gq transfected HEK293Gαq/11-null cells (n=3) (A). 
Ligand-induced CCh depression with or without preincubation of 10 µM FR or LY294002 30 µM in 
non-genome edited HEK293 cells (n=2) (B). Quantification of FR effects on ligand-induced AKT 
dephosphorylation (n=2) (C). 
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of Gq signaling LATS is impaired to phosphorylate YAP. Phospho-untagged YAP is able 
to penetrate through the nucleus and form an active complex with the transcription factor 
TEAD followed by expression of diverse growth promoting genes.  
By blocking Gq signal with FR we could induce increased phosphorylated YAP levels in 
both mutant and wild type transfected cells while vector transfected HEK293Gαq/11-null 
cells remained unaffected (figure 19A). FCS was used as an internal control. Consistent 
with published data FCS decreased the amount of phosphorylated YAP as expected. 
Guan and co-workers identified LPA and S1P, two GPCR-ligands, as the YAP activating 
components in serum. Both compounds are suggested to initiate G12/13 and Gq-
mediated RhoA signaling (Yu et al. 2012). The total YAP protein amount was not affected 
either by 1 hr of FR or FCS incubation (figure 19B). Quantification of the effects revealed 
that inhibition of GαqQ209L was slightly less sensitive towards FR (figure 19C). These data 
strongly indicate, that inhibition of oncogenic Gq signaling by FR is not restricted to wild 
type Gq but can be extended to the GTPase-deficient mutant as well.   
 
Figure 19: YAP phosphorylation regulated by Gq signaling in HEK293 cells. 
Phosphorylation of YAP protein (A) (n=5) or total amount of YAP proteins (B) (n=3) after 1 hr 
incubation with either FR in 10 µM, 100% FCS or vehicle in HEK293Gαq/11-null cells transfected with 
vector, wild type or GTPase-deficient Gq. Quantification of FR potency on wild type vs QL 
transfected cells (n=5) (C). Dots and bars represent the mean with s.e.m. of n independent 
experiments. Significance was calculated by using the one-sample t-test (A) or Wilcoxon test (B). 
 
 
4.3.3. FR triggers mass redistribution in cells expressing GTPase-deficient 
mutant  
A broad-range of G protein-mediated signaling is related to morphological changes of 
cells (Schröder et al. 2010; Schröder et al. 2011). Gq and G12/13-proteins are known to 
activate small RhoGEFs that are involved in dynamic processes of the cytoskeleton 
(Rojas et al. 2007). Compound-induced dynamic mass redistribution can be measured in 
real-time by using Coring Epic technology (Schröder et al. 2010; Schröder et al. 2011). 
DMR is not only able to detect agonist-provoked GPCR-signaling but is also able to 
uncover constitutive receptor activity. Thereby, inverse agonists have been shown to form 
opposite directing DMR traces to agonists (Lee et al. 2014) indicating reversed 
movements of the mass within the cell. However, label-free detection of receptor 
independent constitutively active G protein inhibition has not been addressed so far.   
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Thus, we were positively surprised, as we could indeed evaluate FR effects on the 
GTPase-deficient mutant GαqQ209L by taking advantage of this label-free method.  
Cells perfectly responded to endothelin growth factor (EGF) and forskolin (Fsk), 
independent of the transiently expressed protein (figure 20A). Cell response to these 
compounds does not rely on G protein activation and therefore, they were used as 
general cell viability controls. Carbachol served as a transfection control. In HEK cells 
CCh binds to the muscarinic Gq-coupled receptor M3, whose activation triggers upwards 
directed traces in this cell system (Schröder et al. 2010).  
Cells lacking Gq/11 proteins consequently did not response to carbachol, as these cells 
miss the proteins to transfer the signal of the M3 receptor into the cell. Cells expressing 
the Gq protein constructs responded to carbachol addition (figure 20A) indicating the 
presence of the signaling adaptor for the receptor.  
FR exposition on HEK cells transfected with vector or wild type Gαq did not elicit shifts in 
the DMR traces compared to buffer injection. In contrast, FR application on HEK cells 
expressing constitutively active GαqQ209L triggered upwards movement of cellular mass 
from the sensor within the detectable area of the cell mono-layer (figure 20B). Upwards 
movement of mass then was translated to negative optical DMR traces.  
Likewise, inverse agonists of constitutively active receptors that reverse the signal 
direction of agonists, Gq inhibition by FR led to opposite directed optical traces compared 
to ligand evoked Gq activation. By this means we can conclude, that inhibition and 
activation of Gq induces adverse cell reactions regarding the cell’s mass redistribution. In 
contrast to the negative FR triggered traces, CCh induced pm shifts of the reflected light 
that revealed cellular mass movement towards the sensor. This movement was 
converted into positive traces.  
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Signaling amplitude of the negative FR traces was concentration-dependent and could be 
converted to a concentration-response curve by calculating the negative area under the 
curve of FR initiated traces within the first hour of measurement (figure 21). Even tough, 
basal wild type Gq tonus was detectable in the IP1 assay of transfected genome edited 
HEK293Gαq/11null-cells, this tonus apparently was insufficient to instigate notifying changes 
within the cell after FR application by DMR. Negative traces seem to appear only as an 
inversion of permanently elevated Gq signaling.    
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Figure 20: DMR bio-sensing of intrinsic Gq inhibition by FR  
DMR profiles of cell viability controls EGF in 50 µM, Fsk in 30 µM and transfection control CCh in 
30 µM (A). DMR traces induced by FR application in indicated concentrations (B) in 
HEK293Gαq/11-null cells transfected with 1.3 µg/9 cm² plasmid with or without insert encoding wild 
type or Q209L Gαq. Shown are representative traces of n=3 independent experiments. 
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Figure 21: Quantification of DMR bio-sensing of intrinsic Gq inhibition by FR 
FR concentration-inhibition-curve of negative DMR traces upon FR application in either wild type 
or GTPase-deficient Gq transfected HEK293Gαq/11-null cells. Dots represent means of 3 
independent experiments with s.e.m. 
 
4.3.4 FR might act as a GDI on the GTPase-deficient GαqQ209L protein  
The inhibition of the GTPase-deficient GαqQ209L by the macrocyclic FR, was unpredicted, 
as this mutant is reported to be completely receptor independent und therefore, 
constitutively GTP-bound (Kleuss et al. 1994). According to this concept FR as a GDI 
was thought to miss its target, the GαqQ209L protein (Kimple et al. 2011). Thus, against this 
concept, we were able to proof FR to interfere with this mutated version of the Gq protein. 
In the following step, we wanted to enlighten the mechanism behind FR’s mode of action 
on this GTPase-deficient mutant. 
4.3.4.1 DMR reveals receptor-activatable fraction of GαqQ209L  
The first possible hint was buried in the DMR whole cell experiments. Initially thought as a 
control for wild type Gαq transfection, CCh surprisingly evoked a response in mutant 
GαqQ209L expressing cells. This signal was compromised but still detectable. CCh 
mediated signal in wild type as well as in Q209L transfected cells was clearly receptor 
mediated, as the signal was sensitive to atropine (figure 22A), a competitive antagonist 
on the muscarinic receptor subtypes M1-M5 (Wall et al. 1992). GPCRs are known to 
activate heterotrimeric G proteins (Oldham and Hamm 2008). Most likely GαqQ209L exists 
also in the GDP-bound-heterotrimeric version.  
Compromised CCh signals could not be related to poor cell viability of these cells, as Fsk 
and EGF, the non-G protein dependent controls, showed signals that were similar in the 
pm-shift range compared to wild type Gq transfected cells (figure 22B). This 
carbachol-promoted traces could be abolished by FR in a concentration-dependent 
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manner unaffected by the mutational state of the protein. Notable FR-induced negative 
traces could also be observed in the presence of the receptor agonist, but again these 
traces were unnoticeable in wild type Gαq transfected cells. These results again suggest 
that negative traces reveal only high permanent intrinsic activity, and further, that this 
behavior cannot be mimicked by receptor activation (figure 22C). Quantification of CCh 
signal inhibition by FR exposed no difference in sensitivity between both versions of the 
protein calculated by the positive AUC within one hour of measurement (figure 22D). 
 
Figure 22: DMR bio-sensing of intrinsic Gq inhibition by FR  
DMR profiles of carbachol 30 µM pretreated with buffer or atropine in 100 µM for 1 hr (A) or of cell 
viability controls EGF in 50 µM, Fsk in 30 µM (B) or of carbachol 30 µM pretreated with buffer or 
FR in indicated concentrations(C) in HEK293Gαq/11-null cells transfected with 1.3 µg/ 9 cm² 
plasmid with or without insert encoding wild type or Q209L Gαq. (D) Quantification of the FR effect 
on CCh calculated by the positive area under the curve of 1 hr normalized on the buffer control. 
Shown are representative traces of n=3 independent experiments (A-C). (D) Dots represent the 
mean with s.e.m. of three independent experiments. 
 
As FR functions as GDI on GDP-bound Gq and as we obtained first hints, that GαqQ209L 
exists at least fractionally in the GDP-bound state, this might be an explanation for FR to 
interact with the GTPase-deficient mutant.  
4.3.4.2 Immunoprecipitation confirmed GDP-bound GαqQ209L  
To further confirm the nucleotide binding state of constitutively active GαqQ209L we decided 
to perform immunoprecipitation with [32P]orthophosphate-labeled GTP and GDP in 
transfected HEK293 cells. Hence, wild type Gαq was exclusively extracted with GDP 
whereas GαqQ209L was found to be attached to both versions of the nucleotide (figure 
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23A). The next question to assess was to test our hypothesis, where the GDP-bound 
GαqQ209L subunit would exist as monomer, or if it largely exists in a sedentary state 
committed to the βγ-heterodimer. His-pull-down assay demonstrated that βγ-heterodimer 
was indeed attached to a large amount of GαqQ209L, thereby binding was exclusive for the 
fraction of GDP (figure 23B). 
 
 
Figure 23: Detection of GDP and GTP-bound Gαq  
A) Thin layer chromatography of lysates of [32P]orthophosphate-labeled HEK293T cells 
transfected HA-tagged Gα subunits.  Subunits were isolated either by immunoprecipitation (IP:HA, 
left panel) or by their interaction with His6-G isolated by pull-down with talon resin (PD:His, right 
panel) Data was kindly provided by Daniel Cervantes-Villagrana from the working group of Prof. 
José Vázquez-Prado ( from the Cinvestav-IPN, Mexico). 
 
4.3.4.3. Binding site comparison of FR on wild type and GTPase-deficient Gαq 
indicate FR to act as GDI on both proteins 
Signaling conducted by either wild type Gq or GTPase-deficient mutant was in both cases 
sensitive to FR in the phospho-YAP assay. Thus, we made use of this readout to 
investigate, whether binding surface of the molecule differ between the both proteins. In 
2010 Nishimura et al. published the co-crystallization of the Gαi/qβγ-heterotrimer with YM, 
the structurally closely related macrocycle. They identified thirteen residues mainly on the 
interdomain linkers that created a hydrophilic gap for YM (Nishimura et al. 2010). Binding 
into this gap, the molecule was shown to act like a wedge in the cleft of these linkers. 
Thereby, YM compromised the flexibility of switch 1 (linker 2). Flexibility within this region 
has been reported to be a major requirement for GDP release (Oldham and Hamm 
2008). By preventing GDP-GTP-exchange, YM enabled the alpha subunit to be activated 
by the receptor (Nishimura et al. 2010). To address the question, whether FR binding on 
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wild type or GTPase-deficient Gq protein would be the same, we mutated residues in 
both linkers between the GTPase and helical domain. Thus, we assumed FR and YM to 
share the same interface on the protein as suggested in the structure relationship study 
of Strømgaard and co-workers (Zhang et al. 2018).  
Mutation of the non-polar amino acid phenylalanine on position 75 in linker 1 to lysine led 
in both proteins to a slight shift in FR inhibition curve. More severe was the reduction of 
activity when isoleucine on position 190 was exchanged to the sterically much bigger 
tryptophan. As mutation mediated loss of function behavior of FR was the same for wild 
type and the GqQ209L protein, we postulate direct interaction and similar binding mode of 
FR for both proteins (figure 24A). The mutation Q209L that drives the GTPase-deficiency 
and consequently leads to the constitutive activity, is located in the Ras like domain, but it 
is not directly affecting FR binding site as illustrated (figure 24B). 
Crystal structure comparison between transducin, a Gα-subunit that is activated by a 
light-inducible receptor, in the GTP-bound and the GDP-bound state, both published by 
Paul Sigler and co-workers (Lambright et al. 1994), showed that nucleotide variation only 
has minor impact on the overall structure of the Gα protein. However, the key regions, 
where these structural differences occurred, were the three flexible switches. As switch 1 
is part of the YM and apparently also of the FR binding pocket and is shifted about 2 Å, 
Nishimura et al. predicted YM not to bind on the GTP-bound Gα (Nishimura et al. 2010). 
Therefore, it is likely that FR also binds to GαqQ209L in the GDP-bound state also acting as 
a GDI. 
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Figure 24: FR binding on wild type and GTPase-deficient Gαq   
(A)Quantification of FR potency in YAP phosphorylation assay initiated by Gαqwt or GαqQ209L and 
modification of these proteins by side directed mutagenesis in HEK293Gαq/11-null cells transfected 
with 1.3 µg/ 9 cm² of indicated constructs. (B) Cartoon illustrating FR binding site on Gαq high 
lighting modified residues. Illustration was kindly provided by Stefania Monteleone from the 
working group of Peter Kolb, Philipps-University Marburg. (Pdb 3AH8)  
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4.3.5 Addressing FR’s inability towards canonical PLC signaling induced by 
GTPase-deficient Gαq 
4.3.5.1. FR inhibits PLC-interaction of a GTPase impaired Gαq, that is still substrate 
for GAP  
If FR functions as GDI on mutational GαqQ209L, signaling of all effector proteins should be 
affected. The answer to the question, why FR is unable to inhibit canonical PLC signaling 
may lay in the properties of the effector itself. Interaction between PLCβ and Gαq is quite 
fast, and is described to have a kiss-and-run like dynamic (Adjobo-Hermans et al. 2013). 
PLC catches activated Gαq that is deactivated shortly afterwards by the GAP-activity of 
the effector. In the presence of Gq-coupled receptor ligands that bind to the receptor, the 
PLC-inactivated Gq protein can be reused for PLC interaction post reactivation by the 
ligand-induced receptor (Harden et al. 2011). In this state the G protein cycles between 
activated and inactivated state (Oldham and Hamm 2008) as illustrated in figure 25.  
 
Figure 25: Schematic description of PLC-Gq interaction and GAP activity. 
Ligand-activated GPCRs provoke the exchange of GDP versus GTP in the α-subunit of the Gq 
protein (I). This nucleotide-exchange releases the α-subunit from the βγ-heterodimer. In the 
monomeric state the α-subunit can interact with its canonical effector PLCβ. This interaction is 
fast, as GAP activity of PLCβ accelerates the GTPase function and therefore promotes the 
autocatalytic switch-off function of the α-subunit (II). This favors the formation of the inactive 
heterotrimer (III). By applying FR to the system, an accumulation of the protein is achieved. In the 
complex with the inhibitor the Protein is no longer available to the activation circle (IV).   
 
Substitution of glutamate on position Q209 to leucine lead to a dramatic loss of GTPase 
function and was reported to lose sensitivity towards GAP activity by PLCβ1 or RGS4 
(Berman et al. 1996). R183 is another hot spot residue known to impair GTP hydrolysis. 
Proteins with substitution of the arginine by cysteine on this position are also known as 
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oncogenes in certain cancer types. In contrast to the Q209 residue, where GTPase 
activity is reported to be majorly impaired, mutation on R183 decelerates the enzymatic 
function less. Additionally, R183C mutation has been shown to be a substrate for GAP 
proteins, as it did not to interfere Gq-affinity towards RGS2 (Nance et al. 2013; O’Hayre 
et al. 2013).  
To investigate inhibition properties of FR for this GTPase-deficient but still GAP sensitive 
mutant, we transfected HEK293 cells with this R183C analog of Gαq. Specifically, we 
wanted to know whether FR would succeed to blunt PLC mediated effects conducted by 
GαqR183C. Therefore, we used IP1 accumulation as a direct PLC readout. 
As expected from the slower hydrolysis rate and by this means from the bigger fraction of 
GTP-bound protein, the transfection of the construct led to elevated IP1 levels compared 
to cells transfected with wild type Gq. In contrast to the GTPase-deficient Q209L the 
R183C construct was FR sensitive with a similar IC50 value (figure 26A). As R183 is 
much closer to the FR binding region compared to Q209 (figure 26B), it is unlikely that 
the amino substitution on position Q209 itself modifies the FR binding pocket and thereby 
causes the inability of FR to inhibit PLC- GαqQ209L interaction. 
 
Figure 26: FR inhibition of PLC-β downstream signaling initiated by GTPase 
impaired Gq R183C 
(A) Inhibition of cell-intrinsic IP1 tonus of HEK293Gαq/11-null l cells 48 hrs. post transfection with 
the indicated constructs after 1 hr incubation with FR in stated concentrations n=5 in stimulation 
buffer. Dots represent the means of n independent experiments with error bars representing s.e.m. 
(B). Cartoon illustrating FR binding site on Gαq, highlighted are the two hot-spot mutations R183C 
and Q209L. Illustration was kindly provided by Stefania Monteleone from the working group of 
Peter Kolb, Philipps-University Marburg. (Pdb 3AH8)   
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Another possibility for different inhibition effects on IP1 accumulation by FR could be 
different kinetics between PLC-Gαq and PLC-GαqQ209L. While activated wild type Gq 
cycles between PLC-bound Gα-GTP and PLC-unbound heterotrimer, the GTP-bound 
fraction of the GTPase-deficient Gα is darn to stay permanently PLC-bound. By losing the 
ability to perform proper GTPase activity, PLC might be unable to release the GαqQ209L 
from the complex. In this model FR would be impaired to prevent PLC-GαqQ209L 
interaction, as they stick together from the beginning. This hypothesis will be investigated 
next. 
4.3.5.2. FR decreased kinetic on-rate for PLC- Gαq but not PLC- GαqQ209L 
To enlighten the FR inhibition properties on the direct interaction of GαqQ209L and PLCβ 
we made use of FRET tagged constructs. FRET assays helped us to measure the 
interaction of the proteins on HEK cell membranes that were prior transfected with tagged 
PLC together with either tagged Gαqwt or GαqQ209L and the non-tagged M3 muscarinic 
receptor. 
Stimulation of membrane preparation form cells transfected with wild type Gq with 
carbachol initiated interaction between PLC and Gαq that was translated to elevated 
fluorescence resonance energy transfer. Basal FRET signal of membranes transfected 
with the GTPase-deficient analog were elevated compared to wild type protein. These 
results suggest that PLC and GαqQ209L are already interacting without ligand stimulus. 
This interaction could not be further enhanced by Gq-receptor ligand carbachol 
application (figure 27A). 
The adjoining step was to look for FR provoked changes on PLCβ and Gαq interaction in 
real time. As expected, the addition of CCh to membranes with wild type Gαq-induced the 
interaction between the proteins. The interaction reached a signaling-plateau, describing 
a steady-state between the PLC-bound-Gαq-GTP and non-PLC-bound Gαβγ-
heterotrimer. The PLC-Gα interaction was reversible and could be abolished quickly after 
carbachol removal, as detected by decreased FRET-signal. When Gq-inhibitor FR was 
applied during the phase of ligand-induced steady-state, FR reduced the on-rate of PLC 
and Gαq, as FRET signal was significantly depressed over time compared to just 
carbachol eluted membranes. After a wash-out period CCh was only able to re-evoke 
signaling in non-FR treated cells (figure 27B). 
This result implements that steady-state under FR treatment was no longer sustainable, 
and therefore signal amplitude started to decline. PLC releases Gα by its GAP activity 
and therefore favors the re-association of α-subunit with βγ-heterodimer to form a 
heterotrimer. This heterotrimer then again is available for receptor activation. In the view 
of the fact, that FR inhibits Gq in the GDP-bound heterotrimeric state, it is likely that, FR 
catches the Gαβγ-complex by preventing the guanine dissociation and thereby withdraws 
the protein from receptor activation. Furthermore, withdrawal of the protein from this 
activation cycle by FR is irreversible, since washing out FR did not re-provide the protein 
to the activatable system, as observed by carbachol addition. 
A completely different picture occurred when we looked for membranes provided with 
GαqQ209L. As already stated, the basal interaction of PLCβ- GαqQ209L-FRET levels were 
already elevated and could not be further enhanced by receptor activation. But we could 
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also observe that this elevated basal FRET level could not be lowered by FR addition. 
Remarkably, PLC- GαqQ209L seem to be stacked together (figure 27B).  
 
Figure 27: PLCβ3 interaction with wild type Gαq and GTPase-deficient GαqQ209L 
interaction in presents and absents of FR. 
(A,B) Single cell FRET imaging in HEK293T cells expressing M3-R, Gβ1γ2 , YFP-PLCβ3 and CFP-
Gaq-wt shown in absolute FYFP/FCFP ratio of experiments (wt n=35; QL n=40) A). And single cell 
FRET imaging of cells super-fused with buffer and buffer with 10 µM CCh consecutively as 
indicated. Cells were or were not additionally exposed to 1 µM FR900359 during the long period of 
CCh exposure. (wt n= 17; QL n=24) (B). Significance was calculated by using unpaired t-test (A, 
and B at 360 s). FRET images were kindly provided by the lab of Professor Buenemann from the 
University of Marburg. 
 
4.3.5.3. FR does not interfere with PLC-Gαq protein-protein interaction 
Taking advantage of the available crystal structure of YM with the Gαi/q chimera and our 
knowledge that FR and YM share similar binding sites, we modeled the Gαq-PLCβ-FR 
complex. Here we were able to demonstrate that FR does not interfere the binding of the 
Gα-subunit with PLCβ, as there is enough space for FR to fit in (figure 28).  
So far, no crystal structures of Gαq in complex with Trio are available, but structure of 
p63RhoGEF that is closely related to TRIO was published in 2007 (Lutz et al. 2007). The 
specific binding site of p63RhoGEF is also found in the other protein family members 
TRIO and DUET. Superimposition of those crystal structures could show, that the two 
effectors PLC and p63RhoGEF are engaged to the Gα subunit in a strikingly similar 
manner. In both cases the α3 helix and switch II of the Gαq interacts with a helix-turn-helix 
structure of the effectors (Charpentier et al. 2016).  Thus, differences in inhibition of TRIO 
(YAP) and PLC (IP1) activation most likely cannot be explained by inhibition of special 
protein-protein-interaction. These findings support the theory that lack of PLC inhibition 
by FR must be due to PLC-specific feature. 
 
 
 
Results 
72 
 
 
 
 
 
 
 
 
 
 
 
4.4. Evaluation of FR capability to inhibit oncogenic Gq-signaling 
in uveal melanoma 
As already stated, activating mutations of GNAQ and GNA11 are oncogenic drivers in 
specific types of cancer. They have been detected in 5.6% of human tumor with approx. 
66% occurrence in the eye and ~6% in the skin melanoma. The most prominent ocular 
cancer with constitutively active Gq/11 is the uveal melanoma (O’Hayre et al. 2013). 
About 83% of the patients harbor a genetic alteration in one of the hot spot residues 
Q209 or R183 of either GNAQ or GNA11 (van Raamsdonk et al. 2009). Consequently, 
we wanted to evaluate effects upon Gq inhibition by FR in this therapeutically relevant 
system.  
4.4.1. Targeting canonical effector PLCβ in uveal melanoma 
We tested 5 non-metastatic UM cell lines. Of these two cell lines had no mutations in 
GNAQ or GNA11: Mel290, Mel285 and three carried a mutation in the GNAQ gene: 
Mel270 (Q209P), Mel202 (Q209L) and 92.1(Q209L). Additionally, we tested the 
metastatic cell line OMM1.3 with a mutation in GNAQ (Q209P) (Griewank et al. 2012).  
Initially, we verified the absence or presence of intrinsic Gq activity by examining elevated 
IP1 levels under non-stimulating conditions. In all cell lines increment of cell number 
enhanced detectable the absolute amount of IP1 accumulation in a proportional manner 
(figure 29A). Surprisingly, also the GNAQ wt cell line Mel290 showed quite high IP1 
tonus. But further activation of G proteins by [AlF4]- only enhanced IP1 levels of GNAQ wt 
cell lines Mel285 and Mel290 (figure 29B). [AlF4]- mimics the γ-phosphate of the GTP 
and therefore serves to activate the G proteins (Lyon and Tesmer 2013). Lack of 
response of the cell lines with constitutively activated Gαq to [AlF4]- implicates that PLC-
Gαq-interaction is already at the maximum. These findings corresponded to the 
observations we made in the FRET-PLC- Gαq experiments in transfected HEK cell 
membranes. Receptor agonist carbachol could only enhance the interaction between the 
PLC
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Figure 28: PLC-β3 interaction with wild type Gαq and GTPase deficient GαqQ209L 
interaction in presents and absents of FR. 
Cartoon illustrating the overall surface structure (A) and zoom-in view of the binding site (B) of an 
AlF4--dependent complex of Gαq and PLCβ3 (PDB: 3ohm). FR (dark green) fits easily between the 
domain interfaces of the active Gαq-PLCβ3 complex. Cartoon was modelled by Stefania 
Monteleone from Professor Peter Kolb’s lab, Philipps-University Marburg. (PDB 3ohm) 
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wild type Gαq and PLC, whereas ligand-induced receptor activation did not increase 
FRET signal in membranes when GTPase-deficient GαqQ209L was transfected.  
 
 
Figure 29: Intrinsic Gq activity in uveal melanoma cells expressing either wild type 
Gq or GTPase-deficient mutant. 
(A) Quantification of cell-intrinsic IP1 production in UM lines of 10 and 50 kc/w after 1 hr incubation 
in stimulation buffer. (B) Inositol-monophosphates (IP1) from AlF4- (300 µM) stimulated cells 
accumulated over 1 hr using 30 kc/w.  Data for Mel280, Mel290, 92.1, and OMM1.3 (n=4); data for 
Mel270 and Mel202 (n=3). All biological replicates are independent experiments with at least two 
technical replicates. Bars represent means with error bars denoting s.e.m. 
Next, we tested PLC activity towards FR sensitivity. Results here were quite unexpected 
as they apparently not only vary by mutational state of Gq protein but also within the 
different cell lines. Whereas FR uncovers Gq as the perpetrator for basal IP1 tonus in 
Mel285 cell line, the same was not observed within the other wild type GNAQ/GNA11 cell 
line Mel290, where PLC activity was elevated. The IP1 tonus in these Mel290 cells was 
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even higher compared to the mutated GNAQ cell lines Mel202, Mel270 and OMM1.3. 
Surprisingly, in this case FR was unable to depress the quite high basal activity. 
 
Figure 30: Intrinsic Gq activity in uveal melanoma cells expressing either wild type 
Gq or GTPase-deficient mutant. 
(A) FR sensitivity of basal IP1 accumulation of indicated uveal melanoma cell lines in 30 kc/w and 
(B) sensitivity towards inhibition by Gq inhibitor FR (concentration effect mode and maximal 
inhibition @ 10 µM FR. Dots and bars represent means and s.e.m. of n=4 biological replicates.  
To our astonishment, all cell lines harboring the GNAQmut gene were at least to some 
extent sensitive towards FR. Inhibition curves of IP1 accumulation were only slightly 
shifted to the right compared with GNAQ/GNA11 wild type cell line Mel285. Only in 92.1 
cell line IP1 levels remained mostly unaffected up to 3 µM (figure 30A). But clearly most 
of the IP1 tonus in this cell line was Gq mediated, as we were able to depress 
accumulation to less than 30% of basal level by using very high concentrations up to 10 
µM of FR (figure 30B). 
Conspicuously, the IP1 tonus in the other mutated cell lines Mel270, Mel202 and 
OMM1.3 was quite low and therefore did not indicate excessive PLC activity. Cellular 
background with its protein composition in quantity but also in its facility of different 
protein isoforms might be a crucial factor when it comes to PLC inhibition. Whereas HEK 
cells harbor the PLCβ isoforms 1 & 2 (Atwood et al. 2011) which both are known to 
accelerate GTP-hydrolysis, UM cells also express the PLCβ4 that is generally highly 
present in retina and cerebellum. Little is reported so far about GAP activity of the β-4 
isoform and its GAP function (Lyon and Tesmer 2013; Johansson et al. 2015). 
Furthermore, other components within the cell might vary, like the GDP/GTP content as 
well as the expression pattern of GAP proteins like RGS.  
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While FR only had minor impact on basal IP1 levels in Mel290 cells, G protein-stimulated 
IP1 accumulation by [AlF4]- was completely blunted with the inhibitor. By this means, we 
were able to exclude the probability of FR to be incapable to penetrate through the 
membrane of Mel290 cells (figure 31A). These findings also assume an additional driver 
for basal IP1 enrichment than the Gq protein. 
Johansson et al. identified in 2015 an activating mutation in the PLCB4 gene encoding for 
the PLCβ4 isoform. This mutation affected position D630 (c.G1888T) and was thought to 
bestow the protein with elevated enzymatic activity. As PLC is a Gq downstream effector 
the mutation was suspected to be an alternative oncogenic operator in uveal melanoma 
cells (Johansson et al. 2015). As this would be the perfect explanation for high basal IP1 
production we sequenced Mel290 for this mutation but could only show absence of 
PLCB4 mutation in this residue (figure 31B).  
4.4.2 FR inhibits pro-survival signaling in GNAQmut but not GNAQ/11wt cells 
Since the discovery of GTPase-deficient mutations of the Gq/11 protein in uveal 
melanoma as one of the major oncogenes in 2008/2009 (Onken et al. 2008; van 
Raamsdonk et al. 2009) many different Gq downstream effectors have been targeted to 
prevent cell proliferation (Chen et al. 2014; Ambrosini et al. 2013). Here we will evaluate 
the inhibition capacity of ERK, AKT and YAP signaling by direct targeting of the oncogene 
with FR. 
4.4.2.1. FR blunts ERK signaling in GNAQmut but not GNAwt cells 
Activation of the MAPK pathway upon Gq activation is linked to signaling conduction by 
PLCβ (Gutkind 2000). This paradigm could not be observed in Hcmel12 cells, as ERK 
inhibition was reached within very low FR concentrations but IP1 accumulation was 
Figure 31: FR blunts [AlF4]--mediated IP1 accumulation in Mel 290 cells. 
Inhibition of IP1 production after 30 min stimulation with 300 µM [AlF4]- in Mel290 cells pre-treated 
with FR or vehicle for 1 hr (n=4) with 30 kc/w. Values were normalized to the [AlF4]- stimulated 
vehicle control. Sequencing of PLCB4 for mutation at residue c.G1888T (p.D630Y) confirms 
absence of hotspot mutation. 
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insensitive to treatment with the inhibitor (figure 12). In this context we wanted to 
evaluate any correlations between elevated basal ERK phosphorylation and IP1 
accumulation in the uveal melanoma cell by using HTRF® technology by Cisbio. All cell 
lines showed elevated pERK significantly over background. Thereby, ERK 
phosphorylation in all cases was sensitive towards trametinib (figure 32A). Trametinib is 
a potent MEKi that has shown impressive response rates of over 20% in melanoma 
patients in phase III study (McArthur and Ribas 2013) with mutated B-Raf but was mainly 
unresponsive in uveal melanoma patients in a phase I study (Carvajal et al. 2016).   
Interestingly, high IP1 values could not always be associated with high basal ERK 
phosphorylation or vice versa. Highest tonus of mitogen-activated protein kinase 
signaling was detected for Mel290 and Mel285 even though IP1 levels of Mel285 were 
quite low. In addition, no correlation between these two signaling pathway readouts could 
be drawn in the cell lines with Gαqmut. Despite 92.1 had quite high IP1 tonus its extent of 
phosphorylated ERK was comparatively weak to the other cell lines as Mel270, Mel202 
and OMM1.3 that showed moderate basal ERK activation. MAPK-pathway in wild type 
GNAQ/GNA11 UM cells seem to be under promotion of another origin than Gq as ERK 
phosphorylation was not sensitive towards Gq inhibitor FR. In contrast, all cell lines with 
mutated GNAQ gene responded to Gq inhibition with depressed fraction of 
phosphorylated ERK1/2 protein (figure 32B). Further effects of FR on the total amount of 
ERK proteins were not detected (figure 32C).   
These observations were in perfect line with the results obtained by a study made by 
Woodman and co-worker. By knocking down GNAQ with siRNA they were able to block 
activation of MAPK in cells with GNAQmut Mel202 and 92.1 whereas MAPK activity the 
GNAQwt cell lines Mel290 and Mel285 remained unaffected (Khalili et al. 2012).  
Taken both observations together, we can conclude that FR truly inhibits ERK signaling 
only in cell lines when ERK signaling is under promotion of GNAQ that functions as an 
oncogene. 
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Figure 32: FR inhibits ERK signaling in uveal melanoma cells carrying GTPase-
deficient Gq mutant. 
(A) Comparison of basal phosphorylated ERK1/2 amounts in the absence and presence of MEK 
inhibitor trametinib in 1 µM (tram) (Mel290, Mel285, 92.1 n= 4; Mel270, Mel202, OMM1.3 n=3). (B) 
FR modulation of pERK1/2 levels in wild type and mutant UM lines (concentration effect mode and 
maximal inhibition @ 10 µM FR, n=3 for all cell lines). (C) Impact of FR and trametinib on total 
ERK amount in indicated cell lines. (A-C) Incubation time 1 hr in medium. Bars and dots represent 
the mean of indicated n number with s.e.m. Significant effects to neg. control were calculated by 
using the one-sample t-test (A). 
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Another interesting information we gained from this data, was that inhibition of the 
MAPK-pathway again was more sensitive in GTPase-deficient cell lines than PLC 
activation, even though it was clearly detected that both pathways were driven by Gq. 
Likewise, unexpected was the observation that FR potency regarding ERK 
phosphorylation varies between the amino acid substitution on position Q209.  
While in the cell lines OMM1.3 and Mel270 glutamine is substituted for proline, in Mel202 
and 92.1 cells leucine replaces the original amino acid and disturbs GTPase activity. 
Dephosphorylation of ERK was slightly easier achieved in OMM1.3 and Mel270 
compared to the other two mutated cell lines. But if we also consider the results of the 
cutaneous melanoma cell lines BRIM4 (GNAQQ209P) and HCmel12 (GNA11Q209L) (table 1) 
it is more likely that variations regarding pathway sensitivity may lay in the different 
cellular background with different protein features, as HCmel12 cells that carry a leucine 
on this hot spot position was extremely sensitive towards FR in this assay. Another 
possibility could be that amino acid variations in Gq and its consequence towards FR 
sensitivity might not be transferrable one-to-one on the G11 protein.  
 Mel270 OMM1.3 Mel202 92.1 BRIM4 
HCmel1
2 
GNAQ/ 
GNA11 
GNAQ 
Q209P 
GNAQ 
Q209P 
GNAQ 
Q209L 
GNAQ 
Q209L 
GNAQ 
Q209P 
GNA11 
Q209L 
pIC50 
±s.e.m. 
8.02 ± 
0.42 
7.71 ± 
0.08 
7.20 ± 
0.13 
6.51 ± 
0.23 
8.83 ± 
0.23 
8.47 ± 
0.11 
 
4.4.2.2. FR and MEK-i trametinib inhibit proliferation GNAQmut UM cell lines 
Proliferation activity is known to be upregulated as neoplastic promotion in uveal 
melanoma (Krantz et al. 2017). Hence, we looked for ramification of FR treatment on cell 
growth after 72 hrs. on the uveal melanoma cell lines. Again, Mel290 and Mel285, both 
provided with the wild type GNAQ/GNA11 genes, were insensitive towards Gq inhibition. 
Conclusive with the fact that ERK was not under Gq promotion, trametinib showed better 
effects on proliferation in these cell lines. But still ERK inhibition did not stop the cells 
completely form proliferation. Most likely, these two cell lines have another oncogenic 
driver and may use an additional proliferation pathway than just MAPK.  
A completely different picture occurred in all cell lines with mutated Gq protein. 
Proliferation was inhibited by targeting the oncogenic Gq protein with FR in a nanomolar 
concentration rage. Despite of OMM1.3 all other cell lines showed impressive responded 
to the MEK-i trametinib. Thereby, results were very similar to Gq inhibition (Figure 
33A/B).  
Table 1: FR inhibition potency in correlation to amino acid substitution at 
position Q209 
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Figure 33: FR inhibits proliferation in GTPase but not wild type Gq uveal melanoma 
cell lines. 
(A) Effect of FR on cell growth of Gq wildtype and mutant UM lines in culture after 72 hrs. of FR or 
trametinib exposure. For the quantification, the effects were normalized to vehicle-treated controls. 
(B) FR modulation of proliferation in wildtype and mutant UM lines (concentration effect mode and 
maximal inhibition @ 10 µM FR, n=3 for all cell lines). All bars and dots represent the means of n 
indicated experiments with s.e.m. Significant effect to vehicle control was calculated by using the 
one-sample t-test. 
Results from proliferation assays could be confirmed by bright field microscopy imaging. 
Not only cell density but also cell adhesion to the PDL-coated surface of the wells and 
cell shape appeared to be impaired in the FR- and trametinib-treated plate-wells cultured 
with mutated uveal melanoma cell lines in a concentration-dependent manner after 72 
hrs. of drug application. Cells were significantly reduced, and the remaining cells were 
either rounded or looked stressed. Treatment with either of the substances seems to 
provoke cell death. The imaging pictures of GNAQ/GNA11 wild type cells again 
reconfirmed the observations from the proliferation assays. Cell density and cell shape of 
Mel290 and Mel285 did not differ in the vehicle treated versus FR treated wells. 
Additionally, in the MEK inhibitor trametinib was superior to Gq inhibition, as the cell 
density seemed to be slightly lower. But none of the two inhibitors could show satisfying 
results in the wild type cells (figure 34).  
From these results we can conclude, that ERK activation in uveal melanoma most likely 
is then driven by Gq when this protooncogene has gained proper function as oncogene. 
Further we were able to show that ERK activation does not correlate in all cases with 
proliferation activity as shown in GNAQ/GNA11 wild type cells. But even MEKi was quite 
promising for cell lines with mutated Gq protein, targeting only this pathway could not 
proof itself in clinical trials. 
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Figure 34: Inhibition of ERK signaling prevents cell growth in GNAQmut UM cells 
lines 
(A) Bright field imaging of cells after 72 hrs. of treatment with FR in 10 and 100 nM and trametinib 
in 100 nM and 1 µM at cell culture conditions. Shown are representative images from n=3 
independent experiments. Images were kindly provided by Julian Patt, working group of Professor 
Evi Kostenis, University of Bonn. 
 
In a Phase I dose-escalation trail published in 2012 Fecher and co-workers could not 
detect any significant response of 16 UM patients with this specific MEKi. In vitro and in 
vivo does not always seem to have a good correlation (Falchook et al. 2012). Therefore, 
we went along to investigate other Gq downstream signaling pathways that are known to 
promote tumorigenesis and progression. 
 
4.4.2.3 AKT signaling is partially under Gαq promotion in Gαq mut UM cell lines 
The phosphatidylinositol-3-kinase (PI3K)/AKT/mTor signaling pathway regulates 
numerous events in cell growth, cell survival, cell cycle and cell division. It is known to be 
upregulated in cells under pathological conditions and therefore, seems to be crucial in 
cancer. Phosphorylated AKT is upregulated in over 50% of uveal melanoma samples 
(Carvajal et al. 2016). Babchia et al. could demonstrate that targeting ERK and AKT in 
combination inhibited cell proliferation also in UM cells with mutated GNAQ with a 
synergistical effect. PIPI3K activation of AKT positively regulated cell cycle processes by 
increasing Cyclin D1 expression and promoted tumorigenesis in this manner (Babchia et 
al. 2010). Furthermore, elevated pAKT levels have been connected to metastatic 
diseases (Harlé et al. 2015).  
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Thus, it was no surprise that we measured valid amounts of phosphor tagged protein 
within all UM cells using FRET-based HTRF® technology (figure 35A). Extreme high 
values were detected for the Mel290 cell line. For this GNAQ/GNA11 wild type cell line 
we could correlate the elevated tonus of this pathway with proliferation activity, as light 
microscopy revealed that by inhibiting the AKT activating kinase PI3K with a molecule 
called LY294002 (LY), we were able to visibly decrease the cell number compared to 
vehicle treated cells after 72 hrs. This not was observed for the other GNAQ/GNA11 wild 
type line, Mel285. While phosphorylated protein amount was comparably high, in Mel285, 
inhibition of this pathway only slightly affected the cell density after three days of LY 
incubation. 
In the GNAQmut cell lines with moderate pAKT tonus, PI3K-AKT signaling seems to be 
involved in cell cycle progression. Most severe was this observation for the metastatic 
OMM1.3 cell line, since even 3 µM LY compound was enough to reach maximal effect of 
growth inhibition, whereas the effect on visible proliferation in all other cell lines could 
benefit from 10-fold increase of the substance (figure 35B). 
 
Figure 35: AKT pathway activity in uveal melanoma cells 
(A) Intrinsic ATK phosphorylation on Ser473 and after 1 hr incubation of PI3K I LY294002 in 30 
µM or vehicle. Each dot represents the mean of an individual experiment day. The means of n 
experiments are represented by the horizontal line and the vertical line indicate s.e.m. (B) Bright 
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field imaging of cells after 72 hrs. of treatment with LY in 3 and 30 µM at cell culture conditions. 
Cell Images provided by Julian Patt, University of Bonn, lab of Evi Kostenis. Significant effect to 
neg. control was calculated by using the one-sample t-test. 
 
In the following step, we wanted to investigate Gq involvement in AKT phosphorylation in 
the different UM cell lines. PI3K inhibitor LY thereby served as a control. LY inhibited the 
activation of the protein in all UM cell lines within the first 15 min to its fullest extent 
(figure 36A). Thereby, the total protein amount was not decreased (figure 36B). Kinetic 
measurement of AKT dephosphorylation with the Gq Inhibitor showed a depression-
maximum after 1 hr incubation in GNAQ mutant cells while wild type GNAQ/GNA11 cells 
remained completely unaffected over 2 hrs. During the time of kinetic measurement FR 
did not trigger AKT total protein degradation (figure 36C/D). From these observations we 
concluded that wild type Gq signaling is not involved in this pro-survival pathway in either 
Mel290 nor in Mel285. The need of longer incubation time for FR in comparison to LY 
may occur due to the fact, that LY targets the enzyme responsible for AKT 
phosphorylation directly whereas FR interferes more upstream in the signaling cascade. 
 
Figure 36: Time dependent inhibition of AKT phosphorylation in UM cells  
(A,C) Kinetic measurements of total and (B,D) phosphorylated amount of AKT protein in UM lines 
in absence and presence of AKT inhibitor LY294002 in 30 µM(A,B) or Gq inhibitor FR (C,D) in 10 
µM  (n=4 pAkt and total n=3 AKT). The data was generated with the totalAKT or the pAKT HTRF® 
assay kit from Cisbio. Each dot represents the mean of n experiments with s.e.m.. 
After determination of the ideal time point, we quantified FR effects on all cell lines. In 
none of them AKT phosphorylation was exclusively triggered by Gq, as we could detect 
GNAQmut
Mel 270
Mel 202
OMM 1.3
92.174
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pAKT signaling over background after application of high FR concentrations in all cell 
lines.  
Whereas 83% of all UM samples carry an activating mutation in GNAQ/GNA11 
metastatic UM samples have even 13% higher statistics for one of these mutations 
(Krantz et al. 2017). AKT signaling-pathway is associated with higher risk of metastatic 
diseases. This might hint that oncogenic GNAQ signaling trough AKT activation in 
GNAQmut cells is most essential for cells with metastatic properties. Notable is, that 
inhibition of this pathway had the biggest impact on cell proliferation in this cell line. This 
could be an explanation why the metastatic cell line OMM1.3 responded to Gq inhibition 
stronger that the primary tumor cell lines.  
Interestingly again, sensitivity of inhibition curves were quite similar between those cell 
lines with the same amino acid substitute Q209P and for those with Q209L, as an plateau 
is reached approximately between -7.5 and -7 logM for Mel270 and OMM1.3 (both P209) 
and no plateau was reached for Mel202 and 92.1 (both with L209) up to 10 µM FR. 
Variation in amino acid might have an impact on FR inhibition of the AKT pathway (figure 
37A/B).   
 
 
Figure 37: FR inhibits partially AKT phosphorylation in UM cells with mutated 
GNAQ 
(A) FR inhibition potency on AKT phosphorylation after 1 hr of incubation (Mel290, Mel285, 
Mel202 n=3) (Mel270, OMM1.3 n=4). (B) pAKT inhibition @ 10 µM FR. Dots and Bars represent 
the means of n independent experiments, Error bars indicate s.e.m.. 
 
Results 
84 
 
4.4.2.4. FR reveals diverse picture of oncogenic Gq involvement in YAP 
phosphorylation 
Nuclear enrichment of the gene expression regulator YAP has been claimed to correlate 
with mutational status of the Gq protein in human UM tissue samples. Yu et al. could 
show that YAP is primarily located in the nucleus in UM cell lines with mutated GNAQ 
genes, while cells with mutated B-Raf were detected with high cytoplasmic protein levels. 
In line with these findings, they were able to correlate Gq activity with the fraction of non-
phosphorylated YAP protein in GNAQ mutated cell lines. By using short hairpin RNA to 
knockdown Gq they could enhance phosphorylated fraction of YAP in Mel270 and 92.1. 
Furthermore, knockdown of YAP restricted tumor size in a xenograft model with 92.1 cells 
injected to nude mice emphasizing the role of YAP in tumor formation (Yu et al. 2014). In 
parallel Feng et al. obtained similar results. By using OMM1.3 cells in an analog 
xenograft experiment with shYAP they were able to prove YAP involvement in tumor 
growth in a similar way, as vehicle treated tumors were significantly larger. In vitro 
knockdown of either Gq or its downstream effectors Trio, RhoA or ROCK decreased the 
mRNA expression of the YAP-regulated genes CYR61 and CTGF in OMM1.3 cells 
massively. Again, these results were pointing out the role of oncogenic Gq as regulator 
for YAP activity in these cells (Feng et al. 2014).  
In agreement with both back-to-back published articles we measured tendency of higher 
phosphorylated basal YAP in Gq wt cell lines while pYAP was lower in cells with mutated 
Gq (figure 38).  
 
Figure 38: FR inhibits partially AKT phosphorylation in UM cells with mutated 
GNAQ 
Non-stimulated, basal ÝAP phosphorylation after overnight starvation. Each dot represents an 
individual sample. Horizontal line indicated the average of n experiment days and vertical line 
shows s.e.m.. Mel290, Mel202 and OMM1.3 n=4; Mel285, Mel270 and 92.1 n=5. Significant effect 
to neg. control was calculated by using the one-sample t-test. 
 
Next, we wanted to ascertain if Gq inhibition by FR could elevate the phosphorylated 
amount of YAP protein and thereby inactivate the protein in the different uveal melanoma 
cell lines. The first step was to monitor time dependent effects after 15-, 30-, 60- and 120-
min incubation with 10 µM FR under cell culture conditions. Results were only very 
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moderate but most promising after 1 hr incubation as small increase of pYAP could be 
noted for 92.1 and OMM1.3. But cell lines Mel290, Mel270 and Mel202 remained 
completely unaffected (figure 39).  
Ligand-induced Gs activation has been reported to antagonize Gq effects on YAP activity 
(Yu et al. 2012). By using forskolin to directly activate the Gs downstream effector 
adenylyl cyclase Yu et al. could enhance phosphorylated fraction of YAP in the 92.1 cell 
line. These cells harbor GαqQ209L version of the Gαq protein. Therefore, we added forskolin 
as an additional control and repeated the experiment after 1 hr incubation.  
 
 
 
 
 
 
 
 
 
 
 
 
Cytoplasmic localized YAP can be bound by an adaptor protein called 14-3-3. After 
attachment of the adaptor, degradation by the ubiquitin-proteasome system can occur 
due to further phosphorylation of the complex. Thus, the amount of total protein might be 
influenced as well (Zhao et al. 2010). To exclude biased effects because of fluctuation in 
the total protein amount, we detected both total and phosphorylated YAP protein after 1 
hr of treatment with the Gq inhibitor FR and forskolin (figure 40A/B).  
None of the cell lines showed decreased amount of total protein by Gq inhibition nor Gs 
activation (figure 40A). Additionally, as the quantitative effects of Gq inhibition again 
were quite small. Significant increase of the phosphorylated protein over 25 % could only 
be detected in 92.1 and OMM1.3 cells, while Mel285 and Mel202 only showed tendency 
of elevated fraction of phosphorylated protein that was not significant even after 6 
repetitions of the experiment under exact same conditions. Adenylyl cyclase activation 
and thereby activation of PKA by forskolin was expected to elevate pYAP as it was prior 
published (Yu et al. 2014). But again, effects of forskolin-induced YAP phosphorylation 
 
Figure 39: Time dependent FR effect on YAP phosphorylation in diverse UM cell 
lines. 
Phosphorylated fraction of YAP protein in UM lines treated with FR in 10 µM at the indicated time 
points. Dots represent the average of 3 independent experiments with s.e.m.. 
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were quite weak and could only be shown for Mel285 and 92.1 cells (figure 40B). It must 
be stated that these results are not in any objection with the published article, as 92.1 cell 
line was used as the only example for an UM cell line with mutated GNAQ to show 
forskolin mediated effects by Yu et al. (Yu et al. 2014). Very likely AC activation in the 
other cell lines may not participate in the regulation of the YAP pathway, and a 
generalization of YAP-pathway involvement cannot be drawn so easily. One can 
speculate about different expression patterns of the AC itself or its effector proteins in the 
different cell lines that might explain the varieties in pYAP outcome. Furthermore, YAP is 
very downstream of Gs or Gq and many other regulators as G12/13 or the Hippo-
pathway control its activity (Yu et al. 2012). Thereby the results could be additionally 
influenced by any compensatory mechanism driven by the other regulators. 
 
Figure 40: FR induces YAP phosphorylation only in certain UM cells with mutated 
GNAQ 
Total (A) or phosphorylated (B) YAP in UM cell lines after 1 hr of 10 µM FR or 10 µM Fsk 
treatment. Each bar represents the mean of n experiments. Error bar indicate positive s.e.m.s.. 
Total YAP n=3 of each cell line; phosphor YAP Mel290, Mel285, Mel202 n=6; Mel270 n=7, 92.1 
n=7; Omm1.3 n=5. Significant effect to vehicle control was calculated by using the one-sample t-
test. 
Apart from 92.1 no other cell line showed reliable increased effects on both of these 
signaling pathways, Gq inhibition and Gs activation. Therefore, we made use of this cell 
line to indorse, if both pathways would affect YAP phosphorylation simultaneously. Gq 
and Gs should antagonize effects on YAP phosphorylation. Parallel Gq inhibition and Gs 
activation consequently should act additively. To proof this concept, we combined Fsk 
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and FR treatment and determined the outcome head to head with the mono-treatment of 
both compounds. Indeed, combination of Fsk and FR resulted in approximately 60% 
enhancement while mono-treatment with either of the compounds elevated basal level 
about 30% (figure 41, table 2).                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.3 Label-free whole cell response of UM cell lines upon FR application 
YAP signaling trough Gq is suggested to be involved in actin polymerization as UM cells 
with activating Gq mutation also showed elevated levels of phosphorylated cofilin. 
Activated cofilin triggers actin polymerization (Feng et al. 2014) and influences 
cytoskeletal dynamics in this manner. Thus, we wanted to investigate, if we could again 
take advantage of DMR to detect whole cell response in real time in the different cell lines 
as response to Gq inhibition. 
It has been shown that even for conserved G protein mediated signaling pathways 
phenotypical cell response might differ between cell lines depending on the cellular 
background. G protein interaction partners can vary in occurrence of diverse isomers or 
in stoichiometry in many tissues and therefore also in different cell lines (Schröder et al. 
2010). Furthermore, inducing detectable cell shape changes or overall molecular 
movement within the cell upon signaling deprivation might be harder to achieve as upon 
signaling activation. Success of signaling disclosure additionally should correlate with the 
extent of constitutively activity as seen by our prior results. Here HEK293Gαq/11-null cells 
transfected with wt Gαq showed quite high basal activity in IP1 assay (figure 17). But this 
was not high enough as only inhibition of constitutively active GαqQ209L evoked the 
negative signaling traces in DMR, while cells transfected with wild type Gαq did not react 
with detectable mass redistribution upon FR application (figure 20).  
Table 2: pYAP over basal (%) increase± s.e.m.
by AC activator forskolin and Gq inhibitor FR  
 
 
Figure 41: Combined Gq inhibition and Gs activation results in additive YAP 
phosphorylation in 92.1 cells 
(A) Quantification of phosphorylated YAP in 92.1 cells in the density of 75.000 cells/ well in PDL 
coated 96 well-plates after 1 hr of 10 µM FR or 10 µM Fsk or combination treatment. Each bar
represents the mean of 5 independent experiments. Error bar indicate positive s.e.m.  
 FR 10µM 
Fsk 
10µM 
FR + Fsk 
pYAP  31,5 ± 6.7 32,7 ± 10,7 64,2 ± 11.3 
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All UM cell lines responded to 10% FCS, that was used together with forskolin as Gq 
independent viability control. Interestingly not all cells reacted to the adenylyl cyclase 
activator. In UM line Mel285 and OMM1.3 cell-response upon forskolin application was 
silent, while Mel270 and Mel290 only responded with minor signaling. Remarkably, 
forskolin triggered quite high optical traces in the cell lines Mel202 and 92.1. Correlations 
between activation of YAP, as downstream of ROCK activation, and morphological 
changes within the different cell lines are hard to draw. Even though the forskolin signal 
was strong in YAP phosphorylation and in DMR for 92.1 this was not the case for Mel202. 
Cellular background seems to be a crucial factor for downstream signaling of activated 
proteins (figure 42).  
Figure 42: Bio-sensing of cell viability and adenylyl cyclase activation via DMR 
DMR profiles of 10% FCS and 30 µM forskolin in UM cell lines. Shown are the representative 
traces of n independent experiments performed in at least two technical replicates. n=2 for 
OMM1.3 and n=3 for all the other cell lines.  
 
DMR furthermore, was not able to expose GTPase-deficient Gq signaling by inversing 
activity with FR throughout all the UM cell lines. In agreement with the highest Gq tonus 
in IP1 assay and best response of FR in YAP phosphorylation assay, only 92.1 showed 
concentration dependent DMR response upon FR addition. Inhibition of Gq signaling in 
these cells was defined by an initial upwards movement of cellular mass away from the 
sensor plate creating negative optical traces similar to the traces observed in HEK cells 
transfected with the GαqQ209L construct. The early upward oriented movement then was 
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superimposed with a later signaling event leading to an inversion of the direction (figure 
43).  
 
Figure 43: FR-induced DMR profiles in different UM cell lines  
DMR profiles of FR in indicated concentrations. Shown are the representative traces of n (n=2 for 
OMM1.3 and n=3 for all other cell lines) independent experiments performed in at least two 
technical replicates.  
The preceding negative signals of the 92.1 cell line were used to calculate a dose 
response curve, where the negative area under the curve for the first 3600s was plotted 
against enhanced compound concentrations. The pattern of an early negative shift was 
analog to the observed DMR traces initiated by FR in GαqQ209L expressing HEK cell 
system (figure 44). Thereby, higher compound amounts perfectly correlated with higher 
signaling amplitude. But quite high concentrations of FR were needed to induce 
detectable mass movement within the cell as no clear plateau was reached by using 
concentrations up to 100 µM.  
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4.4.4. FR inhibits tumor growth of in mice transplanted with UM harboring 
Gqmut 
Throughout this study we were able to demonstrate the inhibition capacity of FR on 
diverse Gq related pro-survival pathways in uveal melanoma cells expressing the 
GTPase-deficient mutant GαqQ209L/P. However, inhibition of certain pathways driven by an 
oncogene is not a warrant for tumor suppression as other pathways might take over as a 
compensatory mechanism upon pathway inhibition. This has been reported in B-Raf 
mutated UM cells. In a study from 2010, Zhang and co-workers could demonstrate that 
melanoma cells with mutated B-Raf gained resistance to inhibition by the Raf-inhibitor 
PLX4720 but were then sensitive towards AKT inhibition (Jiang et al. 2011). Furthermore, 
a study from 2011 by Steeg and co-workers reveled discrepancies between their in vivo 
and in vitro observations in regards of drug-generated ERK activation in certain 
melanoma cells. They suggested that the micro-environment in vivo might be blamed for 
the different outcomes (Gril et al. 2011). For these reasons, we were eager to verify our in 
vitro results in an in vivo experiment.  
To investigate FR efficiency in vivo, immunodeficient mice underwent transplantation with 
Mel270 (Q209L) UM cells or A375, a human skin cancer cell line with mutated B-Raf. 
Tumor treatment for 14 days started when the size of the neo-plasmatic tissue reached 
100 mm3. With nearly 90% reduction in ERK signaling, 30% reduction of phosphorylated 
AKT and over 90% reduction of cell growth in vitro the Mel270 cell line seemed quite 
promising for these further analyses in vivo. In line with these in vitro observations, tumor 
size was significantly reduced in the mice already after 10 days of treatment (figure 45A). 
This effect was even more impressive after 14 days of sequential FR application. During 
these 14 days the size of the tumors was monitored very 3 to 4 days. Tumors in the FR-
Figure 44: Quantification of FR response in 92.1 cells  
Neg. Area under the curve calculated for 1 hr measurement directly after FR application in n=3 
independent experiments. Dots represent the mean with s.e.m. 
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group did not gain size throughout the whole treatment-time, whereas the tumors in 
control group grew progressively. Additionally, histological analysis of sliced neoplastic 
tissue could remarkably show the growth inhibiting effects of FR on tumor size (figure 
45B).  
In contrast to the UM Mel270 induced tumors, inhibition of Gq did not led to impaired 
tumor growth in mice injected with CM A375 B-RafV600E driven cells. Here treatment with 
FR did not show any advantage compared to vehicle-control application after the same 
time period. In both treatment groups the tumor started to grow in an exponential manner 
during the monitored treatment phase (figure 45C). This time, the histologically prepared 
slices of the necrotic tissue showed comparable size and form after the 14 days (figure 
45D).    
   
Figure 45: FR inhibits tumor growth in UM with mutated GNAQ  
(A,C) Effect of FR or vehicle control treatment on tumor growth of UM line Mel270 or skin 
melanoma A375 in a xenograft mouse model in vivo (n= 5 animals per control- and FR-treated 
group for Mel270 and n=6 animals in both groups for A375). The tumor size was monitored every 
3-4 days during treatment. (B,D) Representative histological section of Mel270 and A375 tumor 
tissue stained with hematoxylin and eosin after the treatment with FR or vehicle. Data points in (A) 
are means of the indicated number of experiments and error bars denote s.e.m. Statistical analysis 
in was performed with two-way ANOVA. Xenograft experiments were conducted by Xiaodong 
Feng from Professor Gutkind’s lab, San Diego, Californian.  
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4.5. Comparison of mitogenic-signaling-inhibition potency of the 
two Gq inhibitors FR and YM  
FR900359 is a depsipeptide extracted from Ardisia crenata, an ever-green plant coming 
from East Asia. The non-ribosomal peptide synthase gene cluster produced by symbiotic-
bacteria Candidatus Burkholderia crenata has recently been decoded (Crüsemann et al. 
2018). These bacteria strain is concentrated in the knots of the leaves and has been 
suggested to produce FR as a defense chemical against insects. The structure of this 
macrocyclic peptide shows some uncommon characteristics as the cis-configured peptide 
bond, the two-adjoining ester-bonds as well as some rare N-methylated amino acid 
building blocks. These features are also found in another structurally very close related 
depsipeptide YM254890 (Crüsemann et al. 2018), which has been as well characterized 
as a selective Gq- inhibitor (Nishimura et al. 2010). YM254890 is produced by 
Chromobacterium sp QS3666, a Gram-negative rod with peritrichous flagellae and was 
first described in 1988/1989 by Fujioka et al (Fujioka et al. 1988).  
FR and YM both have been reported to inhibit Gq protein signaling by the same 
mechanism of action (Schrage et al. 2015; Nishimura et al. 2010)  with similar potency 
(Reher et al. 2018a). Thus, we wanted to know, whether one of the molecules would 
provide any advantage over the other and therefore, would be more suitable as a base 
for further drug development. To approach this question, we first looked for general 
differences like drug vulnerability and binding in HEK293 cells transfected with the target 
protein, before we moved on and investigated effects in the therapeutically relevant uveal 
melanoma context.  
Both molecules harbor an α,β-unsaturated carbonyl group, which in many cases likes to 
react with nucleophilic binding partners via Michael-addition and thereby form a covalent 
binding. But as prior studies have shown for YM as well as for FR the hydrogenated 
analogs of these molecules still have Gq inhibition potency. This would not be the case, 
when binding would occur only due to nucleophilic reaction (Schrage et al. 2015; Reher 
et al. 2018a). Thus, binding mode of the molecules to the interdomain cleft on the Gαq 
would unlikely be of such covalent nature. However, FR-dependent Gq inhibition has 
been shown to be resistant to extensive washing in vivo as well as in vitro experiments. 
Therefore, the binding of FR has been described as pseudo-irreversible (Schrage et al. 
2015).  
Despite their small structural differences, no major inequalities between mechanistic and 
functional properties have been described so far for these two resembling molecules. 
Thus, we reasoned to perform a head-to-head comparison of these two Gq inhibitors.  
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4.5.1. Drug vulnerability comparison between FR and YM in wash-out 
experiments  
Results from cell-based wash-out experiments can provide information about the drug-
target engagement and therefore gives information about drug vulnerability (Tonge 2017). 
First in line wash-out experiments indeed showed significant but not major alteration 
regarding stickiness of the molecules. The attempt to remove both Gq-inhibitors from the 
system completely seemed un-achievable, as initial state could not be restored by 
washing. But YM was marginally more likely to come off the Gq protein as slightly 
enhanced IP1 accumulation was detectable for high ligand concentrations after excessive 
washing of the cell suspension for 6 times with puffer (figure 46). 
 
Figure 46: Vulnerability comparison between FR and YM.  
IP1 accumulation in HEK293 cells (40 kc/w) after 1 hr of preincubation with FR or YM followed by 
30 min stimulation with CCh in indicated concentrations. Cells were either washed or not washed 
before CCh stimulation. Washing included 6 repetitions of removing buffer and resuspension in 
buffer inserted with 5 min Incubation time. Dots represent the mean with s.e.m. of n = 3 
independent experiments. Significance was calculated by unpaired t-test between washed probes 
of YM and FR incubated cells treated with 1 mM CCh.  
By this means, the vulnerability of FR seems to be lower to some extent, as recovery 
from drug treatment seems to be harder to achieve compared to YM. This result might 
indicate that binding mode and maybe binding kinetic of these both molecules may not be 
100% identical.  
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4.5.2. Evaluation of FR and YM binding addressed by site-directed 
mutagenesis 
To evaluate alterations between the binding modes of the depsipeptides, we mutated 
residues critical for YM binding as described in the PNAS paper from 2010, where 
Nishimura et al. were able to co-crystalize the depsipeptide with the Gi/q chemeric-
heterotrimer. Amino acids I56, K57 and I190 from the GTPase domain together with V184 
and T186 from linker 2 have been shown to form a hydrophobic pocket. This pocket can 
be utilized by the phenyl-group of YM and create hydrophobic interactions to hold the 
molecule tight. Substitution of the non-polar isoleucine on position 190 with the polar 
amino acids arginine  led to a dramatic decrease in YM potency (Nishimura et al. 2010).  
When we tried to reproduce the results obtained by these loss-of-function mutations, we 
were quite surprised. These described key mutations, which decreased pIC50 of YM in the 
depicted SRE assay from the Nishimura paper by more than the factor 700 (I190N), in 
our hands shifted the YM inhibition curves in IP1 assay only 0.5 log M to the right which 
equalize approximately a factor of 3. Even more surprising was the fact, that this mutation 
did not affect FR’s inhibition properties in IP1 accumulation assay in any significant way. 
Similar results were gained for the residues V184 and R60 (figure 47A). Arginine on 
position 60 with its guanidino group was reported to form hydrogen bonds with the 
macrocycle and so to ensure its V-shape within the binding pocket.  
As our outcome differed from these published data, we wanted to exclude an assay 
biased effect. To clarify discrepancies, we chose carbachol evoked ERK activation as a 
Gq readout. ERK is known to be very close upstream to SRE activation in the signaling 
cascade (Gutkind 2000), and therefore amplified effects between these two read-outs 
should be smaller. Indeed, shifts in inhibition curves in pERK assay were improved 
compared to the shifts obtained in IP1-assay. But still loss-of-function was not as 
dramatic as it was described in the PNAS paper. In accordance with Nishimura I190N 
and R60K ended in loss of YM potency the same extent. Moreover, IC50 shifts were again 
smaller for FR (figure 47B).  
Overall, these results emphasize the importance of both likers for binding of the 
depsipeptides. Observations of FR to be more resistance to mutation-induced potency-
decrease could be reconfirmed as alterations of the inhibition curves were only minor 
compared with the smaller but structurally similar macrocycle YM in IP1 as well as in 
pERK assay. 
To make more valid conclusions, we chose to make further mutations on position I190, as 
it seemed to be one of the most critical residues for binding of the depsipeptides. This 
position I190 is only conserved between Gαq, Gα11 and Gα14. The other two members of 
the Gq family Gα15 and Gα16 harbor an arginine on this residue. Notable is that G15 and 
G16 are not sensitive to neither FR nor YM (Nishimura et al. 2010; Schrage et al. 2015) .   
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Figure 47: Loss-of-function mutagenesis study for FR and YM.  
(A)IP1 accumulation in HEK293Gαq/11-null cells 48 hrs post transfection with the indicated 
constructs. 60,000 cells/well were preincubation with FR or YM in the stated concentration and 
followed by 30 min stimulation with CCh in 100 µM. (B) ERK phosphorylation of 60,000 cells/well 
in 96-well plate format. Adherent cells were preincubation with FR or YM in the stated 
concentration and followed by 3 min CCh stimulation in 100 µM. (A,B) Dots represent the mean 
with s.e.m. of n = 3 independent experiments.  
Here we replaced isoleucine 190 with two additional amino acids to the already 
represented arginine. We chose phenylalanine and the sterically very big tryptophan. YM 
as mentioned, responded to switches between non-polar (I) to polar (N) amino acids 
more dramatically than FR. However, loss in potency could not only be explained by 
change in polarity nor by pure satirical properties. Arginine compared to Isoleucine shows 
higher polarity but additionally its average volume and accessible surface area is also 
larger (Trinquier and Sanejouand 1998; Miller et al. 1987) . However, both macrocycles 
were more sensitive to substitution trough phenylalanine, that has much more similarities 
regarding polarity and size to isoleucine than arginine (table 3) (Darby and Creighton 
1993).  
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When we replaced the amino acid with the sterically big tryptophan, both molecules seem 
have a hard time to stick to the protein. Most likely, the hydrophobic binding pocket does 
not offer enough space for tryptophan to fit in. In this case, the obtained losses in 
potencies were most severe. Conclusive, the succession of IC50 shifts increased neither 
synergistically to the size of the amino acid that replaced isoleucine nor to the accessible 
amino acid surface area. However, by modulation of this position greater loss of inhibition 
was achieved for the smaller depsipeptide YM (figure 50A).  
 
Amino acid  Average volume 
(Å
3
) 
Accessible 
surface area (Å
2
)  
 aa polarity 
ranking 
isoleucine 169 140 1 
asparagine 225 196 15 
phenylalanine 203 157 2 
tryptophan 240 217 6 
 
 
Table 3: Comparison of amino acid properties. Data collected from Trinquier and 
Sanejouand 1998 Protein Engineering, Design and Selection, Miller et al.1987J Mol 
Biol. 
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Figure 48: Loss-of-function mutagenesis study for FR and YM.  
(A,B) ERK phosphorylation of 40,000 HEK293Gαq/11-null -cells 48 hrs post transfection with Gq 
constructs with single amino acid replacement on position I190 (A) or F75 (B) in 96-well plate 
format. Adherent cells were preincubated either with FR or YM in the stated concentration and 
followed by 3 min CCh stimulation in 100 µM before lysis and detection. Dots represents the 
means of at least n=3 experiments with s.e.m.. 
A position that is conserved in the whole Gq family is the phenyl on position 75 on the αA 
helical domain. Nevertheless, Nishimura et al. observed that this residue is also crucial 
for binding (Nishimura et al. 2010). In the head-to-head comparison between FR and YM 
we could further confirm the importance of this contact point for both molecules. But 
again, loss of function was greater for YM as it was for FR. Even more surprising was that 
by modifying F75 to alanine we only decreased YM`s potency whereas potency of FR 
remained fully.  
All in all, we looked for two positions on linker 1 (R60, F75) and for two (I190, V184) on 
linker 2. For all of the generated Gαqmut constructs, it was easier to detect loss of function 
for YM (table 4). The tree additional methyl groups might help FR to anchor tighter to the 
binding cleft. Only substitution with the big amino acid tryptophan led to similar functional 
reduction of the two macrocycles.   
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4.5.3 FR suppresses cancer hallmarks of uveal melanoma cells with mutated 
Gq protein with higher potency than YM 
Based on this mutagenesis study and the knowledge we gained from the wash-out 
experiments, we draw the conclusion that both molecules indeed seem to have different 
binding properties. Next, we wanted to evaluate these differences in a biological relevant 
matter. Thus, we examine both molecules in parallel in the therapeutically relevant 
system, the uveal melanoma cell lines.  
4.5.3.1 FR superpowers YM in proliferation assay with uveal melanoma cells 
To assess the question whether one of the molecules could be superior to the other 
respectively to the inhibition of cancer relevant out-comes, we first looked for effects on 
proliferation activity as one of the major cancer hall marks. It was not surprising that Gq 
inhibition with YM failed to inhibit proliferation in wild type GNAQ/GNA11 UM cell lines 
Mel290 and Mel285, as we already knew from the FR-data that Gq does not play any 
proliferative role in these cells. In line with the results observed by Gq inhibition with FR in 
GNAQ mutant cell lines Mel270, Mel202 and 92.1 also Gq inhibition with YM led to a 
decreased proliferation activity. Thereby, efficacy regarding cell growth blockade was 
comparable between the two depsipeptides but potency did differ to some extent. FR was 
clearly more vigorous in Mel270 and 92.1 cells (figure 49).  
These results were somehow unexpected as ERK inhibition with FR or YM in the HEK 
cells system was comparable after 1 hr of incubation for wild type Gq (table 5). To 
elucidate the ostensible discrepancies, we looked for the two factors that were different 
between these two experiments regarding the assay conditions. On the one hand 
inhibition of activation of the proliferation driving protein ERK were prior measured on wild 
Table 4: Comparison of pIC50 values and the ΔpIC50 (log M) shift from wt for FR and 
YM obtained in pERK assay  
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type Gq. GTPase-deficient Gq might have different properties towards binding of YM than 
it has for FR. On the other hand, time could also be a crucial factor. Proliferation assays 
were performed after 72 hrs of incubation whereas pERK assays were measured after 1 
hr incubation.  
 
Figure 49: FR and YM in head-to-head comparisons in cell proliferation assay with 
UM cell lines. 
Effect of FR or YM in the indicated concentrations on cell growth of GNAQ/GNA11 wild type and 
mutant UM lines in culture after 72 hrs of compound exposure. All dots represent the means of 
n=2 independent experiments with s.e.m. 
 
4.5.3.2 Extended application time reveals inequality between macrocycles 
To address both variables in one assay, we choose to perform ERK assays on Mel270. 
This cell line harbors the oncogenic GαqQ209P protein and was very sensitive regarding 
inhibition of the MAPK pathway by FR. We redesigned the ERK assay to include 
variations of incubation time as an additional factor. In our new experiment we measured 
ERK phosphorylation after 1 hr and 24 hrs of FR or YM application (figure 50). 
Pharmacological inhibition of Gq with either FR or YM resulted in equipotent ERK 
dephosphorylation after 1 hr of incubation with IC50 values in the nanomolar range. 
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However, when we looked for inhibition capability after 24 hrs YM had lost around 7-fold 
of its activity whereas FR potency remained stable (table 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Incubation 
(h) 
FR pIC50 ± 
s.e.m. 
YM pIC50 ± 
s.e.m. 
FR ΔpIC50 to 
1 hr  
YM ΔpIC50 to 
1 hr  
1 hr 8.15 ± 0.06 8.17 ± 0.06 0 0 
24 hrs 8.20 ± 0.05 7.30 ± 0.08 0.05 -0.87 
Table 5: Comparison of pIC50 values and the ΔpIC50 shift from 1 hr to 24 hrs for FR 
and YM obtained in pERK assay in Mel 270 UM cells(figure) 
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Figure 50: Time-dependent ERK inhibition of FR and YM on Mel270 
Quantification of pERK inhibition potency by FR and YM after 1 hr and 24 hrs of incubation under 
cell culture conditions.  All dots represent the means of n=3 independent experiments with s.e.m. 
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As in the HEK293 cells expressing wild type Gq, also the UM cells expressing GTPase-
deficient Gq, did not show different results of ERK inhibition between YM and FR after 1 
hr of incubation. But differences in inhibition potency seem to arise by longer incubation.  
To further asses incubation time as critical factor, we went on to determine the inhibition 
capacity of the two Gq-inhibitors on cell proliferation after an even longer period of 
incubation. For that reason, we decided to look for cell proliferation in Mel270 cells after 4 
days and 6 days after FR/YM treatment and evaluated the outcome by bright field 
microscopy.  
After 4 days, cells treated with YM were less dense compared to control, but the cell 
shape seemed to be unaffected. Proliferation inhibiting effect of YM seems to weaken 
over time, as cells density was increased on day 6 nearly to the density of vehicle treated 
cells. Compared to this FR effect on cell growth was more dramatic. On the day 4, only 
few cells survived the presence of the slightly larger Gq-inhibitor FR. Cells were detached 
from the plate and normal elongated cell shape was not found under treatment 
conditions. Furthermore, recovery in the FR-treated wells was not as fast as in the wells 
treated with YM. At day 6 the cells still were detached from the plates and cell shape was 
not retained. Anti-proliferative assets of FR were tremendously compared to YM’s (figure 
51). 
 
Figure 51: Time-dependent ERK inhibition of FR and YM on Mel270 
Representative bright field imaging of n=3 independent experiments of Mel270 cells 4 and 6 days 
after FR/YM application in 10 µM 
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Discussion 
Tumorigenesis arises from a complex network of pathogenic events, whereby the cell 
attains properties of self-sufficiency in regards of growth control and proliferation. Cancer 
cells learn to support themselves with oxygen and initiate angiogenesis to nourish their 
excessive cell dividing. Leading cause for cell transition to gain these abilities are often 
the accumulation of genetic alterations of gain-of-function oncogenes and loss-of-function 
tumor suppressors (Luo et al. 2009).  
Deep sequencing has revealed gain-of-function genes GNAQQ209L/P and GNA11Q209L/P as 
frequent mutations in uveal melanoma (van Raamsdonk et al. 2009). Gq and G11 
proteins are known to promote many pro-survival and pro-metastatic pathways through 
multiple effector proteins (Feng et al. 2014; Mizuno and Itoh 2009). Furthermore, 
mutation in one of this genes is believed to be an early event in this type of melanoma 
formation and suspected to be a crucial initiator for its development (Onken et al. 2008).  
Hence, targeting the oncogenic Gq and G11 protein should be a reasonable approach to 
prevent tumorigenesis.  
Two macrocyclic depsipeptides produced by bacteria (YM) or by symbiotic bacteria (FR) 
were described to specifically target this subfamily of G proteins. Under non-pathological 
circumstances the protein is activated by different GPCRs that are regulated by diverse 
extracellular stimuli. Receptor activation leads to the exchange of the attached guanine 
nucleotide from GDP to GTP (Oldham and Hamm 2008).  
The two depsipeptides bind into a certain cleft of the protein and prevent the activation by 
preventing GDP dissociation (Schrage et al. 2015; Nishimura et al. 2010). The gain-of-
function mutation of the protein affects the GTPase domain. This domain functions as an 
autocatalytic switch-off that allows the protein to return from the active GTP- to the 
inactive GDP-bound from. The hotspot mutation on Q209 to either proline or lysin has 
been reported to trap the protein in permanent on-set and inhibition by preventing its 
activation was thought to be less effective (Nishimura et al. 2010; Kimple et al. 2011). 
Contradictory to this hypothesis, in the framework of this study, we were able to 
demonstrate that inhibition of oncogenic Gq signaling indeed is a rational approach and 
can be achieved with the guanine dissociation inhibitor FR.  
In a mouse melanoma cell line with mutated G11 protein we could show that FR is able to 
diminish multiple hallmarks of cancer cells. By using genome edited HEK293 cells we 
further were able to proof direct interaction of the oncogenic Gq demonstrated in a site-
directed mutagenesis approach to target the molecules binding side. Moreover, we were 
able to understand the mode of FR action on the GTPase-deficient mutant as we could 
show a GDP-bound fraction of the GTPase-deficient mutant by using label-free dynamic 
mass redistribution technology. Additionally, we evaluated different uveal melanoma cell 
lines with either mutated or wild type Gq protein for their sensitivity for FR. Thereby, we 
established Gq-inhibition as a reasonable strategy to prevent cancer development and 
could introduce FR as a lead compound suitable for further therapeutic development. In 
different head-to-head comparisons between the two known Gq inhibitors FR and YM, we 
could demonstrate the long-term superiority of FR in regard of cell proliferation and 
mitogenic signaling inhibition. These findings will be discussed here in detail.  
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5.1. FR as a tool to blunt mitogenic signaling in CM 
Malignant cutaneous melanoma is characterized to go through distinct phases to develop 
its malignant pathogenesis. Unrestricted cell growth is followed by invasive behavior and 
development of metastasis. The most prominent genetic alteration in CM is an amino acid 
substitution in the B-Raf protein where valine is exchanged to glutamic acid at position 
600 in amino acid secondary structure (Gray-Schopfer et al. 2005). Raf and also the 
common mutated Ras belong to the p21-GTPase proteins. Like G proteins, they are 
activated by the exchange of GDP to GTP and are switched off by their GTPase domain 
(Platz et al. 2008). HCmel12 mouse melanoma cell line is derived from the genetically 
engineered mouse model of Hgf-CdkR24C mice. These mice form spontaneous 
melanomas. Thereby, the malignancy proceeds from melanocytic naevi that form in most 
cases metastasis (Landsberg et al. 2010). Unlike the most malignant melanoma types 
that carry mutations in the Raf-Ras-MEK-ERK signaling pathway (Platz et al. 2008) these 
cells harbor a gain-of-function mutation in GNA11 gene at the hot-spot residue Q209 
(Kilian et al. 2016). Reports about GNAQ/11 mutations in cutaneous melanoma are rare 
(Patel et al. 2016) but they are frequently found in intradermal melanocyte neoplasms as 
blue naevi (van Raamsdonk et al. 2009).  
Here we could show that inhibition of GTPase-deficient G11 with FR initiated HCmel12 
cells to differentiate, as we observed morphological cell changes and increase of the 
differentiation marker gp100. Most likely, differentiation in these cells is under the control 
of ERK promotion as MEK-i trametinib also enhanced this marker. In line with this 
observation, we detected elevated levels of phosphorylated ERK protein. Furthermore, 
we could show that G11 indeed showed constitutive activity by measuring its canonical 
effector activity. In terms of ERK activation this constitutive activity of G11 protein could 
be identified as the promoter for this signaling pathway by using our Gq/11 inhibitor. FR 
inhibited phosphorylation and thereby activation of ERK in a nanomolar concentration 
range.  
As described by literature, IP1 accumulation as direct readout for PLC activation 
conducted by the Gα11Q209L protein was not sensitive towards the inhibitor. However, our 
experiments showed that FR clearly is not an ERK inhibitor by nature as it blocks this 
signaling cascade only in case it is under the control of Gq/G11 proteins as the initial 
drivers. This was concluded as in melanoma cells with additionally B-Raf mutation FR 
had only minor effect whereas after incubation with the B-Raf inhibitor vemurafenib, 
almost no phosphorylated ERK was detected. 
Vemurafenib is the first selective B-RafV600E inhibitor and has been successfully used for 
many years for the treatment of cutaneous melanoma in patients with mutated B-Raf 
profile.  In patients vemurafenib has been shown to be well tolerated and more 
importantly has been proofed to increase survival by 11.5 month (Czirbesz et al. 2017). 
As over-activity of Gq apparently participate in activation of the same pathway as B-Raf, it 
is very reasonable transfer the concept of direct targeting of the oncogene to melanoma 
cells with gain-of-function GNAQ/11.    
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5.2. Mechanistic insights into inhibition of the GTPase-deficient 
mutant 
As mutations in GNA11/GNAQ are mutually exclusive, one of these proteins always 
exists in the non-mutated state in our melanoma cell context. Thus, we wanted to proof 
interaction of the molecule FR with the GTPase-deficient mutant in a clear Gq/11-null 
background by using genome edited HEK cells. Hereby, we were able to show FR 
interaction with both, unmutated and mutated Gq in different assays. Clear proof for the 
specificity of the results, by this means that the obtained inhibition effects were related to 
FR interaction with the respectively Gq-analog was achieved, as the vector-transfected 
cells lacking the target constructs remained unresponsive.  
To enlighten the question of the mechanical aspect behind the unexpected inhibition 
capability of FR on the GTPase-deficient mutant, we attempted two different approaches. 
First, we validated the existence of a receptor inducible fraction of the GTPase-deficient 
Gq protein by using DMR. Here, ligand-induced traces of the GαqQ209L transfected cells 
clearly indicated a GDP-bound fraction. This could be confirmed by immunoprecipitation 
of GDP-bound GαqQ209L. Second, we were able to show direct binding of FR for Gαqwt and 
GαqQ209L by loss-of-function mutagenesis studies.  
The direct interaction was shown by mutation of the binding site. Hereby, we were able to 
show loss of FR function by modulating amino acids in the binding pocket on the Gα-
subunit. The binding surface inherit the two linkers that connect the helical and the 
GTPase domain (Nishimura et al. 2010). Thereby, linker 2 is one of the flexible regions 
that are known to undergo conformational changes upon GDP/GTP-exchange (Oldham 
and Hamm 2008). This binding site is described to be only targetable in the GDP-bound 
state (Nishimura et al. 2010). Therefore, we suggest that FR functions as a GDI on the 
GTPase-deficient mutant.  
A premise for GαqQ209L to exist in the GDP-bound state is that its deficient GTPase 
function might not be as compromised as often reported (Kimple et al. 2011; Patel and 
Tall 2016). Undeniably, many reports about Gα and the catalytic function of its GTPase-
deficient analogs exist and are selectively discussed here: 
Even though, it has been shown, that Gα proteins with analog mutation to the Q61L of 
Ras protein have a slower GTPase catalytic kinetic, the function of the GTPase domain 
was shown not completely dysfunctional. The Gs analog GαsQ227L  still remained 
approximately 1/30 of the wild type GTPase activity (Scheschonka et al. 2000). However, 
the GTPase properties obtained by Gs and Gi might not be completely transferrable to 
Gq because wild type hydrolysis of Gq (kcat-GTPase=0.7 min-1) differs to Gi/Gs (kcat-
GTPase=0.3 min-1) (Berstein et al. 1992). Indeed, the less GTPase-impaired GqR193C was 
shown to lose kcat-GTPase (140-fold) activity even more than the described loss for GαsQ227L. 
In a study to investigate PLCβ1 GAP on Gq, kcat-GTPase of this mutant was reduced 140 fold 
compared to wild type but GAP activity of PLCβ1 was still functional (Chidiac and Ross 
1999).  
Additionally to PLCβ also regulators of G protein signaling are known to function as GAP 
on Gq proteins and thereby enhancing their GTPase function (Kimple et al. 2011). GAP 
activity of e.g. RGS proteins may not be only limited to wild type proteins. Scheschonka 
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et al. could demonstrate in a study published in 2000 that both RGS2 and RGS3 were 
able to block CREB reporter gene activity provoked by either GαqQ209L/Gα11Q209L in 
HEK293 cells and GαqQ209L-induced IP3 production. Thereby, it remained unclear if 
inhibition was due to GAP activity or inhibition of protein-protein interaction (Scheschonka 
et al. 2000).   
As we could see by our results, GαqQ209L is not entirely trapped in the GTP-bound active 
state. This is further supported by studies showing functional but compromised GTPase 
function of these proteins. According to these assumptions, FR should be able to bind to 
the GDP-bound- GαqQ209L as heterotrimer, because the mutation does not alter the 
binding pocket. By locking the GαqQ209L in the GDP-heterotrimeric complex, FR, as a GDI, 
could accomplish inhibition of the interaction of the protein with its effectors. 
5.3. Hypothesis of FR pathway-selectivity 
The term ‘guanine dissociation inhibitor’ (GDI) was first used for a small protein that was 
found to bind to the Ras-like protein Rab. GDI binding to Rab traps the protein in its 
inactive state and prevent over all Rab-signaling (Pfeffer et al. 1995). This term was 
adopted for YM, the first described cell permeable inhibitor that selectively targets 
Gαq/11/14 proteins. Like the original termed GDI implicates, YM enables its target protein to 
be activated by GTP-GDP exchange (Nishimura et al. 2010).  Later in 2015 FR that is 
structurally closely related to YM, was also categorized as a GDI (Schrage et al. 2015). 
According to the GDI mechanism of action, FR and YM should be able to switch of all 
downstream effectors that require former activation by GDP-GTP exchange as schemed 
in figure 53 for wild type Gq. This should also account for the GTPase-deficient mutant if 
FR and YM retained their mode of action as prior suggested. Contradictory, YM failed to 
inhibit IP1 accumulation in HEK cells transfected with the constitutively active G11-
construct  Gα11Q209L while inhibition of Gα11wt was perfectly succeeded (Xiong et al. 2016). 
Similar observation was gained by this study. IP1 accumulation of HCmel12 cells 
(Gα11Q209L) was achieved up to very high amounts of the inhibitor but surprisingly 
mitogenic signaling was diminished in nanomolar concentrations. This behavior was not 
restricted to the G11 subfamily as in our hands intrinsic IP1 tonus of HEK cells 
transfected with the GαqQ029L construct displayed the same insensitivity towards FR. In 
this present study we introduced a hypothesis that might explain differential behavior of 
the canonical Gq/11 effector PLCβ towards inhibition by FR.  
PLCβ is not only an effector, but it also displays an important role as a switch of regulator 
(Litosch 2013). Thereby, its GAP activity controls the durance of PLCβ and Gαq/11 
interaction, whose dynamic-fashion is described as kiss-and-run reaction (Adjobo-
Hermans et al. 2013; Harden et al. 2011).   
Interestingly, PLCβ signaling of the GTPase-deficient mutant GαqR183C was perfectly 
inhibited with FR, pointing out that slower GTPase activity cannot solely explain the 
inability of FR towards PLC signaling driven by GαqQ209L. A notable difference besides the 
kcat-GTPase between the two Gq analogs R183C and Q209L is their sensitivity towards GAP 
activity of the PLC. While GαqR183C-sensitivity towards PLCβ-GAP is still functional, GAP 
activity towards GαqQ209L is greatly impaired (Chidiac and Ross 1999; Berman et al. 
1996).  
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Figure 52: FR as a GDI on wild type Gq 
Scheme (A) shows the activation circle of Gq proteins in the attendance of a ligand. Here the G                        
protein circles between an activated and inactivated state. In the monomeric active state, the Gq 
protein interacts with different effectors. Thereby some effectors like PLC additionally serves as 
GTPase-accelerating proteins and favors the transition of GTP-bound α-monomer to the inactive 
GTP-bound heterotrimer. (B) Shows the inhibition of this signaling circle by FR. FR binds to the α-
subunit in the heteromeric state and prevents the activation by the receptor. 
FRET experiments further demonstrated that although FR inhibits the on-kinetic of PLCβ 
and Gαqwt it did not affect protein-protein-interaction of PLCβ with GαqQ209L. One possible 
explanation could be reasoned by the mechanism of PLCβ-GAP activity that is thought to 
release the Gα-subunit from PLCβ. The crystal structure of the PLCβ3 isoform, which was 
also used to conduct our FRET experiments, together with Gαq, published by Waldo et al. 
in 2010, emphasized two amino acids in the monomeric Gαq to be important for GAP 
activity. They could demonstrate that Q209 and R260 of Gαq interact with the EF3 and 4 
hands of the PLCβ. One of these GAP relevant residues is mutated in the GTPase-
deficient mutant. GAP activity of PLCβ presumably cannot enfold its proper function when 
glutamine is substituted with leucine in the Gα-subunit (Waldo et al. 2010). In this case 
PLCβ and Gα might be clued together and FR is unable to drive its GDI activity. 
Consequently, all other interactions might be perfectly inhibited while FR is unable to 
separate the two effectors completely as schemed in figure 53. But here we would have 
to assume that ERK is not downstream of PLCβ as often stated (Gutkind 2000). 
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Figure 53: Mechanism of biased inhibition of the GTPase-deficient Gq  
Scheme of (A) pathway activation of the oncogenic Gq protein: The protein exists in both forms, 
the active and the inactive form. Due to the GTPase malfunction it becomes independent of the 
receptor (the receptor is shown as transparent pictogram). In the monomeric active state, the 
oncogenic Gq protein interacts with different effectors. (B) By applying FR to the system, the 
protein accumulates in the inactive state. However, as PLC is unable to function as a GAP protein, 
the interaction of the two proteins cannot be disrupted easily. Therefore, the inhibition of other 
effectors, that are not permanently attached to the active protein, is more effective by FR. 
5.4. Targeting the oncogenic protein in a therapeutically relevant 
system 
The mutations affecting the GTPase domain of the Gαq or Gα11 protein occurs most 
prominently in the context of uveal melanoma. Therefore, we were eager to test the 
inhibitor in cell lines originated form the tumor tissue of UM patients and to demonstrate 
its antiproliferative effects in vitro and in vivo in this highly relevant system. 
Interestingly, despite the presents of GTPase-deficient Gq UM cell lines Mel270, Mel202 
and OMM1.3 showed quite low intrinsic IP1 tonus, implementing a minor role for PLCβ in 
these cells. Surprisingly, this low activity was perfectly sensitive towards inhibition with 
FR. This might hint that inability towards PLCβ inhibition can be overcome dependent on 
the cellular protein composition. Also, variety in PLCβ-GAP activity between different 
isoforms might play a role, as UM cells are known to harbor the quite uncommon PLCβ4 
that is exclusively found in the eye and in brain tissue (RebeCChi and Pentyala 2000). 
Only the 92.1 cell line, harboring the oncogenic GαqQ209L, had a quite high IP1 tonus but 
also showed decreased FR sensitivity compared to the other GNAQmut-cell lines. 
However, more importantly, we could show that different mitogenic pathways such as 
ERK and AKT but also partially YAP could be blunt in UM cell lines with mutated Gq. In 
contrast, wild type Gq did not display the role of an oncogene in the uveal melanoma cell 
lines Mel290 and Mel285. Here the pro-survival pathways were unresponsive to FR 
inhibition. 
Different reports exist, which highlight the importance of different pathways for 
proliferation in uveal melanoma with mutated GNAQ (van Raamsdonk et al. 2009; Yu et 
al. 2014; Zuidervaart et al. 2005).  
A                                            B 
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By western blot analysis Zuidervaat et al. could determine ERK activity in all UM cell lines 
(Zuidervaart et al. 2005), which were also used in this present study. Thereby, we were 
able to confirm their findings, that wild typ GNAQ cell lines Mel290 and Mel285 displayed 
highest ERK activity. But by using FR we were further able to show, that ERK 
phosphorylation in these cells was not driven by the GNAQ. Despite of the high ERK 
tonus, which was sensitive to MEKi by trametinib, proliferation was not entirely ERK 
dependent, as cells remained approximately 50% of their viability after 72 hrs of MEKi. 
ERK phosphorylation of GNAQmut cell lines was sensitive to FR whereby the efficacy and 
potency did differ throughout cell lines.  While ERK activation was almost completely 
sensitive in OMM1.3, Mel202 and Mel270 cells towards FR, ERK inhibition was not 
completely driven by GNAQ in 92.1. After FR treatment still 30% of phosphorylated ERK 
was detectable. Even though ERK was GNAQ dependent and additionally completely 
sensitive towards MEK-inhibition by trametinib in OMM1.3 cells, the MEK inhibitor 
underlay the direct targeting of the oncogene in the proliferation assays. This might 
indicate that more than one Gq- effector participate in proliferation promoting 
mechanisms. 
Although ERK inhibition with the MEK inhibitor trametinib seemed to stop proliferation in 
most cell lines with mutated GNAQ in this study expect the above mentioned OMM1.3 
line, these inhibitors could not proof their benefit in clinical studies. In a randomized 
phase 2 trial in 2013 beneficial effect of the MEK1&2 inhibitor selumetinib as adjuvant 
therapy to the chemotherapeutic agents temozolomide or dacarbazine was investigated 
on 120 patients with metastatic melanoma. In this study selumetinib improved the 
progression-free survival from 7 to almost 16 weeks but did not enhance the over-all 
survival rate. Patients with mutations in GNAQ/GNA11 genes seemed to have greater 
progression-free survival, but this was not valid, as most of the tumors were only scanned 
for mutations of exon 5 of GNAQ/GNA11, whereby exon 4 in most cases was not 
analyzed (Carvajal et al. 2014). SUMIT, the follow-up randomized multicenter phase 3 
study was assed to clarify the safety and efficacy of this treatment. Patients again treated 
with either dacarbazine in combination with selumetinib or placebo, but this time 
progression-free survival was not improved. Interestingly the frequency of GNAQ and 
GNA11 mutations were extremely high with 94 % of the investigated samples (Carvajal et 
al. 2018).  The poor clinical results are not restricted to selumetinib exclusively as a MEK-
i. In a prior phase 1 first-in-human study trametinib was tested in patients with different 
kinds of melanoma cells regarding its safety, efficacy but also variability in response in 
correlation with genetic alterations. For the 16 UM patients included in the study, stable 
disease as best result, was only achieved 4 patients (Falchook et al. 2012).   
One reason for limited success might be that in cells with mutated GNAQ/GNA11 gene 
other pathways might take the proliferating activity over when MEK is inhibited. By using 
microarray gene expression analysis Ambrosini et al. could identify a pattern of genes 
that are regulated by MEK in UM cell lines with mutated GNAQ. OMM1.3, 92.1 and 
Mel270 cells showed significant increase of a gene called c-Jun after treatment with 
selumetinib. Remarkably this was not the case in melanoma lines with mutated B-Raf. C-
Jun is part of the activator protein 1 transcription complex that regulates different 
signaling events leading e.g. to cell proliferation or apoptosis. As knockdown of this gene 
in the mentioned UM cells increased anti-proliferative effects of the MEK-i Ambrosisini et 
al. propose that this might be a mechanism for the cells to gain drug resistance. By this 
means, selumetinib treatment of GNAQmut cells upregulate a gene that impairs the 
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function of the drug itself. The authors of this study suspect PKC, as another GNAQ 
downstream effector, to be involved in this negative feedback mechanism (Ambrosini et 
al. 2012). Supporting this theory, Babchia and co-workers could observe synergistic 
effects by combining PKCi and MEKi in vitro in UM cells with mutated GNAQ (Chen et al. 
2014).  
Similar results were obtained by inhibition of the AKT signaling additionally to the ERK 
signaling. AKT seems to participate in cell proliferation of UM cells, as the combination of 
the two inhibitors were twice as effective than mono-treatment (Babchia et al. 2010) 
(Khalili et al. 2012; Ambrosini et al. 2013). While Kahlili et al. did not see any correlation 
of GNAQ signaling to activate AKT in 92.1 cell line Ambrosini could show reduced 
fraction of the phosphorylated protein by using GNAQ siRNA in multiple cell lines 
including the 92.1 cells. By using FR in our study for the different cell lines, we were able 
to support the observation of Ambrosini et al. and proof GNAQ involvement in this 
pathway for Mel270, Mel202, OMM1.3 and 92.1. But it must be stated that 92.1 was 
among the GNAQmut cell lines the one that was least affected by FR. Only 25% of the 
pAKT fraction was blunt by Gq inhibition, whereas 60% inhibition was gained in OMM1.3 
cells. Again, these results are pointing out that proliferation promoting signaling trough 
GNAQ in UM cells cannot be easily stereotyped by the mutational status of the Gq 
protein. Activation of the different pro-survival pathways by the oncogenic GNAQ seems 
to be quite diverse dependent on the cellular background. Hench, it is much more 
reasonable to directly target the oncogene instead of the downstream effectors that seem 
to have variations in each cell system. 
Beside AKT and ERK signaling another pathway regulated by the oncogenic Gq has 
become more prominent as cell press released two big articles back to back published in 
cancer cell in 2014. These two articles were centered around the role of the 
transcriptional co-activator YAP in uveal melanoma harboring the GTPase-deficient 
mutant Gq. GNAQ signaling could be identified as perpetrator for YAP activation as 
knockdown of GNAQ by shRNA/siRNA in 92.1, Mel270 (Yu et al. 2014) and in the 
metastasic-porne  UM cell lines OMM1.3 (Feng et al. 2014) inverted YAP localization or 
phosphorylation state. Further knockdown approaches to elucidate GNAQ signaling 
pathway to YAP activation reveled a new pathway involving TRIO, Rho and Rac.  
In line with their observation we found higher pYAP (inactive YAP) in cells expressing 
wild type Gq, but inhibition of Gq in our study with FR only led to significant increase of 
phosphorylated fractions of the protein in two cell lines, the 92.1 and OMM1.3. This was 
quite disappointing as the YAP pathway was claimed to take over the key player role over 
MAPK activation overall in these genotyped cells. But interestingly the cell lines, which 
were picked for the two articles, were the same showing also response to FR, despite of 
Mel270. YAP signaling might play a role only in certain cell lines, here again cellular 
background seems to be a key factor. 
To sum up, constitutive active Gq drives different effectors within the uveal melanoma 
cells activating proliferation and migration. Due to the unavailability of direct Gq-inhibitors 
so far, many attempts have been drawn to target the downstream effectors alone or in 
combination (Krantz et al. 2017). As signaling of these downstream proteins may vary 
dependent on the micro-environment within different cells this approach might fail in 
some cases. Additionally, other GNAQ pathways might take over the role of the targeted 
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survival pathway leading to drug-resistance (Ambrosini et al. 2012). In the frame of this 
study we could show, how FR is able to simultaneously switch off multiple GNAQ driven 
pro-survival pathways, and therefore we propose this as a new model to treat uveal 
melanoma patients with mutated Gq. 
This allegation was furthermore sustained by a xenograft mouse model, where FR could 
significantly reduce tumor size of Mel270 cells after 14 days of treatment but was without 
effect in mice injected with tumor cells with B-Raf mutation.  
5.5. macrocyclic Gq-i FR and its analog YM in comparison 
FR and YM are two structurally very close related molecules that are reported to have 
similar inhibition potencies with a slight prevalence for FR (Xiong et al. 2016). In our 
hands the two molecules showed no difference in potency after one-hour incubation. 
Superiority of FR was first revealed after extend washing and a longer period of 
incubation time. These results indicated different drug vulnerability for YM and FR.  
In drug discovery IC50 values are often used as numeric scale to evaluate lead 
compounds but this number cannot fully account for the real drug-target engagement that 
might be important in regards of the drug use (Tonge 2017).  
5.6. Limitation of this study and future perspectives 
Despite the study could show remarkable results of FR in vitro and in vivo on the 
constitutively active Gαq, several questions remained for further investigations. 
In cutaneous melanoma we were able to show biased inhibition of mitogenic ERK 
signaling over canonical PLC. This was surprising as Gq mediated activation of ERK is 
believed to be PLC related (Gutkind 2000; Rozengurt 2007). By taking advance of 
different inhibitors of Gq downstream effectors we could show that ERK activation seems 
to be regulated by multiple proteins like PKCs and Rho kinases. Results with the PLC-i 
U73122 were inconclusive as the inactive control molecule was not inactive and thus, 
leaving the result’s specificity as questionable. Therefore, we could not truly clarify if PLC 
signaling is related to ERK and how exactly ERK activation by Gq is achieved in these 
cells. 
In order to enlighten the mechanism of action we could show that GαqQ209L exist in the 
GTP-bound monomeric as well as in the GDP-bound heterotrimeric form. FR has been 
characterized as a GDI (Schrage et al. 2015). We were able to transfer this mechanism to 
the GTPase-deficient Gαq as we could show that ligand-induced DMR signal of cells 
transfected with the GαqQ209L construct was block with FR perfectly, therefore could 
conclude that FR inhibits most likely the heterotrimer. But we cannot exclude the 
possibility that FR additionally binds to the monomeric form of GαqQ209L and therefore 
inhibits protein-protein interaction. To clarify this question further, binding studies with FR 
must be done on GTP versus GDP-bound GαqQ209L.   
In addition we were able to show that PLC GAP activity most likely does not function on 
the GTPase-deficient as it is described to work for the wild type protein (Litosch 2013; 
Harden et al. 2011; Waldo et al. 2010) and therefore explain FR’s inability to inhibit this 
canonical effector protein. This hypothesis was concluded by the fact, that basal elevated 
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FRET signals between PLC and the GαqQ209L could not be depressed by FR application. 
In theory, if GAP activity of PLC functioned on GαqQ209L it would release GαqQ209L-GDP 
from the PLC-GαqQ209L-GTP interaction complex and the Gβγ heterodimer should then be 
able to capture the GDP-bound monomer and form a FR accessible GDP-bound 
heterotrimer. In this case FR should lower the basal FRET signal as it would withdraw the 
α-subunit from the activation process, but this was not the case in our experiment. But 
some major questions were left out to be answered. The experiment we performed was 
done with the PLCβ3 isoform, therefore it would be interesting to see, whether this loss of 
GAP activity can be transferred to other PLCβ isoforms. Waldo et al. could show that 
Q209 of the Gαq is an important residue in the GTPase-accelerating process of PLCβ3. 
More in depth analysis is needed to state if this is also the case for other PLC isoforms.  
In context of uveal melanoma, FR could surprisingly blunt PLC signaling driven by the 
GTPase-deficient Gαq. These cells are known to harbor the PLCβ4 isoform (Johansson et 
al. 2015). An alternative explanation that could be further investigated is that also other 
factors like GTP and GDP content as well as the total amount of accessible proteins 
within a certain cellular background might modify the GAP activity of a certain PLCβ 
isoform. 
Another interesting observation we made was that in the UM cell lines with constitutively 
active Gq FR was more potent on ERK and AKT phosphorylation when constitutive 
activity was caused by the substitution of proline on Q209 versus the substitution by 
leucine. But we only investigated two cell lines with proline and 2 with leucine 
substitution. A higher number of different cell lines should be taken in account before 
further conclusion can be drawn, as we do not know if cell permeability varies throughout 
the different cell lines. Another option would be to use the clear artificial HEK293 cell 
background and test the two constructs in the same cell line to exclude bias dur to 
different permeability and cellular background. 
Using the uveal melanoma cells as a therapeutically relevant system, we could show the 
impressive consequence of Gq inhibition on different pro-survival pathways in the cell, 
cell proliferation and in-vivo tumor growth, but nevertheless this study is limited to proof 
the concept of direct targeting the oncogenic Gq rather than offering a new 
therapeutically option. Reasons for why FR as unmodified molecule should not be 
systemically applied will be discussed next.  
FR, as stated, inhibits the signaling transduction of Gαq/11/14 isoforms (Schrage et al. 
2015; Kukkonen 2016). Almost 40% of the GPCRs are couple to Gq/11 proteins and 
thereby these proteins translate signals from many hormones and neurotransmitters into 
a cellular response (Sánchez-Fernández et al. 2014). The systemic function of the Gq/11 
proteins are indispensable as shown in different knock-out mouse models. Baby mice 
lacking all 4 alleles of GNAQ and GNA11 did not show any morphological abnormalities, 
but they were unviable as they could not take up breathing. The mice in this study could 
only survive with at least one intact GNAQ allele. But these animals develop a 
hyperplasia of cells of the endocrine system, that produce growth factors and showed the 
syndrome of dwarfism (Wettschureck et al. 2005). In another knock-out model GNAQ 
deficient mice show prolonged bleeding time and were unresponsive to platelet 
aggregation agonist (Offermanns et al. 1997). Additionally many Gq-CPRs as muscarinic, 
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histaminic or prostaglandin receptors regulate bronchial constriction (Matthey et al. 2017). 
Therefore, systemic application would not be a suitable approach to treat human. 
As systemic application is not advisable one solution might be to modify the molecule 
chemically in a way that targets only the mutated analog of the protein. Unfortunately 
prior structure-activity-relationship studies showed that even small changes within the 
structure of the molecule can led to huge loss of potency (Xiong et al. 2016; Reher et al. 
2018a). Nevertheless, some modifications that show similar potencies might differ in 
drug-vulnerability as shown in this study for FR and YM. In this study the evaluation of 
kinetics was only restricted to long term incubation and on wash-out experiments. To find 
the perfect candidate for further modulations more investigation regarding the kinetic and 
off-kinetic of the molecule should be done in the future. Also other known FR and YM 
derivatives, that could be synthesized (Xiong et al. 2016) or can be extracted form Ardisia 
(Reher et al. 2018b), could be implemented in further testing. 
Another method to avoid side effects would be to apply FR just locally. In a study to 
investigate FR as a drug in asthmatic disease in a mouse model Wenzel and co-workers 
applied the compound as an aerosol directly on to the lung of the mice. By monitoring the 
heart rate and blood pressure during treatment, no effects were observed in the 
cardiovascular system as side effect. Further biodistribution measurements, 10 minutes 
after FR application to the lung were obtained by lung, liver, heart and blood. This 
measurement revealed that by this local application method FR was 10 times higher 
present in the lung than in the other tissues (Matthey et al. 2017). As tissue preparations 
were obtained shortly after FR application it is hard to predict of long-term application 
would lead to higher accumulation and therefore cause side effects. 
Transferring a local application for tumor therapy would require a drug target delivery 
system. This term means the that the drug, in this case FR, would be tagged to a vehicle 
that recognizes some specific features of the targets, in our case the uveal melanoma 
cells, and releases the drug at the destination. As the oncogenic Gαq protein is not found 
in the cell surface but is a intracellular protein the carrier, like in the case of siRNAs 
should be able to enter the cytoplasm by overcoming the cell membrane barrier (Bae and 
Park 2011). The development of such an analog of FR might be challenging, but 
desirable, as the results provided by our study seemed to be very promising.  
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Summary 
Malfunctions of GPCRs and G proteins are involved in many diseases including cancer, 
chronical lung diseases or multiple sclerosis and that is the reason why over 30% of the 
current drugs on the market have GPCRs as their targets. Modulation of the signaling 
cascade on the G protein level is more challenging, as there are only few tools known 
that specifically target this family of proteins. A common understanding is that inhibition 
on the receptor-level is more specific since only 4 families of G proteins are transducing 
the signaling of over 800 GPCRs. However, in some cases multiple receptor signaling via 
one specific G protein is involved in pathology, as it is reported in asthma. Another 
scenario in which targeting the G protein itself is desirable instead of the receptor is when 
the G protein starts to signal independent of ligands and receptors. This is the case for 
the Gq and G11 protein in uveal melanoma.  
Uveal melanoma is the most common cancer in the adult eye. The malignancy arises 
from melanocytes of the uveal contact and patients often suffer under visual field loss or 
blurry vision. However, the most disastrous consequence of the disease is that over 50% 
of the patients develop metastasis that are most commonly found in the liver but also in 
lung or bone. Once the cancer has spread the median survival drops to 13.4 months. 
Unfortunately, no curing therapy is available so far. Deep-sequencing could expose that 
over 80% of the uveal melanoma patients carry an activating mutation in the GNAQ or 
the GNA11 gene that bestow the protein with constitutive activity. 
In the presence of a ligand-activated receptor the non-mutated proteins circle between a 
sedentary heterotrimeric GDP-bound and an active monomeric GTP-bound state. 
Activation of the protein by a receptor causes the nucleotide exchange from GDP to GTP 
and leads to dissociation of the protein’s α-subunit from the βγ-heterodimer. An 
autocatalytic switch-off GTPase domain is present in the α-subunit. By promoting the 
hydrolysis of the γ-phosphate of the GTP it triggers the nucleotide’s transformation back 
into the di-phosphate and thereby inactivates the protein. The amino acid substitution on 
the position Q209 to leucine or proline that is commonly detected in uveal melanoma 
impairs the GTPase activity and traps the protein in its active state. 
As a sequel to this discovery, a lot of reports emerged during the last 10 years that 
elucidated the role of the mutated Gq and G11 proteins as the perpetrator for the on-set 
of different pro-survival pathways. In that regard many attempts were made to inhibit cell 
growth and tumor formation by targeting these downstream pathways but none of these 
efforts could show any clinical success. A more straight-forward approach would be to 
target the oncogenic protein itself but the only known specific Gq and G11 inhibitors FR 
and YM were not believed to be suitable to block signaling of the mutated protein 
because of their mode of action. Former studies demonstrated the mode of action of 
these macrocyclic depsipeptides as guanine-dissociation inhibitors. By this means these 
molecules prevent the activation of the protein by blocking GDP dissociation. Therefore, it 
was long believed that these inhibitors would not counteract the protein with this specific 
gain-of-function mutation, as the protein is already in the activated state. This conclusion 
was supported by literature that described the inability of FR and YM to inhibit the 
canonical effector protein PLC, in case it was activated by the mutated analog of the 
protein.  
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Inconsistent with this hypothesis, Evelyn Gaffal and Thomas Tüting demonstrated that FR 
indeed suppressed typical hallmarks of cancer cells in a mouse melanoma cell line 
harboring a somatic gain-of-function mutation in the GNA11 gene. However, mutations of 
this gene occur in a mutually exclusive manner and therefore one of the proteins would 
always remain unmutated. This was the leverage point for this study that served to proof 
and to understand how the Gq inhibitor FR with GDI mode of action blunts mitogenic 
signaling of the GTPase-deficient GαqQ209L.   
Cell-based assays in genome-edited HEK293 cells lacking alleles for GNAQ and GNA11 
helped to verify the direct interaction of the molecule with the protein. These cells offered 
an ideal background to reintroduce the constructs and to clearly distinguish between wild 
type and GTPase-deficient Gαq. Mutagenesis studies furthermore served to verify that the 
binding region of the molecule is similar between the wild type and mutated protein. 
Furthermore, whole cell biosensor experiments did not only help to underline interaction 
of the molecule with its cellular target but also indicated a receptor-activatable fraction of 
the GTPase-deficient protein, that rationalized FR’s inhibitor properties on the active 
protein, as this fraction indicates existence of a heterotrimeric GDP-bound inactive form. 
Additionally, we could confirm the existence of the GDP-bound heterotrimeric GTPase-
deficient protein by immunoprecipitation together with His-pull-down assays. With the 
help of FRET experiments we were further able to understand and to build up a 
hypothesis that might explain the biased inhibition of signaling cascades by blocking the 
GTPase-deficient Gαq. Finally, we rationalized the inhibition of Gq as a potential 
therapeutic approach to treat uveal melanoma and evaluated the two most prominent Gq 
inhibitors in regard of their drug vulnerability in this context. 
In conclusion the results of this study suggest that molecules like FR are suitable 
candidates for drug-development. Stratified uveal melanoma patients could benefit from 
these compounds in the future. Ideally, these compounds should be modified in a way 
that either specifically target certain tissue or the mutated form of the protein and 
therefore could extend the survival rates for these patients without major side effects.  
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